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Abstract 
 
 
Muscle mass loss in the critically ill is substantial, between 1-2% per day. Muscle 
wasting and weakness delays patient recovery and rehabilitation. Understanding the 
relationship between nutritional and inflammatory markers will help to identify a 
notional “nutritional tipping point”, where anabolism exceeds catabolism, which will 
allow us to target nutritional therapy more successfully.  
Muscle depth on ultrasound, inflammatory markers, cytokines, urinary markers of 
protein breakdown and nitrogen balance data were collected in 78 critically ill 
patients. Patients lost a significant amount of muscle depth during their intensive care 
unit (ICU) stay. Results indicate that a nutritional tipping point is unlikely to exist 
during an ICU admission. Data suggests that nitrogen balance remains negative over 
20 days, indicating that whilst patients should continue to receive standard nutrition 
support during their ICU stay, any additional nutritional strategy should be targeted 
outside of the ICU environment. Multilevel modelling indicated that each additional 
day spent on ICU was significantly associated with decreased C-reactive protein, 
muscle depth and interleukin-10 levels. With every year increase in a patient’s age 
muscle depth and 3-methylhistidine levels were significantly reduced and interleukin-
10 levels were significantly increased. Sample size estimates from current data 
provide some guidance for future studies, however estimates should be viewed with 
caution. 
The feasibility of providing a leucine-enriched essential amino acid supplement to 
trauma ICU patients was furthermore assessed. Inflammatory and nutritional makers 
were assessed along with protein turnover. Although it was feasible to use the 
supplement in the trauma population, studying this patient group was more 
complicated than anticipated. Whole body protein turnover was enhanced in trauma 
patients with breakdown far exceeding synthesis.  
These studies suggest that although it may be feasible to provide amino acid 
supplementation to critically ill patients, this type of intervention should be targeted 
outside of the ICU environment. 
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Chapter 1. Introduction 
 
 
For many survivors of critical illness, discharge from the intensive care unit 
(ICU) merely marks the start of substantial challenges prior to full recovery. A 
problem common to virtually all ICU patients is the deterioration in nutritional 
and functional status during their stay on ICU. The recent National Institute of 
Clinical Excellence clinical guideline ‘Rehabilitation after Critical Illness’ has 
recommended that research is urgently required to examine muscle mass loss 
in the critically ill along with developing strategies to ameliorate this loss 
(http://www.nice.org.uk/Guidance/CG83, accessed 1 July 2013). 
 
In the United Kingdom, approximately 75,000 patients are discharged alive 
from intensive care units per year, and of these around 68,000 are discharged 
home. Data from ICU follow up clinics (Broomhead and Brett 2002) report 
physical and non-physical difficulties such as depression, anxiety and 
cognitive dysfunction which have a major impact on patients and their families 
as relationships alter and finances become strained. Furthermore, this slow 
non-physical recovery is compounded by a very slow recovery of physical 
strength and functional status. This was best characterised in a well studied 
cohort of patients who survived the acute respiratory distress syndrome 
(ARDS). Muscle weakness was confirmed to be the single greatest 
determinant of outcome and showed that recovery should be measured in 
months to years rather than days to weeks (Herridge et al. 2003). 
 
The consequences of sepsis, trauma and multi-organ failure present a myriad 
of problems for clinicians throughout the patient’s pathway of care long after 
they have been discharged from the ICU. A prolonged stay in hospital and a 
lengthy period of rehabilitation is frequently required (Bolton 2005;Griffiths and 
Jones 2007a). 
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Although muscle loss on ICU is often masked by accumulation of fluid in 
tissues, muscle mass declines at a rapid rate of up to 2% loss per day 
(Gamrin et al. 1997;Griffiths and Jones 1999). For the elderly, who are 
increasingly represented in the intensive care population, this will be 
additional to age related muscle mass loss and will seriously compromise 
recovery to independance. It is known that poor nutrition following admission 
to hospital is linked to increased morbidity and mortality and that there is a link 
between quality of life and nutritional status (Hickson and Frost 2004).  
 
1. 1 Muscle mass  
1.1.1 Muscle mass in health 
 
In order to the describe muscle mass decline that critically ill patients typically 
experience, a brief look at muscle mass in health is required. Structural 
proteins in muscle consist of actin and myosin. In health there is a fine 
balance between muscle protein synthesis and breakdown. A healthy 70kg 
adult male may have approximately 12kg of body protein of which 220g would 
consist of free amino acids. Skeletal muscle contains around 7kg of protein 
which makes up around 400-450g/kg of total body mass (Wagenmakers 
1999). Muscle contains the majority of the free amino acid pool, estimated to 
be over 60% (Rooyackers and Nair 1997;Wagenmakers 1999). Anabolic 
stimuli in healthy adults include ingestion of protein or amino acids in 
combination with resistance exercise (Cermak et al. 2012;Cermak et al. 
2013;Dickinson and Rasmussen 2010). 
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1.1.2 Muscle mass in critical illness 
 
Skeletal muscle provides an important fuel source during times of 
physiological stress when muscle is broken down into amino acids and 
converted via gluconeogenesis in the liver to glucose, an essential fuel for the 
brain. Skeletal muscle also provides vital amino acid precursors for immune 
function (antibodies and acute phase proteins) as well as wound healing and 
tissue repair during trauma and severe infections. Muscle mass loss on ICU is 
of immense concern with patients losing between 1-2% of lean body mass per 
day (Gamrin 1997;Plank and Hill 2000a;Reid et al. 2004). 
 
Muscle wasting and weakness was observed one year after discharge from 
ICU in a cohort of patients who survived the acute respiratory distress 
syndrome (Herridge 2003). Physical disability has been identified up to five 
years after ICU admission for severe lung injury with exercise capacity only 
reaching 76% of the predicted test distance for the 6-minute walk test 
(Herridge 2011b). Muscle weakness and wasting are important contributors to 
the longer term physical impairment experienced by these patients (Bienvenu 
et al. 2012;Herridge et al. 2011). This wasting is an aggressive and multi-
factorial phenomenon with the following factors thought to contribute to the 
process: the neuro-endocrine response to trauma and critical illness; 
corticosteroid use; critical illness myopathy; nerve and neuromuscular junction 
changes; polyneuropathy; disuse atrophy (prolonged sedation and paralysis) 
and inadequate nutrition (Anzueto 1999;Stevens et al. 2007). However, 
despite energetic nutritional support, muscle wasting still occurs in the 
critically ill (Reid 2004). Preservation of muscle mass is clearly crucial for 
patients’ survival and their subsequent rehabilitation, however optimal 
nutritional support during critical illness has yet to be defined.  
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1.2 Skeletal muscle mass control 
 
Skeletal muscle mass is controlled by myostatin and various signalling 
pathways which regulate between protein synthesis and breakdown 
(Jespersen et al. 2011). Myostatin is a protein that inhibits muscle 
differentiation and growth. It is produced mainly in skeletal muscle cells and 
acts on muscle tissue. Myostatin pathways along with the serine/threonine 
protein kinase (Akt)-dependent signalling pathways, mammalian target of 
rapamycin (mTOR), glucose synthase kinase 3β (GSK3β) and the forkhead 
box O (FoxO) pathways control skeletal muscle mass (Jespersen 
2011;McCarthy and Esser 2010;Puthucheary et al. 2010b). The exact 
mechanisms and interactions of skeletal muscle mass regulation pathways in 
the critically ill remain unclear. 
The Akt pathways relate to muscle protein synthesis and are thought to be 
activated by both insulin and insulin-like growth factor 1 (IGF-1) (Jespersen 
2011). The mTOR pathway is activated by Akt and the GSK3β pathway is 
inhibited by Akt. mTOR appears to be a major regulator of muscle protein 
synthesis in response to growth factors and nutrients, such as essential amino 
acids (EAA) (Rennie, Jespersen 2011). 
 
1.2.1 Skeletal muscle breakdown and synthesis 
 
In healthy subjects undergoing bed rest it has been shown that the balance 
between muscle protein synthesis (MPS) and muscle protein breakdown 
(MPB) is changed mostly by a reduction in synthesis (Ferrando et al. 2006a). 
Muscle protein breakdown occurs in a stressed state due to increased acute 
phase protein synthesis in the liver and synthesis of proteins involved with 
immune function and wound healing. Skeletal muscle is commonly referred to 
as a metabolic reserve for protein metabolism (Ferrando and Wolfe 2007). 
Studies focusing on MPS and MPB in critical care are rare, investigators are 
nonetheless attempting to understand the pathophysiological changes in 
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order to develop new interventions that might facilitate rehabilitation 
(Puthucheary et al. 2010a;Puthucheary et al. 2012).  
 
Muscle protein breakdown is accelerated in the critically ill, however it remains 
unclear whether muscle protein synthesis would be decreased or similar to 
that of healthy subjects. Recent investigation using protein turnover studies 
and muscle biopsies showed that critically ill patients had normal protein 
synthesis rates and that the breakdown was markedly increased (Klaude et al. 
2012). Klaude et al showed that ICU patients had a 160% higher MPB 
compared to control subjects (healthy volunteers) and that there was no 
differences seen in MPS between ICU and control subjects when protein 
turnover was assessed (Klaude 2012) however length of stay ranged between 
1-18 days and a wide range of pathology was included in this study.  
 
Muscle mass loss on ICU, although multi-factorial and complex has largely 
been attributed to the following factors (see Figure1-1): Immobility or disuse 
atrophy (Chambers et al. 2009), age related breakdown (Attaix et al. 2005), 
the role of various pro-inflammatory cytokines (Winkelman 2010) and 
hormonal effects (Soeters and Grimble 2009). Figure 1-1 illustrates some of 
the factors thought to contribute to muscle breakdown in the critically ill along 
with potential strategies to stimulate muscle protein synthesis in these 
individuals, some having failed to show direct benefit. 
 
Each of the factors thought to contribute to the process of muscle protein 
breakdown in critical illness will furthermore be discussed in Section 1.3. 
Similarly, factors that may contribute to muscle protein synthesis in the 
critically ill are discussed in Section 1.6. See Figure 1-1. 
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Figure 1-1: Muscle mass on the Intensive Care Unit: Factors involved in 
breakdown and potential strategies for muscle building 
[The dotted arrow denotes potential or previously attempted strategies to influence 
muscle synthesis] 
(BCAA: branched-chain amino acid; EAA: essential amino acid; GH: growth hormone; GI: 
gastrointestinal; HIF-1α: hypoxia inducible factor 1 alpha; HMB: β-hydroxy β-methylbutarate; 
mTOR: mammalian target of rapamycin). 
 
 
1.3 Skeletal muscle breakdown 
1.3.1 The stress response 
 
The metabolic response to insult or injury is generally characterised by 
hypermetabolism, hypercatabolism, persistent muscle wasting and 
hyperglycaemia. This complex interaction involves numerous mediators, 
hormones and cytokines. The familiar description by Sir David Cuthbertson, 
the so called ‘Ebb and Flow Phase’ post traumatic stress, with initial decrease 
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in metabolism followed by increased metabolic activity (Cuthbertson 
1970;Cuthbertson and Tilstone 1969) has subsequently been replaced by 
newer definitions. The ‘Ebb’ phase was largely conducted on animal models 
and the ‘Flow’ phase, characterised by increased energy expenditure, insulin 
resistance and muscle catabolism (Griffiths et al. 1999) was deemed to be 
overestimating metabolic rates (Desborough 2000). More recent  definitions 
include the Systemic Inflammatory Response Syndrome (SIRS), the 
Compensatory Anti-Inflammatory Response Syndrome (CARS) and Multi-
organ Dysfunction Syndrome (MODS) (Bone 1992) which may themselves 
soon be replaced by more modern definitions based on detailed phenotype. 
Most clinicians would now agree to a definition which refers to an initial acute 
phase of the stress response which is followed by a more established phase 
of critical illness if organ failure persists (Cuesta and Singer 2012). 
 
1.3.2 Neuro-endocrine response 
 
The neuro-endocrine response to stress is activated by the hypothalamic-
pituitary-adrenal (HPA) axis (Marik and Zaloga 2002). The anterior pituitary 
releases adreno-corticotrophic hormone (ACTH) and growth hormone, the 
posterior pituitary releases vasopressin, the adrenal cortex releases cortisol 
and aldosterone and in the pancreas glucagon is released as a direct result of 
the presence of adrenaline (Desborough 2000). Adrenaline stimulates 
glucagon, mobilises liver substrates (glycogen is converted into glucose), 
oxidises triglycerides into free fatty acids and converts muscle glucagon into 
pyruvate and lactate which is converted into glucose in the liver (Frayn 1986).  
 
Insulin resistance occurs due to higher levels of circulating growth hormone, 
cortisol and fatty acids which may inhibit downstream signalling resulting in 
raised blood glucose levels (Marik and Raghavan 2004;Muntoni and Muntoni 
2011). 
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Hormonal effects on protein metabolism post sepsis or injury are summarised 
in Table 1-1.  Of particular interest are the catecholamines and 
glucocorticoids released after severe infection or injury which are important 
hormonal mediators resulting in proteolysis (Hasselgren 2000;Soeters 2009). 
Testosterone has been noted to be reduced in trauma patients potentially 
further exacerbating lean body mass loss (Ferrando 2000).  
 
Table 1-1: Hormonal effect on protein metabolism 
Hormone Effect on protein metabolism 
Insulin ↓ protein catabolism, ⁭ amino acid uptake 
Insulin-like growth factors Stimulates protein synthesis 
Growth Hormone Stimulates protein synthesis 
Testosterone Stimulates protein synthesis 
Glucagon Stimulates amino acid catabolism 
Glucocorticoids Stimulates protein catabolism 
Noradrenaline/Adrenaline Stimulates amino acid catabolism 
Thyroid Hormones Stimulates protein catabolism 
(Adapted from Awad S et al, Short term starvation and mitochondrial dysfunction, 
(Awad et al. 2009) 
 
1.3.3 Cytokines and muscle breakdown 
 
Cytokine release may contribute to skeletal muscle breakdown. Cytokines are 
small proteins that signal between cells to activate inflammation and to 
respond to infections. The metabolic response to stress is a complex 
interaction involving numerous mediators, hormones and cytokines. Cytokines 
released during trauma and critical illness regulate tissue repair and immune 
response (Nicolaidis 2002). Although the inflammatory response is crucial for 
survival the accelerated muscle breakdown is clearly deleterious to patients. 
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Interleukin-1, IL-6 and TNF, as inflammatory cytokines, are directly linked to 
muscle breakdown (Frost and Lang 2005;Hasselgren 2000;Soeters 
2009;Wagenmakers 2001).  
 
Interleukin-1, a pro-inflammatory cytokine linked to a systemic inflammatory 
reaction, it causes fever, acute-phase protein synthesis and lymphocyte 
reaction in response to an infection. Interleukin-1β is produced by muscle 
(Winkelman 2004).  
 
Interleukin-6, a pro- and anti-inflammatory cytokine which promotes acute-
phase protein synthesis, has been linked to risk of higher mortality in trauma 
and septic patients (Callahan and Supinski 2009). Interleukin-6 from 
inflammatory cells also promotes myocyte infiltration with inflammatory factors 
(prostaglandins) which leads to protein breakdown (Winkelman 2004).  
 
Interleukin-10 is an anti-inflammatory cytokine which, although not linked to 
muscle damage, may inhibit levels IL-1, IL-6 and TNF. Interleukin-10 inhibits 
pro-inflammatory cytokine production from natural killer cells, neutrophils, 
monocytes and macrophages (Winkelman 2004). 
 
Tumour necrosis factor, another pro-inflammatory cytokine, responds early to 
infection. Tumour necrosis factor alpha receptors are expressed by skeletal 
muscle. When TNFα binds to the receptors proteolysis takes place along with 
a delay of muscle repair. Overexpression of TNFα results in skeletal 
myopathy and muscle wasting (Winkelman 2004).  
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1.3.4 Signalling pathways regulating muscle breakdown 
 
Various catabolic pathways have been implicated in the control of skeletal 
muscle breakdown or atrophy. Three main catabolic pathways include the 
ubiquitin-proteosome pathway (UPP), the lysosomal pathway and the calcium-
dependent calpain pathway as well as caspases which have been implicated 
with programmed cell death (Attaix 2005;Attaix et al. 2008;Jespersen 
2011;McCarthy 2010).  
The regulation of these pathways is highly intricate and remains largely 
unknown in humans. In an attempt to understand the complex pathways I 
designed a simplified schematic representation, Figure 1-2:  
 
Figure 1-2: Simplified diagram of catabolic pathways involved with muscle 
atrophy.  
IGF-1: Insulin-like growth factor 1; IL-6: Interleukin 6; TGF-β: transforming growth factor beta; 
TNF-α: Tumor necrosis factor alpha; ROS: Reactive oxygen species; Akt: Protein kinase B; 
FoxO: Forkhead Box O pathway; Nf-κB: Nuclear factor kappa-B; MuRF-1: Muscle-specific 
Ring Finger-1; Mafbx: Muscle atrophy F-box protein. 
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Proteolytic pathways, along with protein kinases and atrogenes are all linked 
to muscle atrophy. Most of the studies relating to these pathways, the protein 
kinase (Akt) and atrogenes - Muscle-specific Ring Finger-1 (MuRF-1) and 
Muscle atrophy F-box protein (Mafbx) - were performed in cell studies or 
animal models (Bodine et al. 2001;Frost et al. 2007). 
Akt, the serine/threonine protein kinase, is implicated in both muscle synthesis 
(via the mTOR pathway) and muscle atrophy via the Forkhead Box O (FoxO) 
pathway (de et al. 2011). FoxO is inhibited by activation or phosphorylation of 
Akt, and FoxO regulates both the atrogenes MuRF1 and Mafbx, see Figure 1-
2 (Constantin et al. 2011;Jespersen 2011;McCarthy 2010). 
 
Nuclear factor kappa-B (Nf-κB) is a group of proteins involved with immune 
function and inflammation. The Nf-κB pathway (stimulated by cytokines or 
hypoxia) activates MuRF-1 and is thereby linked to muscle atrophy (de 
2011;McCarthy 2010).  
 
The calpain proteolytic system was identified for the first time in a septic 
animal model where calpain-1 release resulted in respiratory muscle wasting 
(Supinski and Callahan 2006). 
 
Myostatin (or transforming growth factor-β, TGF-β) again was identified in 
animal models, TGF-β inhibits muscle growth and phosphorylation of Akt. This 
allows FoxO activity to increase along with the downstream atrogenes, MuRF-
1 and Mafbx (Figure 1-2), which is thought to lead to muscle breakdown 
(Constantin 2011;Jespersen 2011;McCarthy 2010). Myostatin also appears to 
inhibit the mTOR pathway linked to muscle protein synthesis (Trendelenburg 
et al. 2009).  
Constatin et al demonstrated for the first time from muscle samples from ICU 
patients how catabolic pathways were affected:  
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a) Muscle protein synthesis was reduced in ICU patients compared to control 
subjects through reduced activation (phosphorylation) of signalling proteins. 
b) Protein breakdown pathways UPP and cathepsin L were upregulated at 
both the protein expression and mRNA level, thereby activating muscle 
protein breakdown. 
c) Both myostatin protein expression and mRNA expression were significantly 
higher in ICU patients than control subjects (8.5-fold, p<0.001 for protein 
expression and 3-fold, p<0.01 for mRNA) which the authors felt was directly 
linked to the reduced protein synthesis signal observed from the mTOR 
pathway (Constantin 2011). 
 
Jespersen et al (2011) however observed the reverse: mRNA levels of 
myostatin were lower in ICU patients than controls (p<0.001); akt-mTOR 
signalling relating to muscle protein synthesis was higher than anticipated in 
ICU patients and the FoXO and atrogene pathways were lower in ICU patients 
than expected (Jespersen 2011). Eight patients were biopsied between days 
1-3 on ICU and four patients between days 7-17. 
 
The conflicting findings from the above two novel human studies emphasises 
the complexity of these pathways and highlights our poor understanding of 
catabolic pathways at molecular level. The heterogeneity of the ICU patients 
studied may also have contributed to conflicting findings. 
 
1.3.5 Hypoxia, inflammation and wasting 
 
A further factor proposed to contribute to skeletal muscle breakdown is 
hypoxia. Hypoxia induces inflammation and cytokine release may occur due 
to hypoxia alone, not necessarily due to an actual infection (Eltzschig and 
Carmeliet 2011). In environmental hypoxia, such as the high altitude 
environment, decreased muscle fibre mitochondria content has been 
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observed and the hypoxia-inducible factor 1 (HIF-1) and it’s subunit HIF-1α 
has been identified as key factors that regulate gene expression during 
hypoxia (Hoppeler et al. 2003;Mounier et al. 2010;Vigano et al. 2008). 
In short, proposed skeletal muscle wasting mechanisms due to hypoxia 
include: HIF-1α activation of the NF-κB catabolic pathway; HIF-1α inhibition of 
Akt activation and hypoxia reducing mTOR’s capacity for protein synthesis (de 
2011). See Figure 1-3 below: 
 
 
Figure 1-3: Schematic overview of potential direct or indirect hypoxia signals 
with respect to the control of muscle protein turnover.  
(Printed with permission from De Theije et al, Hypoxia and muscle maintenance 
regulation: implications for chronic respiratory disease’ published in Current Opinion 
in Clinical Nutrition and Metabolic Care 2011, 14:548-553 and from “Wolters Kluwer 
Health”, see Appendix). 
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1.3.6 Reactive oxygen species (ROS) and nitric oxide (NO) 
 
Muscle breakdown may in part be caused by oxidative stress (NO and ROS) 
by activation of the nuclear factor kappa Beta and forkhead Box O signalling 
pathways (Dodd et al. 2010;McCarthy 2010), Figure 1-2. These assumptions 
have again only been studied in cell and animal models, human studies are 
still lacking. 
 
1.3.7 Age 
 
Increasing age results in skeletal muscle wasting. Sarcopenia or age related 
muscle wasting is characterised by diminished anabolic signals and promotion 
of catabolic signals, such as pro-inflammatory cytokines. The prevalence of 
sarcopenia has been described as exceeding 40% muscle mass loss in 
healthy subjects over 80 years of age and over 25% muscle loss in 75-80 year 
olds (Baumgartner et al. 1998). Sarcopenia has been attributed to decreased 
physical activity, poor nutrition, increased cytokine release, oxidative stress, 
mitochondrial dysfunction and deranged growth hormone levels with older age 
(Carmeli et al. 2002;Kamel 2003;Morley and Baumgartner 2004;Roubenoff 
2000). With aging muscle protein synthesis is reduced (Attaix 
2005;Rooyackers et al. 1996) however muscle protein breakdown in the 
elderly is not as clearly understood due to methodological issues with earlier 
studies (Attaix et al. 1998;Mitch and Goldberg 1996). With the elderly 
representing a large proportion of our population on intensive care, muscle 
wasting due to both sarcopenia and critical illness per se can be expected. 
 
1.3.8 Drugs 
 
Many medications given to critically ill patients have been implicated in muscle 
wasting of these patients. Neuro-muscular blocking agents (NMBA) were 
initially thought to contribute to ICU acquired weakness (ICUAW) and 
potentially muscle wasting, however previous studies failed to include full 
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neurological examinations making causal relationships hard to establish 
(Stevens et al. 2009). A recent study suggests that there were no differences 
seen in ICUAW between patients in the NMBA group compared to the group 
not receiving this agent (Papazian et al. 2010). An integrative review 
(Puthucheary 2012) confirms no causal relationship. 
  
Corticosteroids may however be linked to muscle wasting (Hasselgren et al. 
2010) and steroids have certainly been associated with the development of 
ICU acquired weakness (Amaya-Villar et al. 2005;De et al. 2002;Herridge 
2003). In animal studies low dose chronic methylprednisolone administration 
resulted in reduced diaphragm function in rats over a 6 month study period 
(van Balkom et al. 1997) and acute high-dose corticosteroid administration 
reduced diaphragmatic function in rabbits whereas pulse-dose administration 
only caused marginal reduction in function (Sassoon et al. 2008). Urinary 
nitrogen excretion as a surrogate measure of protein breakdown was 
increased by 33% in head-injured patients receiving steroid treatment for 5 
days compared to those patients without steroid treatment (Deutschman et al. 
1987).  
 
1.3.9 Immobility and disuse atrophy 
 
Immobility and disuse of muscle of critically ill patients contribute to skeletal 
muscle breakdown. Prolonged bed rest reduces whole body protein synthesis 
along with muscle protein synthesis significantly. Muscle protein synthesis 
appears to be reduced rather than breakdown of muscle playing a major 
contributory role (Ferrando 2006a;Rennie et al. 2010).  
In healthy volunteers undergoing 14 days of bed rest muscle protein synthesis 
was reduced by 50% (p<0.03) along with significant reductions observed in 
lean body mass (p<0.05) and nitrogen balance (p<0.03) (Ferrando et al. 
1996). Bed rest studies as a model for disuse atrophy of critical illness clearly 
do not take into account the severity of injury or infection, nor does it reflect 
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the hormonal and cytokine response experienced by critically ill patients. 
Subjects undergoing bed rest with additional cortisol infused to simulate a 
stress response displayed lower rates of muscle protein synthesis than the 
group receiving cortisol and EAA supplementation (Paddon-Jones et al. 
2003a). In experimental models where space flight is simulated or limbs are 
immobilised, muscle wasting has been recorded as between 1.5-2% per day 
for the first 3 weeks post bed rest (Adams et al. 2003); with a reduction in 
muscle size, strength is also affected.  
 
In a 5 week bed rest study, gastrocnemius and soleus muscles in the calf 
decreased by 12% in size as measured by MRI with 26% reduction in plantar 
flexors observed (Leblanc et al. 1988). After 6 weeks of bed rest knee 
extensor cross sectional area was reduced by 14% and strength by 25-30% 
(Berg et al. 1997). Resistance exercise on the other hand preserved muscle 
strength after 14 days of bed rest (Bamman et al. 1998).  
 
In rats undergoing 28 day hind limb suspension, proteolysis was thought to be 
increased by oxidative stress (Lawler et al. 2003). However in humans 
undergoing a 14 day bed rest period, markers of oxidative stress did not 
change at all (Glover et al. 2010). Few changes occurred in markers of 
muscle breakdown in this same human study; quadriceps cross sectional area 
was significantly reduced by 5.7% (p<0.0001) after the 14 day bed rest.  
However, the ubiquitin-protein markers were not significantly different after the 
14 days of immobility, despite a transient increase at day 2 (Glover 2010).  
 
In contrast to the Glover study, Jones et al assessed candidate genes 
associated with atrophy and anabolism during 2 weeks of immobilisation 
followed by 6 weeks of exercise rehabilitation and identified increases in 
proteolytic pathways (Jones et al. 2004). Quadriceps lean mass was 
significantly reduced after 2 weeks (4.7%, p<0.001) as was isometric strength 
(27% reduction, p<0.001). The ubiquitin-proteosome pathway showed 
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increased gene expression for the 20S proteosome α7-subunit by 26% 
(p<0.05), MAFbx by 62% (p<0.01) and GSK3-α by 28% (p<0.01). There was a 
reduction in muscle specific calpain 3 by 36%, (p<0.001) compared with basal 
results (Jones 2004). Remarkably, as soon as the immobilisation period 
ended and the polyester casts were removed from subjects they were asked 
to perform a series of maximal intensity contractions and muscle biopsies 
were then repeated. There were significant reductions seen in atrogenes 
MAFbx (39%, p<0.01) and MuRF1 (33%, p<0.05) as well as a significant 
reduction in myostatin expression (48%, p<0.05). Expression of calpain 1 was 
significantly increased (32%, p<0.05) as was calpain 2 (109%, p<0.001). 
Suppression of muscle breakdown and stimulation of muscle hypertrophy and 
remodelling was therefore observed (Jones 2004). After 6 weeks of exercise 
rehabilitation leg lean mass and leg strength returned to baseline levels 
(Jones 2004). 
Although some studies promote higher protein and energy intakes to 
counteract losses incurred during critical illness from sepsis, injury and disuse 
(Ferrando et al. 2010;Mansoor et al. 2007;Paddon-Jones et al. 2004;Stein et 
al. 1999), others have found that positive energy balance during 35 days of 
bed rest was associated with greater muscle atrophy (Biolo et al. 2008). 
Medical management of the critically ill has fortunately progressed such that 
patients are kept lightly sedated whilst sitting out of bed in a chair, whilst being 
mechanically ventilated, is encouraged (Bailey et al. 2009;Kress 
2009;Schweickert et al. 2009). Some of the effects experienced from 
prolonged bed rest may therefore hopefully be reduced. 
 
1.3.10 Nutritional problems on ICU 
 
Poor nutrition on the ICU may contribute to skeletal muscle breakdown. It has 
been well documented that patients on ICU suffer inadequate feeding (Figure 
1-1) mainly secondary to GI problems, ileus or large gastric residual volumes, 
sedative use, delays with initiation of feeding or interruption to feeding 
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(Heyland et al. 2010;McClave et al. 1999;Montejo 1999;Reid 2006;Wandrag 
et al. 2011). Negative energy balance has been associated with increased 
infectious complications (Villet et al. 2005) and may also prolong ICU stay 
(Dvir et al. 2006). Patients tend to lose a significant amount of weight during 
their ICU stay (Kvale et al. 2003) and lean depletion makes up a large 
proportion of the overall weight loss (Plank et al. 1998;Plank and Hill 
2003;Reid 2004). Patients with multi-organ failure displayed protein 
breakdown that by far exceeded any synthesis of protein (Arnold et al. 1993).  
 
Nutritional problems on the ICU are numerous, poor nutrition may exacerbate 
muscle loss. Monitoring of the nutritional status in this environment is 
challenging. Few validated techniques to assess change in body composition 
in this population are available due to fluid accumulation and large daily fluid 
fluctuation. Equally, performing body composition assessments via computed 
tomography (CT) or dual energy X-ray absorptiometry (DEXA) scanning is not 
feasible either in the critically ill. 
 
Nutritional monitoring of these patients is not the only challenge, optimum 
nutrition support is yet to be defined. The amount of calories critically ill 
patients should receive to improve outcome remains a topic of much debate 
(Heyland et al. 2011a;Stapleton et al. 2007). It is known that both under-and 
overfeeding may be harmful (Reid 2006), however the amount of calories that 
might be deemed ‘adequate’ is less evident. Patients appear to have 
improved outcomes when caloric intake is matched to measured energy 
expenditure, such as lower hospital mortality observed in a group fed to 
measured energy expenditure (Singer et al. 2011). Indirect calorimetry is the 
gold standard method for detecting energy expenditure in the ICU, however 
old equipment, such as the Deltatrac™, is no longer manufactured or serviced 
by industry. Modern indirect calorimeters have failed to validate against the 
Deltatrac™ (Sundstrom et al. 2012). For most, access to any measure of 
indirect calorimetry is near impossible and clinicians therefore rely on 
predictive equations to estimate energy expenditure. Predictive equations are 
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known to be flawed, they agree poorly to continuous measurement of energy 
expenditure with the further increased risk of under- and over feeding patients 
(Reid 2007).  
 
Most commonly permissive hypocaloric feeding is advocated in the obese 
critically ill patient (Dickerson et al. 2002;Dickerson 2005;Dickerson 2011), 
although some promote this practice in the non-obese (Arabi et al. 2010).  
Others suggest that hypocaloric feeding correlates with increased infectious 
complications with the further difficulty that negative energy balances may be 
near impossible to reverse during the remainder of the patient’s critical care 
stay (Villet 2005). The authors of a landmark observational study performed in 
2772 critically ill patients oppose the hypocaloric feeding principle completely. 
In this study patients received an average of 1034kcal/day and an average of 
47g protein per day. An increase of 1000kcal/day was associated with a 
reduced mortality, with 60 day odds ratio for mortality of 0.76 (95% CI 0.61-
0.95), p=0.014. Additionally, a significant increase in the number of ventilator 
free days was observed when increasing energy intakes to 1000kcal/day, 3.5 
ventilator free days (95% CI 1.2-5.9), p=0.03 (Alberda et al. 2009). This effect 
was only observed in patients with a BMI of < 25 and ≥ 35kg/m2. 
 
Nutritional problems on the ICU extend to assessment and monitoring of 
protein requirements in the critically ill, with limited validated techniques 
available in this population (McClave et al. 2009). Similarly, robust techniques 
to determine protein turnover, such as stable isotope studies, are intricate, 
costly and mostly reserved for the research arena.  
Limited available evidence and poor quality of studies assessing protein 
requirements make formulation of clinical guidelines unachievable (Hoffer and 
Bistrian 2012). Guidelines are often based on ‘best practice’ or expert opinion 
rather than a robust evidence base. The amount, type and dose of protein or 
amino acid to optimise clinical outcomes remain uncertain (Plank 2013). The 
American Society of Critical Care Medicine along with the American Society of 
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Parenteral and Enteral nutrition advocate protein intakes of 1.2 - 2.0g/kg per 
day (McClave 2009) whilst the European Society of Parenteral and Enteral 
Nutrition give no specific recommendation due to lack of evidence base 
(Kreymann et al. 2006). Some suggest that ICU patients receive only half of 
their protein requirement during their ICU stay due to limitations to clinician’s 
awareness of protein requirements and protein metabolism during critical 
illness (Hoffer 2012). Guidelines generally point towards giving patients 1.2 - 
2.0g/kg/day with a recent study suggesting intakes should exceed 2g/kg/d to 
improve nitrogen balance (Dickerson et al. 2012).  
 
Allingstrup et al studied 113 severely ill ICU patients and concluded that 
higher protein and amino acid provision, not energy provision, was associated 
with lower mortality (Allingstrup et al. 2012). This study was observational in 
design and prospective randomised controlled trials would need to confirm 
this finding, it does however seem that after decades of focus on energy 
provision and energy balance in critical care the focus is shifting more towards 
adequate protein provision and protein balance.  
 
An area of ICU nutrition that remains highly controversial is that of 
immunonutrition, where nutrients are added to artificial nutrition with the aim of 
having immune modulating effects. Popular immunonutrients over the last few 
decades include arginine (Beale et al. 1999;Beale et al. 2008), glutamine 
(Andrews and Griffiths 2002;Griffiths 2001;Griffiths et al. 2002), omega 3 fatty 
acids (Gadek et al. 1999;Pontes-Arruda et al. 2006;Pontes-Arruda et al. 
2011), nucleotides and selenium to name a few (Marik and Zaloga 2008). 
Glutamine was previously advocated in ICU nutrition guidelines in intravenous 
format (Heyland et al. 2003;Heyland et al. 2004;Kreymann 2006;McClave 
2009) as it showed decreased infectious complications (Houdijk et al. 1999), 
decreased hospital length of stay (Morlion et al. 1996) and improved long term 
survival for ICU patients (Griffiths et al. 1997). Recent studies point towards 
glutamine supplementation making no difference to any of the clinical 
endpoints studied (Andrews et al. 2011;Heyland and Dhaliwal 2013). 
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Additionally supplementation appeared to increase ICU mortality of patients 
with multi-organ failure (Heyland 2013). It seems that the season for 
glutamine supplementation in intensive care has come to an end.  
 
And finally, perhaps as the ‘holy grail’ of nutritional care in the critically ill, a 
notional “nutritional tipping point” (where anabolism is likely to exceed 
catabolism and nutritional therapy can be targeted) has yet to be identified in 
this setting. No current studies suggest that patients become anabolic during 
an ICU stay, current literature suggests that patients remain in a negative 
nitrogen balance. Previous studies have however mainly used nitrogen 
balance only, no studies have used a combination of nutritional and 
inflammatory markers to see if a nutritional tipping point could be identified 
during an ICU stay. If such a tipping point could be identified nutritional 
strategies could be targeted at that point to maximise efforts of supporting 
patients into an anabolic or recovery phase.  
 
1.4 ICU acquired weakness (ICUAW) 
 
Muscle catabolism combined with polyneuromyopathy causes prolonged ICU 
weakness (Vincent and Norrenberg 2009). Single risk factors identified in the 
development of ICUAW include disuse atrophy, sepsis, severity of illness, 
corticosteroid use, hyperglycaemia (Griffiths and Hall 2010), systemic 
inflammation, multi-organ failure and neuromuscular blocking agents (De et al. 
2009;Stevens 2007;Weber-Carstens et al. 2009). Weakness may be caused 
by polyneuropathy, critical illness myopathy or both, often referred to as a 
critical illness neuromyopathy (Latronico et al. 2005;Latronico and Guarneri 
2008;Weber-Carstens 2009).  
 
An expert group defined ICUAW as a clinically observed weakness where no 
other cause other than critical illness would be suspected (Stevens 2007). 
Three further ICUAW subcategories include: 
 42 
 Critical illness polyneuropathy (CIP): ICUAW with electrophysiological 
evidence of axonal polyneuropathy 
 Critical illness myopathy (CIM): ICUAW with electrophysiological and/or 
histological evidence of myopathy 
 Critical illness neuromyopathy (CINM): Electrophysiological and/or 
histological evidence where CIP and CIM  occur simultaneously. 
 
Several limitations hinder the diagnosis of ICUAW, least of all the lack of a 
gold standard to diagnose ICUAW or its subcategories. Clinical assessments 
include neurological examination and manual muscle testing by the Medical 
Research Council (MRC) score which is described further in the methods 
Chapter (Chapter 2). Although the MRC score is simple to perform it requires 
full cooperation of the patient as does grip strength assessment with handgrip 
dynamometry. Poor scores from grip strength assessment may reflect poor 
cognition of patients recently discharged from ICU rather than an absolute 
deterioration in functional status.  
 
Lack of agreement over the general terminology used to decribe or define 
weakness, myopathy and neuropathy in studies limit application of research. 
 
1.5 Critical illness myopathy 
 
Myopathies are likely caused by electrical alterations in the muscle 
(inactivation of sodium channels), microvascular alterations, altered calcium 
homeostasis, activation of proteolytic pathways, catabolic hormones and 
potential glutamine deficiency and antioxidant depletion (Hermans et al. 
2008). Critical illness myopathy can be divided into three subgroups as 
identified by muscle biopsy: diffuse non-necrotising myopathy, acute 
nectrotising myopathy and thick filament myopathy (Hermans et al. 2009b). 
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Neuro-muscular abnormalities are reasonably common with up to 50% of ICU 
patients with sepsis, multi-organ failure or prolonged mechanical ventilation 
affected by this (Stevens 2007). Hermans et al examined interventions 
proposing to prevent critical illness polyneuropathy and critical illness 
myopathy in their systematic review (Hermans et al. 2009a). They concluded 
that intensive insulin therapy reduces the incidence of critical illness 
polyneropathy and/or critical illness polyneuromyopathy. 
Muscle weakness can lead to increased morbidity, duration of mechanical 
ventilation and ICU length of stay (Hough et al. 2009) and was confirmed to 
be the single greatest determinant of outcome - where recovery should be 
measured in months to years rather than days to weeks (Cheung et al. 
2006;Herridge 2003).  
 
Research has clearly demonstrated that patients who survive a period of 
critical illness have persistent muscle weakness and neuromuscular 
dysfunction which could last years after the original insult (Herridge 2003). 
Follow up on a group of survivors of the acute respiratory distress syndrome 
by Herrdige et al has shown limitations to both exercise capacity (six-min walk 
test) and in health-related quality-of-life (HRQL) 1 year after hospital 
discharge (Herridge 2003). The six-minute walk test, although impoved over 
the 12 month period, was still lower than the predicted value for each subject. 
When assessed again at 5 years it was only 76% of predicted distance 
(Herridge 2011a), and recovery appeared to have plateaued. Patients 
reported that muscle wasting and weakness were the main contributory 
factors. Only 49% of these patients returned to work one year after hospital 
discharge due to fatigue and weakness. Although HRQL had improved over 
the 12 month follow up period, scores remained below those of the control 
population for all domains apart from ‘emotional role’ (Herridge 2003). At 5 
year follow up physical component assessment scores were much lower in 
the patient group than an age and sex matched control group, 41 versus 50 
respectively (Herridge 2011a). 
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De Jonghe et al (De et al. 2007) assessed respiratory muscle weakness in 
116 mechanically ventilated patients, in particular the correlation of respiratory 
and limb muscle weakness and the effect thereof on delayed weaning. After 
one week of mechanical ventilation severe respiratory muscle weakness was 
identified and this was associated with limb weakness (measured via the 
Medical Research Council score) and delayed weaning. This was the first 
study to report an association between the reduction of limb strength and 
respiratory muscle weakness and delayed separation from mechanical 
ventilation.  
In a group of patients ventilated for 5 days or longer, Ali et al (Ali et al. 2008a) 
were able to demonstrate that ICUAW (as assessed by MRC sum score and 
handgrip dynamometry) was independently associated with hospital mortality. 
Although morbidity effects had previously been described, this was the first 
study to show a mortality association. 
 
With the level of cooperation required to perform the MRC sum score or 
handgrip dynamometry, assessments are not easily attained in critically ill 
patients or in patients with prolonged neurological impairment. Muscle 
strength testing may therefore be difficult to assess in this context. 
Investigators have moved towards assessment of changes in muscle depth or 
circumference as repeat CT or DEXA scanning may not be practical and can 
be very costly. Ultrasound techniques have been used to determine depth or 
circumference change of skeletal muscle in critically ill patients (Campbell et 
al. 1995;Reid 2004;Seymour et al. 2009). 
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1.6 Muscle protein synthesis 
 
A schematic representation of anabolic pathways linked to muscle protein 
synthesis is seen below, Figure 1-4: 
 
 
Figure 1-4: Simplified diagram of anabolic pathways involved with muscle 
protein synthesis 
IGF-1: Insulin-like growth factor 1; Akt: Protein kinase B; mTOR: mammalian target of 
rapamycin; GSK3β: glycogen synthase kinase 3β; S6k: ribosomal protein S6 kinase; 
4e-BP1: eukaryotic translation initiation factor 4E binding protein 1. 
(The dotted arrows denote that protein turnover had not yet been demonstrated in 
ICU patients). 
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 46 
1.6.1Signalling pathways and proteins regulating protein synthesis 
  
The main pathway implicated in muscle protein synthesis is the Akt/mTOR 
signalling pathway. Akt is activated by insulin and IGF-1. An additional 
pathway involved with muscle protein synthesis includes the Akt/GSK3β 
pathway (Constantin 2011;Jespersen 2011;Lang et al. 2007;McCarthy 2010). 
In the few ICU studies where anabolic pathways have been explored results 
have been surprising. In the first, septic patients displayed significant 
activation of both Akt and mTOR compared to control subjects, suggesting 
protein synthesis was enabled and not suppressed as once thought 
(Jespersen 2011). In the second study, although gene expression for the Akt 
pathway was significantly higher in ICU patients than controls, the 
corresponding proteins were not (Constantin 2011). In this study anabolic 
signalling was reduced in ICU patients compared to control subjects. The 
activated gene expression may perhaps be related to  inhibition of protein 
synthesis. 
Constatin et al and Jespersen et al appear to be the first groups to have 
identified both the anabolic and catabolic signalling pathways in ICU patients 
(Constantin 2011;Jespersen 2011).  
 
1.7 Potential strategies to stimulate muscle protein synthesis 
 
In the following section strategies which were studied in the hope of 
increasing muscle protein synthesis or reducing muscle breakdown in the 
critically ill are described.  
 
1.7.1 Drugs 
 
A number of potential strategies to promote muscle protein synthesis in the 
ICU population have been explored (Figure 1-1), some of which have been 
shown to be harmful e.g. growth hormone administration.  
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Supplemental growth hormone given to critically ill patients increased mortality 
(Takala et al. 1999). Although earlier studies did not demonstrate harm to 
patients any positive effects from growth hormone (reduced nitrogen loss) 
were only very brief (Voerman et al. 1992).  
 
In one study growth hormone combined with insulin-like growth factor 1 and 
glutamine containing parenteral nutrition was sufficient for ICU patients to be 
in an overall positive protein balance (Carroll et al. 2004). Some studies 
suggest improved muscle protein synthesis and reduced lean body mass loss 
with insulin administration (Jeschke et al. 2004;Thomas et al. 2002). High 
dose insulin did not appear to limit protein breakdown (Whyte et al. 2010). 
 
In children with severe burn injury Propranolol (a beta-blocker) and 
Oxandrolone (a testosterone analogue) showed promise in maintaining lean 
body mass and indeed in reversing some of the muscle breakdown 
experienced (Demling 1999;Demling and DeSanti 1997;Herndon et al. 
2001;Herndon et al. 2012;Jeschke et al. 2007). 10mg of Oxandrolone given to 
children with severe burn injury every 12h also decreased hospital length of 
stay (Wolf et al. 2006) and 0.1mg/kg every 12h reduced hospital stay and 
improved lean body mass (Jeschke 2007). 
 
Propranolol seems to be an effective treatment in children with severe burns 
to help reduce muscle wasting as demonstrated by stable isotope studies 
(Herndon 2001). The proposed mechanisms are not clear, however treatment 
reduces heart rate, energy expenditure, thermogenesis and peripheral 
lipolysis as well as increasing protein synthesis (Gauglitz et al. 2011).  
 
Herndon et al studied 25 children with severe burns in which 13 were 
randomised to receive propranolol and 12 remained untreated as control 
subjects (Herndon 2001). Propranolol treatment decreased energy 
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expenditure, 1321 (SE: 173) kcal in the treatment group versus 1670 (SE: 
221) kcal, p<0.001 in the control group. Treatment furthermore impoved 
protein turnover kinetics and lean mass loss, 9% in control patients and 1% in 
the Propranolol group, (p=0.003). Beta-blockade appeared to decrease 
catecholamine activity which in turn might explain the improvements observed 
in protein kinetics.  
Jeschke et al studied 235 children with severe burn injury and randomised 
them (4:1) to standard burn care (n=190) or Oxandrolone in addition to 
standard burn care (n=45) (Jeschke 2007). Oxandrolone treated patients had 
a significantly shorter ICU stay compared to control subjects, 0.56 (SEM:0.02) 
versus 0.48 (SEM:0.02) day/% (p<0.05) when length of stay was normalised 
to total body surface burn area. There were no significant differences between 
groups for REE assessments. Control patients lost between 9-10% lean body 
mass during the study period whilst Oxandrolone treated patients 
demonstrated an increase in lean body mass by 8% (p<0.05). Mean muscle 
strength, although decreased in both groups, was significantly higher in the 
treated group than in control patients, 55 Newton Meter versus 33 Newton 
meter (p<0.05). Oxandrolone treatment therefore appeared to reverse 
catabolism in children suffering from severe burns. 
No studies were found where Propranolol treatment were given to adult 
critically ill patients to assess changes in lean body mass or protein kinetics. 
Anabolic steroids such as testosterone do not seem to have a role in 
preventing or treating muscle breakdown in the critically ill (Chang et al. 
1998;Gauglitz 2011;Spratt 2001).  
 
1.7.2 Dietary manipulation 
 
The role that amino acid supplementation may have in promoting muscle 
protein synthesis in the critically ill requires further investigation. Numerous 
protein and amino acid preparations have been studied over the past decades 
with varying levels of success. Historically when branched-chain amino acids 
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(BCAA) were studied in the ICU population, studies often failed to address 
baseline nutrition. Furthermore the ratio of BCAA (valine: leucine: isoleucine) 
of 1:1:1 used now appears sub-optimal (Cynober and Harris 2006).  
Interestingly when plasma levels of amino acids were assessed, total plasma 
amino acids and plasma EAA levels were not different between ICU patients 
and controls, however both leucine and valine levels were lower, 22% 
(p=0.08) and 21% (p<0.05) repectively (Jespersen 2011). 
 
Protein losses were halved when trauma and sepsis patients’ protein intake 
increased from 0.9 to 1.2g of protein/kg/day (Ishibashi et al. 1998). No 
improvements were found beyond this amount which could indicate that the 
quality of nitrogen supply warrant further investigation. Enteral 
supplementation of the amino acids cysteine, serine, threonine and aspartate 
have been shown to partially restore muscle protein synthesis in polytrauma 
patients on ICU (Mansoor 2007) and a derivative of the amino acid leucine, 
Beta-hydroxy-B-Methylbutarate (HMB), has shown improved nitrogen balance 
in ICU trauma patients (Kuhls et al. 2007).  
 
Essential amino acid (EAA) supplementation appears to provide a potent 
anabolic stimulus and improved muscle protein anabolism after a cortisol 
infusion was given to healthy subjects to simulate a stress response. This 
form of supplementation may help to minimise muscle loss following 
debilitating injury (Paddon-Jones et al. 2003b). The EAA supplement was 
created to mimic the proportion of EAA found in muscle since it was thought 
that this would stimulate muscle protein synthesis more than normal food or 
whole protein. EAA supplementation showed an increase in muscle protein 
synthesis and with repeated stimulation this might be translated into 
maintenance of muscle mass (Ferrando et al. 2006b). The branched-chain 
amino acid leucine in particular is known to promote muscle protein synthesis 
by stimulating the mTOR signalling pathway (Rennie et al. 2006). A metabolite 
of leucine, beta-hydroxy-beta-methylbutyrate (HMB), has shown some 
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promise in restoring lean body mass in cachectic patients (Clark et al. 
2000;May et al. 2002). 
Four ICU supplementation studies focusing solely on enteral amino acid and 
amino acid metabolites in the critically ill have been identified to assess what 
effect supplementation may have on muscle wasting. This was conducted as 
part of a systematic review I performed (not published yet) where study quality 
was assessed following GRADE methodology (Atkins et al. 2004). One study 
was classed as a high quality study, two as moderate quality and one as low 
quality,  Table 1-2.  
 
High quality study 
Kuhls et al studied 100 trauma ICU patients comparing HMB supplementation 
(3g HMB), HMB with additional arginine and glutamine (HMB+; 3g HMB, 14g 
L-arginine, 14g L-glutamine) or an iso-caloric, iso-nitrogenous placebo product 
(Kuhls 2007). The study aim was to assess the effect on nitrogen balance and 
muscle breakdown. The findings indicate that nitrogen balance improved with 
HMB alone. The mean nitrogen balance was -9, -10.9 and -6.5g/day for the 
control, HMB+, and HMB groups respectively (p=0.05). Interestingly the 
HMB+ group (with additional arginine and glutamine in the formula) appeared 
to remain in a more negative nitrogen balance throughout the study, 
suggesting a possible detriment to added arginine or glutamine. The 3-MH 
and urinary nitrogen results suggest that supplementation did not affect 
muscle breakdown in any group. The main significant effect from HMB 
compared to both control and HMB+ patients appeared to be in the positive 
nitrogen balance observed over the 14 days study period,  -9, -10.9 and -
6.5g/day for the control, HMB+, and HMB groups respectively (p=0.05). There 
were no significant differences between groups for mortality, 28 day antibiotic 
use, inflammatory markers, hospital and ICU length of stay, ventilator days 
and number of new infections. This was a well conducted study which 
followed a randomised, double-blinded and placebo-controlled design. The 
authors provided baseline nutrition at 25kcal/kg and 1.5g protein/kg) via 
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standard enteral feeding with protein powder additions for patients with higher 
protein requirements.  
However, the study did have some important limitations. Although a sample 
size of 100 was reported, only data for 72 patients were analysed, leading to a 
potential type II error. Twenty-eight subjects were excluded from statistical 
analysis as they did not meet 50% compliance for supplementation. 
Additionally 3-MH was used as a sole marker for muscle proteolysis despite 
some of its known limitations as a biomarker (i.e. not a sensitive marker of 
specific tissue pools), whilst pre-albumin was used as a surrogate for protein 
synthesis. Furthermore, it was not clear whether urinary nitrogen was 
measured in the laboratory or calculated by formula using urinary urea. 
Despite the limitations HMB supplementation appears to be a promising 
dietary supplement to improve nitrogen balance in severely injured trauma 
patients, and the addition of arginine and/or glutamine appears to neutralise 
any benefit of HMB alone.   
 
Moderate quality studies 
Twenty eight ICU patients were given EAA (containing 6 times the amount of 
glutamine that was present in the control formula) or non-EAA supplements 
with the aim of comparing plasma amino acid differences, nitrogen balance 
was also assessed (Jensen et al. 1996). Baseline nutrition was provided at 
30-35kcal/kg/day, however no mention was made of protein requirement. The 
authors found no clinical benefit with enteral glutamine-enriched EAA 
supplementation (no difference found in immune function, plasma amino acid 
levels or in nitrogen balance). Although this study received a moderate 
grading due to block randomisation, double blinding and placebo-controlled 
design it had several limitations. Limitations include small sample size with 
lack of statistical power, high dropout rate (only 19 patients were analysed), 
unclear overall aims, unmatched differences between groups (age and BMI 
both higher in the experimental group) and a heterogeneous ICU population 
(majority trauma patients, however not all).  
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Mansoor et al performed a study in 12 trauma ICU patients where six patients 
were randomised (Mansoor 2007) to threonine, serine, cysteine and aspartic 
acid supplementation (AA patient group) and six to alanine supplementation 
(Ala patient group) to determine effects on protein metabolism. The two ICU 
groups were also compared to healthy control subjects (n=8). This unusual 
mixture of amino acids (AA group) was selected based on the authors’ 
previous work demonstrating a demand for these particular amino acids in 
septic rats (reduced weight loss, muscle catabolism and an enhanced 
recovery) (Breuille et al. 2006). The intervention and control supplements 
used in ICU patients were isocaloric and isonitrogenous providing 34kcal/kg/d 
and 1.55g protein/kg/d. Outcome measures included plasma amino acids, 
cytokines, nitrogen balance, protein turnover, muscle breakdown via 3-MH, 
muscle biopsies and indirect calorimetry. In the ICU patients no significant 
differences between the two groups (AA and Ala) were found in either plasma 
protein or whole body protein kinetics. Healthy controls remained in positive 
balance for protein kinetics.  
Nitrogen balance remained negative in both ICU patient groups after 10 days 
with no significant differences observed between the two groups (-35g/kg 
control -32g/kg intervention, p>0.05). This particular blend of amino acids did 
not change leucine kinetics between the two ICU patient groups. Muscle 
protein synthesis was significantly higher in the healthy control subjects than 
the two ICU patient groups, 2.2%/d in healthy controls versus 1%/d in Ala 
patient group and 1.5%/d in the AA group (p<0.05). There was a trend 
towards increased muscle protein synthesis in the AA group compared to the 
Ala group, 1.5%/d versus 1%/d (p=0.065). There were no significant 
differences between the two ICU patient groups for 3-MH excretion. This 
study was limited mainly by the small sample size, lack of statistical power 
and short interventional period. Nutrition support was commenced in 
parenteral format prior to randomisation to enteral supplementation (day 3) 
which is not standard practice.  
Neither of the two moderate quality studies described demonstrated beneficial 
effects (muscle preservation or improved nitrogen balance) from EAA or 
mixed amino acid supplementation in the critically ill. 
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Low quality study 
The final ICU amino acid supplementation study included 34 ventilated COPD 
patients given 3g/d HMB supplementation over 7 days to examine what 
effects HMB might have on inflammation, protein metabolism and pulmonary 
function (Hsieh et al. 2006). The HMB supplement was given in addition to 
standard enteral feed. The group reported significant reductions in CRP from 
baseline in the HMB group and not the control group - in the HMB group 
111.56 (SD: 91.47) at baseline versus 46.19 (SD 45.29) mg/L afterwards 
(p<0.05); in the control group 110.59 (SD: 81.35) at baseline vs 72.65 (SD: 
64.72) mg/L afterwards. For WCC there was also a significant reduction in the 
HMB group but not in the control group compared to baseline - in the HMB 
group 14 (SD: 6.6) at baseline versus 9.64 (SD: 3.19) 103/mm3 (p<0.01); in 
the control group 12.21 (SD: 4.04) at baseline versus 11.10 (SD: 5.17) 
103/mm3 afterwards. A non-significant reduction in blood urea nitrogen (BUN) 
was observed in the HMB group (p=0.079). No changes were reported in 
body weight between groups after the study period. The authors report anti-
catabolic effects however protein metabolism was not adequately assessed in 
this study. This study was limited by small numbers with lack of statistical 
power analysis, a short interventional period, and a lack of true randomisation, 
subjects were only divided into groups by assigning patients in alternate order 
of their ICU admission. No placebo product was used, with control subjects 
received standard feeding only. Thus, although this data again points to the 
potential benefits of HMB, the design flaws limit the value of the data.   
From these ICU amino acid supplementation studies HMB supplementation 
appears to be the most promising dietary intervention tested to date to 
improve nitrogen balance in severely injured trauma patients. 
Dietary supplementation studies in the critically ill are mostly limited by lack of 
statistical power, small sample size, short interventional study periods, lack of 
robust markers for protein metabolism, muscle mass and body composition 
measurements. 
54 
 
Table 1-2: Amino Acid Supplementation Studies in ICU     
Study Quality Markers Population Intervention Comparison Outcome measures Outcomes 
Kuhls et al, 
2006 
High 
Randomised 
Double-blinded 
Placebo 
Controlled 
Power calculation 
included (N=100) 
 
N = 100 
trauma ICU 
patients 
N=72 analysed 
 
 
 
1: 3g HMB (N=28) 
2:3g HMB+ (with 
Arg, Gln) (N=22) 
With standard 
feed. (0.104MJ/kg 
or 25kcal/kg and 
1.5g protein/kg). 
14 days 
with 28d follow up 
3.Placebo with 
standard feed 
over 14 days 
with 28d follow 
up (N=22) 
24h urine collection 
3-MH (muscle 
breakdown) 
Pre-albumin 
ICU outcomes 
Feed tolerance 
Antibiotic days 
Infections 
Urinary excretion of N2: n/s difference between groups (p=0.23) 
Nitrogen balance was affected by Rx (p=0.05) 
Mean N2-bal (g/d): -9 Controls 
                              -10.9 HMB+ group 
                               -6.5 HMB group 
HMB+ group more negative N2 bal than HMB group (p < 0.05). 
No Rx difference for mortality, 28d antibiotic use, LOS,  
ICU LOS, ventilator days, or no of infections.  
N/s change in pre-albumin, CRP or IL-6 
Jensen et al, 
1996 
Moderate 
Block randomised 
Double blinded 
Placebo 
Controlled 
Small (N=19 
analysed) 
 
N=28 
ICU patients 
(18-75y)  
EN with EAA (6x 
gln amount)  
(10 days) 
BCAA ratio: 
val:leu:iso of 1:4:1 
EN provided at 
0.125-0.146MJ) 
(30-35kcal/kg). 
EN with non-
EAA instead of 
extra 
glutamine  
CRP, TLC, Alb 
Plasma AA 
Indirect Calorimetry 
N2 balance 
No difference: Albumin, pre-albumin, N2 balance or 
energy expenditure 
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Study Quality Markers Population Intervention Comparison Outcome measures Outcomes 
Mansoor et al, 
2007 
Moderate 
Block randomised  
Double blinded 
Controlled 
Small N=12 
Short study 
 
N=12 
Trauma ICU 
patients  
 
 
N=6 Feed with 
Threonine, 
Serine, Cysteine, 
Aspartic acid (AA 
group) 
Feed: 
EN of 0.146MJ/kg 
(35kcal/kg) and 
1.55g prot/kg 
 
 
N=6 Feed with 
Alanine (Ala 
group) 
(10 days) 
Same kcal & 
nitrogen 
+ 8 Healthy 
controls (on 
meat free 
controlled diet) 
Plasma proteins. 
TNF-a, IL1-b, IL-6). 
Protein turnover. 
N2 balance, 3-MH 
Muscle biopsies. 
Indirect Calorimetry 
AA did not change plasma protein synthesis nor whole body  
protein synthesis. 
General negative N2 bal in both groups, no significant differences 
between Ala or AA groups. 
Leucine kinetics:↑in both ICU patient groups compared to the control 
(p<0.05).  
Trend towards ↑muscle protein synthesis in AA group compared to  
Ala group, 1.5%/d versus 1%/d (p=0.065).  
No significant differences 3-MH excretion. 
Hsieh et al, 
2006 
Low 
Not randomised 
Blinded 
Controlled 
No Placebo 
Small sample 
 
N=34 
ventilated 
COPD patients  
3g HMB 
supplement via 
NGT (1.5g bd) 
over 7 days. 
No mention of 
composition of 
standard enteral 
feed 
No 
supplement 
over 7 days 
CRP, WCC. 
BUN, s-creatinine 
Lung function 
Body weight 
Significant ↓ in CRP (p<0.05) & WCC (p<0.01) in HMB group. 
↓ BUN (n/s) 
HMB group: Significant ↓ in creatinine (p<0.05) 
Alb: Albumin; AA: Amino Acids; Arg: Arginine; BUN: Blood Urea Nitrogen; COPD: Chronic Obstructive Pulmonary Disease; CRP: C-Reactive Protein; HMB: β-hydroxy methylbutarate; EN: Enteral 
Nutrition; Gln: Glutamine;  IC: Indirect Calorimetry; IL: Interleukin; LOS: Length of stay; 3MH: 3 methylhistadine; N2 Bal: Nitrogen Balance; NGT: Naso gastric tube; N/S: Non-Significant;  REE: 
Resting Energy Expenditure;  TNF-a : Tumor Necrosis Factor alpha; WCC: White cell count. 
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1.7.3 Electrical muscle stimulation  
 
A further strategy proposed to maintain muscle mass in the critically ill 
includes electrical muscle stimulus (Gerovasili et al. 2009;Zanotti et al. 2003), 
Figure 1-1. Electrical muscle stimulation (EMS) has shown initial promise in 
terms of preservation of muscle mass (Gerovasili 2009;Routsi et al. 2010).  
 
Gerovasili et al studied 26 mechanically ventilated patients randomised into 
the EMS group (n=13) or control group (n=13) (Gerovasili 2009). Electrical 
muscle stimulus was applied daily from day 2-9 over the quadriceps and 
peroneous muscles of both legs. The control group received no EMS. Muscle 
mass was assessed by ultrasound (cross sectional diameter of rectus femoris-
vastus intermedius) at baseline and 7 days afterwards. There were no 
differences at baseline between the groups. Although muscle loss occured in 
both groups, the EMS group displayed significantly lower rates of wasting in 
the right rectus femoris, EMS group -8 (SD: 3.9)% compared to controls -13.9 
(SD:6.4)%, p=0.009, and right vastus intermedius, EMS group -12.5 
(SD:7.4)% versus -21.5 (SD:15.3)%, p=0.034. On the left side the diameter 
was less in the EMS group versus control patients, however statistical 
significance was not met. Sample size in this study was small, however EMS 
seemed to preserve lower extremity muscle mass in ICU patients. 
 
Gruther et al studied 46 ICU patients in a pilot RCT where patients were 
stratified into 2 groups, one as an acute immobilisation group (defined as < 1 
week from ICU admission to EMS treatment) and the second as a long term 
immobilisation group (defined as > 2 weeks from ICU admission to EMS 
treatment). Within these two groups patients were randomised to EMS or 
sham treatment, EMS was provided over the quadriceps muscle bilaterally 
(Gruther et al. 2010). Thickness of quadriceps muscle was measured on 
ultrasound. In the acute group muscle thickness was not significantly different 
between EMS and control patients at baseline, 28.9 and 32.9mm respectively 
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(p=0.457). Both groups in the acute patient group had significant reductions of 
muscle thickness after 4 weeks, 18.3mm in the EMS group (p=0.002) and 
20.1 in the control group (p<0.001) versus baseline. In the long term 
immobilisation group the EMS group showed a significant increase in muscle 
thickness from baseline, 18.4 to 19.3mm (p=0.036) whereas control patients 
did not demonstrate a significant increase in muscle depth, 18.6 versus 18mm 
(p=0.162). Although this is a small pilot study evidence suggests that EMS 
might improve muscle thickness of long term ICU patients. Muscle strength 
was not assessed and it therefore remains to be seen whether increased 
muscle thickness leads to improved strength and function. 
 
Routsi et al were the first to assess whether EMS treatment could affect 
muscle function in ICU patients (Routsi 2010). Stimulus was given daily to the 
interventional group (within 48h of ICU admission) to quadriceps and 
peroneous muscle. EMS lasted for 55 min per day until ICU discharge. 
Manual muscle strength testing was performed by two independent 
investigators. A sample size calculation was performed (N=44), although 70 
patients were recruited to the two groups, 28 (40%) died in the EMS group 
with a further 11 (16% ) unable to perform the MRC sum score. In the control 
group 22 (30%) patients died with 22 (30%) unable to perform the MRC 
functional assessment. The final analysis included 24 EMS and 28 control 
patients. Critical illness polyneuromyopathy (CIPNM) was diagnosed in 3 
(12.5%) of the EMS group versus 11 (39.3%) in the control group (OR 0.22, 
95%CI of 0.05 to 0.92, p=0.04). The MRC sum score was significantly higher 
in the EMS group compared to the control group, 58 (IQR: 33-60) and 52 
(IQR:2-60) respectively, p=0.04. Limitations of the study include not using 
sham EMS in the control group and the small sample size. With patient 
exclusions due to death and inability to perform strength testing, the study 
was underpowered. Despite the limitations, 55 minutes per day of EMS 
appeared to prevent development of CIPNM in critically ill patients. This is the 
first study in which function was assessed post EMS administration in the 
critically ill, larger RCTs will be required to confirm these findings. 
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In a post-hoc analysis of the Routsi study, Karatzanos et al assessed whether 
EMS affected strength of various muscle groups in ICU patients (Karatzanos 
et al. 2012). Stimulated patients scored significantly higher than control 
patients for MRC scores in wrist flexion, hip flexion, knee extension and ankle 
dorsiflexion of both sides. No difference in handgrip strength was observed, 
however a significant difference was found in handgrip strength between 
patients diagnosed with ICUAW in comparison to those without, 6.6 (SD:4.4) 
kg versus 23.4 (SD:8.9) kg, p<0.01.  
Some studies indicate no difference in muscle volume post EMS (Poulsen et 
al. 2011). Poulsen et al studied 8 male ICU patients with septic shock, 
patients were immobile for a median of 3 days (1 - 4) prior to entry into the 
study. Electrical muscle stimulus was applied for 60min per day to the 
quadriceps muscle of one leg, patients served as their own controls. Muscle 
volume was assessed at baseline and 7 days later via CT. The non stimulated 
leg decreased by 16% over 7 days (IQR: 4-21%) from baseline, p=0.03 or 
2.3% per day. The stimulated leg decreased by 20% (IQR: 3-25%) from 
baseline, (p=0.04) or 2.9% per day. There was no significant difference 
between the stimulated and unstimulated  leg, p=0.12. This study was limited 
by the small sample size.  
Large prospective studies are required to evaluate the exact role of electrical 
muscle stimulus in terms of muscle strength preservation.  
One such study currently underway, the early rehabilitation in critical care 
(eRiCC) study, will compare functional electrical muscle stimulation-cycling to 
cycling alone and to standard physiotherapy (Parry et al. 2012). 
 
1.7.4 Early mobilisation 
 
Studies looking at early mobilisation of ventilated patients have demonstrated 
feasibility although prospective studies will be required to evaluate the impact 
of such strategies on muscle mass per se as well as potential improvements 
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in functional recovery and strength (Bailey 2009;Kress 2009;Schweickert and 
Kress 2011). 
 
1.8 Anabolic resistance 
 
Although various strategies to promote muscle protein synthesis have been 
discussed in Section 1.7 ‘anabolic resistance’ may inhibit some of these. 
Anabolic resistance has been described as the inability of muscle to retain its 
mass due to inadequate muscle protein synthesis in addition to enhanced 
muscle protein breakdown (Rennie 2009). This may largely be due to older 
muscle’s resistance to insulin and a decreased ability with age to assimilate 
amino acids from blood into muscle thereby reducing muscle protein 
synthesis. Age along with disuse atrophy appear to be the main contributors 
to anabolic resistance (Rennie 2009). It is currently not clear what affect 
‘anabolic resistance’ might have on critically ill patients. 
 
1.9 Nutritional Tipping Point 
 
Attempts have been made in the past to identify a type of “nutritional tipping 
point”. Such a point being an identifiable moment when a patient transitions 
from a state dominated by catabolism, to one characterised by anabolism. A 
previous study described the use of a prognostic inflammatory and nutritional 
index (PINI) which might provide some indication of when patients progress 
from an ongoing catabolic state to that of anabolism (Ingenbleek and 
Carpentier 1985). The index was developed to evaluate nutritional status and 
to improve diagnosis and monitoring of critically ill patients in terms of 
morbidity and mortality. This index was rarely used in the years following 
publication as α1-acid glycoprotein and pre-albumin were too difficult to 
measure. Decades later these two proteins are still not routinely measured in 
most hospitals. The original formula consisted of measurement of CRP, 
orosomucoid (or α1-acid glycoprotein), albumin and pre-albumin (or 
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transthyretin). Multivariate analysis of 11 serum proteins had been performed 
to identify these four markers with the highest sensitivity and specificity.  
The PINI consists of the following equation: 
 
PINI = [orosomucoid (g/L) x CRP (mg/L)]/ [Albumin (g/L) x transthyretin (g/L)] 
 
As the PINI correlated well with clinical outcome of the patients studied, 
stratification was performed by risk of complications or death (Ingenbleek and 
Carpentier 1985): 
 
> 30: Life-risk patients 
21-30: High-risk patients 
11-20: Medium-risk patients 
1-10: Low-risk patients 
< 1: Non-infected subjects 
 
1.10 New PINI 
 
Recently, and in view of the difficulty in obtaining α1-acid glycoprotein 
measurements, a ‘new PINI’ has been identified (Ziegler et al. 2011). 
Alternative biological formulas were compared in a prospective study from 
plasma samples of 106 patients in intensive care, surgical and medical wards. 
In the new formulas, the logarithm of CRP was used to account for the 
enormous potential daily fluctuation in CRP and to therefore avoid 
overestimation of mortality and morbidity risk according to the original PINI 
formula. Six newly proposed formulas were compared and correlated with the 
serum protein values obtained from patients using the original PINI. The six 
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formulas included were: Log (CRP)/ (Alb x pre-albumin); Log (CRP) / pre-
albumin; CRP/Albumin; CRP / (Albumin x pre-albumin); CRP/ pre-albumin and 
Log (CRP) / Albumin. Correlation coefficients ranged between 0.78 and 0.94, 
p<0.0001, however the last three formulas mentioned correlated best with the 
original PINI with r= 0.94, r=0.90 and r=0.91 respectively (Ziegler 2011). 
From the six formulas, the Log (CRP)/ Albumin is of particular interest 
because of its ease of use with readily available markers in the hospital 
environment. Log (CRP)/Albumin correlated well with the original PINI formula 
with r=0.91. 
This new simplified PINI formula is used in this research (Chapter 4). 
 
This research aimed in the first instance to identify a notional nutritional 
tipping point, where anabolism is likely to exceed catabolism and nutritional 
therapy can be targeted. Nutritional problems on ICU have been highlighted 
(Section 1.3.10), targeting nutritional strategies in the very acute catabolic 
phase may be counter-productive, however if a nutritional tipping point could 
be identified nutritional strategies could be targeted at that stage to maximise 
efforts of supporting patients into an anabolic or recovery phase. A further aim 
of this research was to evaluate the feasibility of using an essential amino acid 
supplement to attenuate muscle wasting in critically ill trauma patients. 
 
1.12 Hypotheses 
1.12.1 Main hypothesis  
 
Understanding the relationship between inflammatory and nutritional markers 
of critically ill patients will help to identify a point where patients become 
anabolic and will assist in the development of a strategy to minimise muscle 
mass decline in critical illness and facilitate recovery. 
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1.12.2 Secondary hypothesis 
 
Timing interventions in the knowledge of a notional nutritional tipping point will 
assist in optimising recovery.  
 
1.12.3 Research aims 
 
Study 1 
 
a) To identify a nutritional tipping point where patients move from 
catabolism to anabolism during a period of critical illness. 
b) To explore inter-relationships between inflammatory and nutritional 
markers during critical illness. 
c) To explore data for surrogate endpoints to be used in future nutritional 
clinical trials where effect size and sample size calculations could be 
determined from our current data set. 
 
Study 2 
a) To determine whether the trauma population represent a feasible group 
to study within critical care. 
b) To determine whether the intervention (Leucine enriched essential 
amino acid supplementation) is feasible to study within critical care. 
c) To assess whether the outcome measures and endpoints used in this 
study would be feasible (practical and scientifically sound) for use in 
future clinical trials. 
d) To develop a strategy that will minimise muscle mass decline in critical 
illness. 
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Chapter 2. Core Methods 
 
In this chapter the core research methods used in my PhD research project 
has been outlined. The majority of the research methods described were used 
in both the Nutritional Tipping Point (chapter 4) and the essential amino acid 
supplementation (chapter 5) studies of this research. Stable isotope studies 
were performed during the amino acid supplementation study only. 
Quantitative methods only have been used throughout this research project.  
 
2.1 Cytokines 
2.1.1 Sample preparation and storage 
 
14ml of arterial blood was taken from each study patient by the researcher, 
research nurse or bedside nurse. Blood was taken in EDTA 
(Ethylenediaminetetraacetic Acid) tubes. Samples were put on ice 
immediately and spun at 3000 rpm for 10 minutes. Aliquots of between 6-8 
plasma samples of 1ml each were prepared in screw capped micro centrifuge 
freezer tubes. Tubes were clearly labelled with each patient’s unique study 
number and the sampling date. Samples were stored at -80°C in a locked 
freezer in the dedicated ICU laboratory area at each of our hospital sites. 
Locked freezers were fitted with an alarm system linking to staff emergency 
telephone numbers should the alarm sound. A grid labelling system was kept 
as a duplicate electronic record of where samples were stored in the -80°C 
freezer and in which boxes samples would be found to avoid confusing patient 
samples later. Cytokine analysis of plasma samples were performed via 
enzyme-linked Immuno-sorbent Assay (ELISA) in batches by Ms. May To, 
research assistant, under the supervision of Dr Fred Tam, Imperial College 
London, Hammersmith Hospital Campus. 
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2.2 Enzyme-linked immuno-sorbent assay (ELISA) 
2.2.1 Materials and chemicals 
 
ELISA grade streptavidin HRP (R&D systems, Oxford, UK). 
 
2.2.2 Cytokines 
 
Human IL-10 and IL-6 duosets were obtained from R&D systems, Oxford, UK. 
These were stored between 2-8°C as per manufacturer’s guidance. 
 
2.2.3 Standard solutions and buffers 
 
Phosphate buffered saline (PBS) 
10mM sodium phosphate, 0.9% sodium chloride (Gibco, UK) or PBS – 8g/L 
NaCl, 0.20g/L KCl, 1.44g/L Na2NPO4.2H2O (Di sodium hydrogen phosphate), 
0.20g/L KH2PO4 (Potassium di-hydrogen phosphate), pH 7.2-7.4, 0.2 µm 
filtered.  
Wash Buffer 
0.05% Tween® 20 in PBS, pH 7.2-7.4  
Reagent Diluent 
1% BSA in PBS, pH 7.2-7.4, 0.2 µm filtered  
Substrate Solution 
1:1 mixture of Colour Reagent A (H2O2) and Colour Reagent B 
(Tetramethylbenzidine)  
The following formula was used to calculate the capture antibody, detection 
antibody and standards aliquot concentrations and volumes  
C1V1 = C2V2  
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2.2.4 Capture antibody 
 
Capture antibody was provided from the manufacture as 360ug/mL of mouse 
anti-human IL-10. This was reconstituted with 1.0mL of PBS to produce a 
working concentration of 2ug/ml. One micro plate requires a volume of 11ml: 
 
  360ug/ml x V1 = 11ml x 2ug/ml 
Rearranging the formula V1 = (11ml x 2ug/ml) / 360ug/ml 
    V1 = 0.06ml or 61.11ul  
 
2.2.5 Detection antibody 
 
Detection antibody: 27ug/ml was provided. This was reconstituted with 1ml of 
reagent diluent. To achieve a working dilution of 0.15ug/ml for one microplate 
that requires a volume of 11ml: 
  27ug/ml x V1 = 11ml x 0.15ug/ml 
Rearranging the formula V1 = (11ml x 0.15ug/ml) / 27ug/ml 
    V1 = 0.06ml or 61.11ul  
 
2.2.6 Standards 
 
Standard: 95ng/ml was provided. This was reconstituted with 0.5ml of reagent 
diluents to achieve a working dilution of 2ng/ml for one microplate that 
requires a volume of 11ml. 
  95ng/ml x V1 = 11ml x 2ng/ml 
Rearranging the formula V1 = (11ml x 2ng/ml) / 95ng/ml 
    V1 = 0.23ml or 23ul  
Serial dilution of the standard (Figure 2-1) 
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A seven point standard curve using 2-fold serial dilutions in reagent diluent is 
required. The highest concentration of the standard was 2000pg/ml and the 
lowest 0pg/ml. To achieve standard dilutions eight 1.5ml micro centrifuge 
tubes were required.  
 
 
Figure 2-1: Serial dilution of the standard 
 
2.3 Interleukin-10 and IL-6 human duoset protocol 
 
The IL-10 and IL-6 human duoset protocol was followed using the 
manufacturer’s instructions, see Appendix.  
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This process is summarised in a simplified diagram for IL-10 analysis, Figure 
2-2. 
 
          
Figure 2-2: Simplified diagram of ELISA steps for IL-10 analysis 
 
2.4 Calculation of results 
 
Duplicate readings for each standard and sample were averaged and the 
average zero standard optical density was subtracted. A standard curve was 
created by reducing the data using computer software capable of generating a 
four parameter logistic curve-fit. If samples have been diluted, the 
concentration read from the standard curve had to be multiplied by the dilution 
factor. The standard curve optical density ranged from 0.095 - 1.437 nm. 
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2.5 Assay reliability  
2.5.1Interleukin-10 intra-assay reliability 
 
Intra-assay reliability was determined in 7 samples. Coefficient of variation 
ranged between 0.64 - 9.78%. 
 
2.5.2 Interleukin-10 inter-assay reliability 
 
Inter-assay reliability was determined in 7 samples. Coefficient of variation 
(CV) ranged between 1.93 - 39.64%. 
 
2.6 Interleukin-6 preparation method 
 
A similar technique has been followed for IL-6 analysis. With serial dilution the 
highest concentration of the standard was 600pg/ml and the lowest was 
0pg/ml. The standard curve optical density ranged from 0.04 - 3.71nm. 
 
2.6.1 IL-6 intra-assay reliability 
 
Intra-assay reliability was determined in 5 samples with CV ranging between 
3.31 and 7.15%. 
 
2.6.2 Il-6 inter-assay reliability 
 
Inter-assay reliability was determined in 5 samples, CV ranged between 0.65 
and 28.36%.  
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2.7 Urinary studies: 3-methylhistidine and urinary urea 
 
Non-preservative containers were used for 24h urine collection, all patients 
were catheterised. Twenty four hour urine collections were performed on days 
1, 3, 7, 14 and 20 of the study. Containers were labelled with patient 
information along with the date, start and end collection times of the 24h urine 
collection. Nursing staff were trained on the correct collection procedure and a 
written collection protocol was supplied to bedside nurses. Samples were 
analysed for urinary urea (mmol/24h) and urinary 3-methylhistidine (3-MH) 
(µmol/24h), which was used as a surrogate marker of skeletal muscle 
breakdown. A JEOL amino acid analyser with cation exchange 
chromatography (JEOL UK Ltd., Herts, UK) was used to analyse samples with 
ninhydrin detection and one inferred standard. Urine urea was measured by a 
kinetic urease using an Abbott Architect assay with Abbott reagents. 
Reference ranges for urinary urea and 3-MH per 24h urine sample are not 
provided in the laboratory. 
Urinary 3-MH has been described as a useful marker of skeletal muscle 
breakdown, particularly if a diet is meat free (Elia et al. 1981). When meat and 
chicken is consumed urinary excretion of 3-MH will be enhanced as meat is 
an exogenous source of 3-MH. As ICU patients are artificially fed and artificial 
nutrition support is meat-free the dietary effect on 3-MH is therefore bypassed. 
3-Methylhistidine is derived from the contractile proteins actin and myosin. A 
linear relationship between protein breakdown, assessed by 15N-glycine 
stable isotope studies and 3-MH excretion, has been reported (Lowry et al. 
1985). Although a number of newer methods have been described to 
determine muscle breakdown more accurately than 3-MH, such as 
microdialysis techniques, (Chinkes 2005;Tesch et al. 2008) 3-MH urinary 
analysis only has been used in this research project. Urinary 3-MH sampling 
remains popular in studies assessing muscle breakdown within the critical 
care context (Kuhls 2007;Mansoor 2007;Nissen et al. 1996;Stein 
1999;Voerman et al. 1995).  
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2.8 Nitrogen balance  
 
Nitrogen balance is described as the difference between nitrogen input (diet, 
enteral or parenteral nutrition) and nitrogen loss. Nitrogen loss includes 
urinary losses and additional losses via skin, faeces, dialysate, fistulae or 
abdominal wounds. 
Urinary nitrogen was not measured directly in this research as this analysis 
was not feasible in our institution and financial constraints did not allow for 
samples to be measured elsewhere. Urinary nitrogen therefore  had to be 
calculated. Numerous equations are available to calculate nitrogen loss and 
nitrogen balance, Table 2-1 shows some of the equations used. Many of the 
references for the equations are old and use various assumptions, some are 
poorly referenced making overall interpretation of nitrogen loss difficult. For 
the purpose of this research both the Deacon equation (Deacon et al. 2009) 
and the Parenteral and Enteral Nutrition Group of the British Dietetic 
Association equations were used, Table 2-1. The Deacon equation was 
chosen as this equation was used in our laboratory and published in the 
United Kingdom and the PENG equation was recommended by the British 
Dietetic Association, this equation would be used by dietitians in clinical 
practice within the United Kingdom. 
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Table 2-1: Nitrogen balance equations  
Source 
author 
Source Equation (N Bal g/day) Equation Reference 
Allan Deacon, 
Roy 
Sherwood, 
James 
Hooper 
Calculations in 
Laboratory Science 
2009 (ACB Venture 
Publications, ISBN 
9780902429437) 
Nin- Nout: Nitrogen excretion 
(g/24h) = urea excretion 
(mmol/24h) x 0.028 
20% for other urinary 
losses and a further 2g/day for 
losses by other routes.  
(Deacon 2009) 
British Dietetic 
Association 
Parenteral & Enteral 
Nutrition Group (UK) 
N in – N out 
N out: urinary urea (mmol/24h) 
x 0.033 + obligatory losses.  2-
4gN/d (hair, skin, faeces) 
0.6gN per 1 degree above 37.5 
(Lee and Hartley 1975) 
 
 
(Voerman 
1992) 
Annals of Surgery 
1992;216(6):648-655 
N out (g/d) + change in serum 
urea (mmol/L/d) x 0.019 x body 
weight 
Equation not referenced 
(McCowen et 
al. 2000) 
Crit Care Med 
2000;28(11):3606 
N in – N out (N out: urine urea 
N 24h) – 4g (non-urea nitrogen 
& renal losses correction 
factor) 
(Mackenzie et al. 1985) 
(Dickerson et 
al. 2005) 
Nutrition 2005; 21 
(3): 332 
N in – urinary urea (g/d) – 4 
Serum urea > 5mg/DL added 
to N losses 
(Blumenkrantz et al. 1980) 
(Grimble et al. 
1988) 
JPEN 1988: 12: 100-
6. 
N in - [Urine urea 
nitrogen/0.85] 
Measured in patients 
(Japur et al. 
2010) 
J Crit Care 2010 N Bal=N in – N out 
N Losses = total urinary 
nitrogen + 4g/d, (skin and 
faeces). NB is negative if <0 
and positive if > 0 
(Blackburn et al. 1977) 
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2.9 Muscle depth change with ultrasound 
 
Muscle thickness measurements by ultrasound has been previously validated 
in critically ill oedematous patients (Campbell 1995). The muscle depth that 
correlated best with lean mass from Dual-Energy X-ray Absorptiometry 
(DEXA) was measured over the bicep, the anterior forearm and the anterior 
thigh on ultrasound.   
 
In this research muscle thickness was measured with either a Sonosite M 
Turbo or a Sonosite S Series™ ultrasound machine with a 5 MHz linear array 
transducer (Sonosite Ltd, Hitchin, Herts, UK) during the Nutritional Tipping 
Point study and reliability studies. During the amino acid supplementation 
study a Sonosite Micromaxx ultrasound machine was used with a 5 MHz 
linear array transducer (Sonosite Ltd, Hitchin, Herts, UK). Maximum 
transducer depth was selected at 6cm. Participants were supine and 
measurements were made on the right side of the body, unless access lines 
or limb injury determined a different position. Measurements were made with 
a tape measure on the bicep, forearm and thigh to mark a halfway point on 
the limb from which the ultrasound measurement would be made, following 
the protocol of Campbell et al and Reid et al (Campbell 1995;Reid 2004). 
Markings were made in indelible ink to ensure that the same site would be 
measured throughout the patient’s ICU stay. Three ultrasound measurements 
were made per site using the built-in electronic calliper on a frozen real-time 
cross-sectional image. The average of three measurements for each site was 
used, up to a 0.2cm difference was accepted. The mean value from the bicep, 
forearm and thigh was combined to provide a daily total muscle depth (cm). A 
substantial amount of ultrasound gel was applied to ensure that the probe 
could rest gently on the skin without compressing muscle or distorting 
underlying soft tissue. The transducer was placed perpendicular to the long 
axis of the thigh prior to measurements being made. In Figure 2-3 the skin 
and fascia appear convex rather than a level or ‘flat’ image which illustrates 
that muscle was not compressed at the time of measurement. 
 73 
 
Figure 2-3: Thigh muscle ultrasound 
 
2.9.1 Bicep 
 
The elbow was flexed to 90 and a point on the skin was marked between the 
tip of the olecranon and the acromion with indelible ink. With the elbow 
extended and the patient in a supine position, the forearm was supinated. A 
thick layer of ultrasound gel was applied to the marked area to limit 
compression of the underlying tissue. The ultrasound probe was applied at the 
pen mark on the upper arm to obtain a cross-sectional (axial) view which 
included the humerus, biceps and brachialis muscle, subcutaneous tissue and 
skin. The probe was then moved medially around the upper arm on the pen 
mark until the upper surface of the flat plane of the humerus was parallel with 
the top of the screen and in the centre of the screen. The image was frozen 
and labelled ‘B1’ (Biceps). Beginning at the part of the periosteum of the 
humerus, the internal calliper on the SonoSite ultrasound machine was used 
to measure the on screen vertical distance to the muscle/subcutaneous tissue 
interface. This image was saved, then the callipers were removed from the 
image and the image saved again. This process was repeated for images 
labelled B2 and B3. The mean value of three measurements was used. 
Figure 2-4 illustrates the mid upper arm cross section. 
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Figure 2-4: Cross section of mid upper arm  
(Printed with permission from R Whitaker, www.instantanatomy.net) 
 
2.9.2 Forearm 
 
The patient’s arm was extended and the forearm kept in a supinated position. 
A point between the antecubital skin crease and the ulnar styloid was marked 
with indelible ink. The ultrasound probe was applied at the pen mark on the 
radial (lateral) side of the forearm to obtain a cross-sectional (axial) view 
which included the radius. The probe was then moved medially to the pen 
park on the anterior surface of the forearm until both the radius and ulna were 
in view and then manipulated such that the upper surface of the radius and 
ulna seen on screen were parallel with the top of the screen and in the centre 
of the screen. The image was frozen and labelled ‘F1’ (Forearm) and F2, F3 
for subsequent measurements. The thickness of the flexor compartment was 
measured anteriorly between the superficial fat-muscle interface and the 
interosseous membrane; radial or lateral side of the forearm (Figure 2-5). 
Three measurements were taken and the mean of the three measurements 
was used. 
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Figure 2-5: Cross section of mid forearm  
(Printed with permission from R Whitaker, www.instantanatomy.net) 
 
2.9.3 Thigh 
 
The patient was in the supine position with the knee extended. Two 
measurement points were identified – one as a halfway point and another 12 
cm proximal to the superior portion of the patella. This ‘T12cm’ additional 
measurement point did not feature in the original protocol. This was included 
on the basis that with a probe depth of 6cm the femur could often not be 
visualised in patients with thicker muscle or in overweight and obese patients. 
Halfway point: The midpoint between the tip of the greater trochanter and the 
lateral joint line of the knee was identified. This point was marked. The T12cm 
point: The point 12cm proximal to the superior portion of the patella was 
identified and marked. The thickness of the quadriceps muscle group 
anteriorly between the superficial fat-muscle interface and the femur was 
measured (Vastus intermedius and Rectus Femoris, see Figure 2-6). The 
ultrasound probe was applied at the pen mark on the anterior surface of the 
thigh to obtain a cross-sectional (axial) view which included the femur, 
quadriceps muscles, subcutaneous tissue and skin. The probe was 
manipulated to ensure the femur was in the centre of the screen and the 
image frozen and labelled ‘T1, T2 and T3’ (Thigh halfway point) or ‘T12-1, 
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T12-2 and T12-3’ (T12cm from superior portion of patella) as appropriate. The 
means for both the halfway point and T12cm were obtained. At no point was 
pressure placed on the probe or on the muscle to avoid compression of the 
soft tissue. 
 
 
Figure 2-6: Cross section of mid-thigh  
(Printed with permission from R Whitaker, www.instantanatomy.net) 
 
When serial measurements were performed on alternate days or twice 
weekly, these were taken from the exact site previously identified and marked. 
The muscle depth change could then be compared for total muscle depth and 
for each individual site. 
 
2.9.4 Muscle ultrasound studies 
 
Two reliability studies encompassing muscle ultrasound are included in this 
research project (Chapter 3) before patient data is presented. The first is a 
healthy subject (n=20) reliability study (hospital and college staff) where intra-
rater reliability was assessed. The second reliability study was performed 
between two raters (N=12) to confirm reliability of my technique with a 
research assistant’s technique. Patient data are presented in chapters 4 and 
5. 
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2.10 Activities of daily living (ADL)  
 
Two questionnaires that are routinely used to assess functional status have 
been used, the Katz Index (Katz et al. 1963) and the Barthel Index (Mahoney 
and BARTHEL 1965). These indices were selected for this study due to their 
ease of use and previous use within the ICU setting (De Rooij et al. 
2008;Garrouste-Org et al. 2006). The Katz Index assesses basic activities of 
daily living and relates to a series of questions assessing a patient’s level of 
independence. These are assessed by scoring function in terms of bathing, 
dressing, toileting, transfer, continence and feeding) Patients score “0” if they 
are highly dependent and “6” if they are independent, see Appendix. 
The Barthel Index consists of assessment of 10 areas of activities of daily 
living. Scoring options for each component ranges between 0-5, 0-10 or 0-15.  
In the Barthel Index assessments include feeding, bathing, grooming, 
dressing, bowels, bladder, toilet use, transfer, mobility and use of stairs. 
Patients can score anywhere between 0 -100, 0 indicating the highest level of 
dependence and 100 being completely independent, see Appendix. Reliability 
and validity has been established for this tool, mainly in stroke patients (Wade 
and Collin 1988;Wade and Hewer 1987).  
These questionnaires were completed on study days 1, 3, 7 and 14 for both 
the Nutritional Tipping Point and essential amino acid supplementation studies 
of this research. However, the Katz and the Barthel indices performed poorly 
in this population. Although these indices may be sensitive to change in 
declining health status of older adults outside of the ICU, they appear to be 
limited in their ability to measure the small increments of change that may be 
observed in the critically ill (Hayes et al. 2000). The value of these indices are 
most likely found within the context of follow up on survivors of critical illness 
(Brunello et al. 2010;Fletcher et al. 2003;Griffiths and Jones 2007b;Im et al. 
2004;Navarrete-Navarro et al. 2003) rather than in the acute ICU 
environment.  
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By comparison, a landmark long term ICU follow-up study assessing 
functional recovery in survivors of critical illness used the 6-minute walk test 
and physical components of the Short Form-36 questionnaire (Herridge 2011). 
Despite the potential limitations of these indices prospective studies in the 
critically ill include the use of these tools for functional assessment. In a 
randomised study assessing the impact of early exercise on functional 
recovery after critical illness, both the Katz and the Barthel Indices were used 
in addition to the Medical Research Council Sum Score assessment of 
strength (Schweickert 2009). Others have used these tools in survivors of 
critical illness: the Barthel Index was used to assess functional status one 
week after ICU discharge (van der et al. 2008), a modified Katz index was 
used for a 2 month follow up study (Wu et al. 1995), the Barthel Index was 
used at 28 days and 180 days after ICU discharge (Brunello 2010), the Katz 
Index was used during a 26 month follow up study to examine long term 
outcomes after prolonged mechanical ventilation (Bigatello et al. 2007) and 
the Katz Index was used to assess long term function one year after 
prolonged mechanical ventilation (Chelluri et al. 2004). 
 
2.11 Medical Research Council (MRC) sum score 
 
The MRC sum score is used to assess generalised weakness after critical 
illness. This test is also used to determine ICU Acquired Weakness (ICUAW) 
(De 2002). The assessment consists of a bedside test where muscle strength 
is graded in twelve muscle groups. Six assessments are conducted on both 
the left hand and right hand side of the body. The upper extremity 
assessments include shoulder abduction, elbow flexion and wrist extension. 
The lower extremity assessments include hip flexion, knee extension and foot 
dorsi-flexion.  
Scoring is performed per site by providing a value from 0-5 for the following 
actions: 
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0 - No visible contraction 
1 - Visible muscle contraction, but no limb movement 
2 - Active movement, but not against gravity 
3 - Active movement against gravity 
4 - Active movement against gravity and resistance 
5 - Active movement against full resistance 
 
Scoring ranges from 0 for complete paralysis to 60 for full strength, see 
Appendix. ICUAW is identified as a score of < 48 out of 60 (De 2002). The 
MRC sum score is deemed a reliable technique to determine muscle 
weakness in patients with neurological conditions (Kleyweg et al. 
1991;Molenaar et al. 1999). 
Inter-observer agreement of the MRC sum score has been discussed in a 
number of studies. The first study was conducted in Guillain-Barre patients 
(Kleyweg 1991), the second in ICU survivors (Fan et al. 2010) and a third 
study in a general ICU cohort (Hough et al. 2011). Inter-observer agreement 
has also been established between the MRC Sum score and hand grip 
strength assessment (Hermans et al. 2012). 
 
Limitations to manual strength testing in the critically ill include that patient 
cooperation is required, this may be an issue for patients suffering with 
delirium or slow neurological recovery. In a general ICU cohort only 30 (22%) 
of patients were able to perform the MRC sum score assessment due to 
coma, delirium and injury (Hough 2011). Actual strength may be 
underestimated if patients lack cognition, understanding or concentration.  
 
The MRC sum score was not included at the outset of this research study and 
was only included in the amino acid supplementation study (Chapter 5). The 
 80 
decision was made to include the MRC sum score as the Katz and Barthel 
Indices did not appear to be sensitive enough in depicting functional change 
in the ICU cohort. Advice was sought from Dr Nicolas Hart, a UK based expert 
in ICUAW, he recommended the use of the MRC sum score as a measure of 
strength. I received training from an experienced clinician before patient data 
collection commenced.  
In order to conduct the test the researcher had to assess the alertness and 
cooperation of the patient by asking the following three questions: 
1. “Do you know where you are?” 
2. “Could you please stick your tongue out?” 
3. “Could you please squeeze my fingers?” 
 As 100% cooperation is required, patients had to respond positively to all 
three questions before testing could be performed. (Appendix IV, assessment 
form). 
 
2.12 Protein turnover via stable isotope studies 
 
Stable isotope studies with 1- 13C leucine are ideal to explore dynamic 
aspects of protein metabolism in patients. 1- 13C leucine is considered a 
method of reference for whole-body protein turnover in most physiological 
conditions (Elia 1981;Wagenmakers 1999). As leucine is an essential amino 
acid, leucine rate of appearance (RaLeu) is derived from protein breakdown in 
the absence of consuming any dietary leucine. The 1- 13C leucine stable 
isotope is usually given as a primed intravenous infusion, at around 150 
minutes a plateau will be reached in either the arterial leucine enrichment 
(Matthews et al. 1980) or in the venous α-ketoisocaproic acid (α-KIC) 
enrichment, which is described as a ‘steady state’. α-Ketoisocaproic acid is a 
transamination product of leucine and reflects intracellular levels of leucine 
(Matthews et al. 1982), it is therefore commonly measured instead of leucine 
as it represents leucine content in muscle (Garlick and Cersosimo 1997). 
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2.12.1 Stable isotope study  
 
Five 1- 13C leucine stable isotope studies were performed in trauma ICU 
patients (chapter 5). Each study was conducted at the bedside of each patient 
on either the surgical or medical intensive care units at Kings College Hospital 
London; all patients were mechanically ventilated and sedated. A similar 
protocol was followed to Carroll et al (Carroll 2004) for conducting protein 
turnover studies in the critically ill. To detect protein turnover a primed 
intravenous infusion of 1- 13C leucine 1mg/kg; 1mg/kg/h (MassTrace, 
Somerville, MA) was administered for the duration of the study (0min to 
180min). A bolus dose of NaHCO3 was used to prime the bicarbonate pool. 
Regular blood and breath samples were taken for the measurement of the 
enrichment of α-ketoisocaproic acid (α-KIC), the concentration of leucine and 
the enrichment of expired CO2. Patients received standard enteral feed over 
16h with an 8h break in feeding to allow for administration of the 1- 13C 
leucine stable isotope, such that dietary leucine intake did not interfere. See 
Figure 2-7 and Figure 2-8 for study protocol and preparation. 
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Figure 2-7: Stable isotope study protocol 
 
 
 
Figure 2-8: Stable isotope study preparation with blood sampling tubes and 
breath sampling exetainers (blue, white and pink top) (Photo: L Wandrag) 
1-13C Leucine Infusion
- 10 min 0 min 150 min
160 170 180
Steady State
Time (min)
*Bolus: NaH13CO3
Infusion*
Blood*
Breath*
1-13C Leucine Infusion
* Breath samples: x 4 per time point
Tracer 
sample
* * Bolus and infusion administered peripherally
* Blood sampling can be taken arterial/central/ peripheral
*Bolus: 1-13CLeucine
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2.12.2 Blood sampling  
 
Blood samples were taken from indwelling arterial catheters at the following 
time points: -10min, 0min, 150min (steady state), 160min, 170min and 
180min, a 5ml lithium heparin tube was filled for α-KIC analysis at each time 
point. Blood samples were placed on ice immediately and centrifuged at 
3000rpm for 10min at 4°C. Plasma was aliquoted into 1ml freezer tubes and 
labelled accordingly. The samples were stored at – 80 °C until analysis. 
 
2.12.3 Breath sampling 
 
Breath samples were collected from the expiratory port of the ventilator (Servo 
300, Siemens, Berlin, Germany or Servo I, Maquet, Sweden) at the following 
time points: -10min, 0min, 150min (steady state), 160min, 170min, 180min as 
described in other studies (Carroll 2004;Russell-Jones et al. 1998). At each 
time point 5 exetainer tubes were filled with expired gas. Breath sampling in 
ventilated patients was complex; various methods were explored prior to 
patient data acquisition and advice was sought from experts in the field (Dr 
Kenneth Smith, Nottingham University and Prof Margot Umpleby, Surrey 
University). The first method considered for breath sampling was the use of 
gas sampling collection bags however the volume of expired CO2 still had to 
be determined. The second method explored was a Douglas bag collection 
technique for expired gas. This technique was tested in a number of non-
research ICU patients before study data commenced. The Douglas bag was 
arranged with a flow meter attached to the tubing, attached to the expiratory 
port of the ventilator, Figure 2-9. This allowed for the volume of expired gas to 
be recorded. All the air was removed out of the Douglas bag before sampling 
commenced. Samples were taken via a 3-way tap system so as not to 
contaminate the system with room air. Test samples were given to the 
research team at Surrey University and analysed on mass spectrometry 
before patient data collection commenced. Overall this technique of gas 
sampling was labour intensive, two people were required to perform gas 
sampling, with one person checking the flow meter and the second one 
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syringing expired gas into exetainer tubes. A third person had to perform 
blood sampling at the given time points and had to administer the isotope 
infusion, Figure 2-7. I therefore had to conduct stable isotope studies with the 
assistance of two ICU research nurses.  
 
Figure 2-9: Breath sample collection with a Douglas bag  
(Photo: L Wandrag) 
 
During patient data collection labelling of the exetainer tubes reflected each 
time point as described above. One additional exetainer tube was filled per 
sampling period and the concentration of CO2 was measured on a gas 
analyser (Radiometer ABL 825 flex) in the ICU in order to calculate the CO2 
production rate, see Table 2-2. 
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Table 2-2: CO2 production rate calculation 
 -10 min 0 min 150 min 160 min 170 min 180 min 
Volume in 
Douglas bag 
45L 48L 45L 38L 38L 34L 
Sampling 
time  (min) 
2’59’’ 2’49’’ 2’43’’ 2’27’’ 2’15’’ 2’05’’ 
L/min 17.4 19.3 18.5 16.7 17.7 16.6 
VCO2 % 1.1% 1.2% 1.5% 2.1% 2.0% 2.0% 
VCO2% of 
L/min 
0.1914  0.2316  0.2775  0.3507  0.354  0.332  
CO2 
production 
rate (ml/min) 
191.4  231.6  277.5  350.7  354  332  
 
 
2.12.4 Analytical methods: α-Ketoisocaproate derivatisation 
 
12C KIC (unlabelled) and 13C KIC (labelled) 
 Standard stock solutions were used (1mg/ml). 
 
For quality control the following was used: 
Quality Control 1: Non-spiked plasma from healthy subject. 4ml baseline 
plasma sample was used. 
Quality Control 2: Spiked sample 5.2%. 5ml spiked with 1.2µl 13C KIC 0.0198g 
Quality Control 3: Spiked 10.2%. 5ml spiked with 2.3µl 13C KIC 0.0198g 
 
Patient samples were fully thawed and mixed thoroughly by placing these on 
the Vortex or rocker. Plasma samples were then centrifuged (Sorvall Legend 
RT Centrifuge, Thermo Electron Corporation, UK) at 4°C at 2500rpm for 10 
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minutes to precipitate any proteins. 100µl of each patient plasma sample and 
the quality control was aliquoted into small labelled glass test tubes. The pellet 
that formed after samples were centrifuged was not disturbed and a clean 
pipette tip was used for each sample. 1ml ethyl alcohol was added to each 
plasma sample and this was mixed again on the Vortex. Samples were then 
centrifuged at 4°C at 2500rpm for 10 minutes. The supernatant was 
transferred to a labelled 1 dram vial using a clean glass pasteur pipette, one 
for each sample. Samples were then dried under Oxygen Free Nitrogen 
(OFN) at 50°C. The Parker Filtrations Nitroflow unit was turned on for 
approximately 3 minutes before use and temperature was checked for 50C. 
200µl distilled water was added to each sample once they were completely 
dry. This was followed by 100µl O-phenylenediamine powder freshly made in 
4M HCL 2% (w/v) (i.e. 0.02g/1ml). 6ml was required for patient samples 
therefore 1.2g for 6ml. The three standards were also added at this stage, 
distilled water and the O-phenylenediamine and HCL mixture was added to 
derivatise. Tubes were capped and mixed well by placing on the Vortex. The 
heat block was turned on to reach 90°C. Samples were placed on the heat 
block at 90°C for 1 hour. Tubes were left overnight. The following morning 1ml 
ethyl acetate was added; samples were capped and placed on the Vortex for 
15 seconds. Once the layers had separated the top organic layer was 
transferred to a clean 1 dram vial containing one level spatula of sodium 
sulphate. A clean glass pasteur pipette was used for each sample. The 
extraction of original sample tube was repeated with a further 1ml of ethyl 
acetate. This was then combined with ethyl acetate extracts. Tubes were 
capped and mixed by placing on Vortex. Dried ethyl acetate was transferred 
to clean labelled 1 dram vials. Tubes were placed under OFN to evaporate to 
dryness at room temperature. The heat block was turned on again and 
allowed to reach 120°C. 100µl acetonitrile and 100µl N methyl N (tert-
butyldimethylsily) trifluoroactemadie (MTBSTFA) was added to tubes which 
were again capped and mixed by placing on the Vortex. Tubes were then 
heated at 120°C for 45 minutes. Afterwards, tubes were cooled and excess 
derivatising reagents were removed under OFN at room temperature before 
reconstituting with 100µl decane. Samples were capped and mixed by placing 
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on the Vortex before transfer to autosampler vials for gas chromatography 
mass spectrometry (GCMS) measurements. 
α-Ketoisocaproic acid enrichment was measured as the quinoxalinol-tert-
butyldimethylsilyl derivative under selected ion monitoring by gas 
chromatography (Hewlett-Packard 5890)-mass spectrometry (MSD 5971A; 
Hewlett-Packard, Berkshire, UK) at mass-to-charge ratios 259 and 260, (see 
Appendices XI and XII). Plasma α-KIC enrichment is a measure of 
intracellular leucine enrichment (Matthews 1982).  
 
2.12.5 Isotope ratio - mass spectrometry (IRMS) 
 
13C enrichment of breath CO2 was measured on a VG SIRA series II isotope 
ratio mass spectrometer (VG Isotech, Cheshire, UK, modified with a 
Roboprep G inlet system, Europa Scientific, Cheshire, UK). Mass 
spectrometers are used to determine the steady state enrichment of the 
metabolite by measuring the abundance of ionised particles at a specified 
mass. The expired breath sample in the exetainer tube is delivered to the 
machine. Once injected, gas is moved through a scrubber tube to remove any 
moisture from the sample. It is then passed through the gas chromatograph 
where the different isotopic species are separated. When the gas of interest is 
extracted from the column it is diverted to the mass spectrometer. As the 
sample gas passes through the mass spectrometer it is ionised and the 
isotopes are separated according to mass-to-charge (m/z) ratio. The isotopic 
species m/z 44, 45 and 46 are collected simultaneously at separate detectors, 
each total beam area being integrated separately, allowing measurement of 
the isotope ratios. 
This technique was first described by Matthews (Matthews 1980) for analysis 
of leucine stable isotope analysis in human subjects.  
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2.12.6 Leucine metabolism calculations 
 
Measurements of leucine metabolism were calculated using standard isotope 
dilution equations (Matthews 1980;Whyte 2010).  
Leucine production rate (Ra: a measure of whole body protein degradation) 
was calculated as: 
Ra =F [1/ (APE x 0.01)] 
F is the isotope infusion rate (µmol/kg/min) and APE is plasma α-KIC 
enrichment.  
Leucine disappearance rate (Rd) was assumed to be equal to Ra.  
Leucine oxidation rate (OX) was calculated as: 
OX = (APECO2 x CO2Ra)/APEKIC 
CO2Ra is the production rate of CO2 and APECO2 the enrichment of expired 
CO2.  
In all cases, leucine oxidation was corrected by assuming that 80% of 13CO2 
was expired. A correction factor of 0.899 for CO2 recovery was used: 
Leucine oxidation x 0.899 (Rodriguez et al. 1986).  
Non-oxidative leucine disposal (NOLD, a measure of whole body protein 
synthesis) was calculated as the difference between Rd and OX.  
NOLD (µmol/kg/min) = LeuRd-LeuOX (corrected) 
Net leucine balance (µmol/kg/h) = (NOLD-LeucineRa) x 60 
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2.12.7 Protein turnover calculations 
 
Net protein balance was estimated using the net leucine balance (NOLD - 
Ra), assuming 8 g leucine/100 g whole body protein. 
Whole body protein synthesis (g protein/kg/d) = NOLD (1440/590*) 
Whole body protein breakdown (g protein/kg/d) = LeuRa (1440/590*) 
* Assuming 590µmol leucine/g protein (Matthews 1980). 
 
Protein Balance (g protein/kg/d) = whole body protein synthesis - whole body 
protein breakdown. 
 
2.13 Leucine-enriched essential amino acid supplementation 
 
Leucine-enriched essential amino acid (L-EAA) supplementation was used as 
an intervention in critically ill trauma patients (Chapter 5). During the planning 
phase of this research Professor Robert Wolfe, an international expert on the 
regulation of muscle metabolism and transport of amino acids between blood 
and muscle tissue, was contacted for his opinion on the use of L-EAA 
supplementation in the critically ill. Prof Wolfe reported this was “an excellent 
rationale for using this supplement in ICU as a greater stimulus for muscle 
protein synthesis can be provided than with intact protein while giving less of a 
nitrogen load. We have done some work showing the L-EAA effect persists in 
insulin resistance, but I know of no such study in the ICU.” (Personal 
communication, 22.10.2008). 
The dose of L-EAA supplementation to promote muscle protein synthesis 
used by Prof Wolfe’s group was 11g twice daily (Borsheim et al. 2008). I 
therefore mixed 100g of EAA powder supplement with 35g leucine powder 
supplement (SHS, Nutricia Ltd, Wiltshire, UK) to obtain the ratio of amino 
acids required. This 135g powder mixture was divided into 25g doses. The 
25g dose contained 18.5g EAA plus 6.5g leucine powder, containing a total of 
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9.5g leucine, 2.7 g valine and 2.1g isoleucine. The branched-chain amino acid 
ratio for this supplement was 1:5:1 for valine: leucine: isoleucine ratio. The 
25g dose was divided into five daily doses administered with 100ml water per 
dose via enteral feeding tubes. By providing doses as five 100ml supplements 
distributed throughout the day the osmolarity was distributed (360mOsm/kg 
per dose). Borsheim et al used 22g per day (Borsheim 2008). The optimal 
dose of leucine to promote muscle protein synthesis is approximately 0.12g 
leucine per kg of lean body mass in healthy people (Drummond and 
Rasmussen 2008). 
There are counter arguments to providing leucine supplementation in the 
critically ill. Two papers point towards leucine supplementation not making any 
difference in septic rats as sepsis was thought to interfere with mTOR 
signalling (Kazi et al. 2011;Lang 2007).  
 
2.14 Screening and recruitment 
 
This study was given a favourable ethics opinion for conduct in the NHS by 
the North West London REC 1/Camden & Islington Research Ethics 
Committee with study reference 10/H0722/40. The essential amino acid 
supplementation study was registered in the controlled clinical trials register 
with study ID number ISRCTN79066838. During the Nutritional Tipping Point 
study patients were recruited from adult intensive care units at Charing Cross, 
Hammersmith and St Mary’s Hospitals from September 2010 to February 
2013. The essential amino acid supplementation study patients were recruited 
from Kings College Hospital from medical and surgical intensive care units 
from May 2012 until the end of January 2013. 
 
2.14.1 Procedure of obtaining informed consent or assent 
 
In line with the Mental Capacity Act 2005 for persons who lack capacity a 
legal representative could provide ‘provisional assent’ in vulnerable groups 
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such as critically ill patients, whilst the patient is unable to do so. A ‘Personal 
Consultee’ was approached in the first instance. If no such a person existed, a 
‘Nominated Consultee’ was appointed who was not connected to the research 
study. Under the Act ‘assent’ was sought from these individuals. 
Retrospective consent was sought once appropriate. 
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Chapter 3. Reliability of Methods 
 
Technique Reliability for Measurement in ICU 
 
In this chapter reliability of techniques used in this research is described. The 
indirect calorimeter obtained for this research (the older Deltatrac I™ model) 
required various gas, flow and alcohol burn tests in order to obtain a functional 
calorimeter. These steps along with a comparison study between three 
Deltatrac II models are described in this chapter. As this equipment failed to 
work in our institution, no subsequent patient data collection was performed. 
 
The second reliability study pertains to the muscle ultrasound technique used 
in this research. This technique in which muscle thickness is measured has 
been previously validated in an ICU setting against DEXA scanning. Reliability 
of this technique had to be established for the researcher (intra-observer 
reliability) which is described in this chapter. In addition, as the research 
assistant and I were collecting muscle ultrasound data from different hospital 
sites, inter-observer reliability for the research assistant and I had to be 
determined (sections 3.2.2 and 3.2.3).  
 
3.1 Indirect calorimetry 
 
Indirect calorimetry (measuring O2 consumption and CO2 production to 
determine energy expenditure) is described as the ‘gold standard’ method to 
determine energy expenditure in the critically ill (Boullata et al. 2007;Bracco et 
al. 1995;Frankenfield 2010). The Deltatrac™ metabolic monitor used to 
measure indirect calorimetry has been validated (Takala et al. 1989;Tissot et 
al. 1995) and has been widely used over the past few decades in 
mechanically ventilated patients. 
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The measurement technique will not be described in detail, however the 
Deltatrac™ metabolic monitor utilises the following principles: 
 CO2 production (VCO2) is measured with infrared analysers on a flow 
or air-dilution principle. 
 The respiratory quotient (RQ) is then calculated by Haldane 
transformation*. 
 O2 consumption (VO2) is calculated via paramagnetic sensor and from 
the RQ. 
 
* The Haldane transformation assumes that only O2 and CO2 are exchanged 
in the lungs whilst nitrogen gas remains equal in inspired and expired air: 
Vi = Ve x FeN2/FiN2 
(Vi: Air volume inspired; Ve: Air volume expired; FeN2 and FiN2: Fractional 
concentrations of nitrogen for expired and inspired air) (Wilmore and Costill 
1973). 
The RQ is calculated via the Haldane transformation as: 
(1-FiO2)/[(FiO2-FeO2)/FeCO2-FiO2)] 
Where FiO2 is inspired oxygen fraction and FeCO2 is expired carbon dioxide 
fraction (Takala 1989). 
 
A Deltatrac I™ was obtained for the purpose of this research. Gas, flow, 
pressure calibration and alcohol burn tests had to be performed before 
equipment could be used for research purposes. Service contracts and 
support from industry are no longer available.  I performed these procedures 
systematically in the Deltatrac I™.  
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3.1.1 Alcohol burn testing 
 
Alcohol burn testing is required to determine the Respiratory Quotient (RQ) 
and therefore evaluate the performance of the Deltatrac™. If a known amount 
of ethanol is burnt (5ml) then it is possible to determine the RQ. Ethanol is 
oxidized according to the following equation:  
 
C2H5OH + 3 O2 = 2 CO2 + 3 H2O 
 
From the equation above the RQ can be calculated as RQ=VCO2/VO2 = 2/3 = 
0.67. At 25°C the density of ethanol is 0.78522g/L and 5ml of pure ethanol 
(100%) will yield 3820ml of CO2. 0.64-0.69 is an acceptable RQ range post 
alcohol burn. 
 
3.1.2 Calculations 
 
From a flow calibration test performed with 5ml 99.7% ethanol, testing yielded 
a total of 3760ml VCO2 over 23min. 
 
Equation for new flow rate: 
= 1.03 x (3820ml/total VCO2 in ml) x old flow 
= 1.03 x (3820ml/3760ml) x 40.2 
= 1.03 x (1.01596) x 40.2 
= 42.1ml/min 
42.1ml/min was added in “Factory Settings” and written on the rear of the 
equipment. 
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The alcohol burn test was repeated after gas calibration, pressure calibration 
and the new flow rate was determined. Alcohol burn testing continued for 
approximately 30min; the last 15 readings of the RQ were averaged as per 
manufacturer’s instructions. 
From our test, last 15 RQ’s =10.1/15  
= 0.67 (accepted range is between 0.64-0.69) 
With an RQ of 0.67, patient trials could be attempted on the Deltatrac I™. 
 
A series of ICU patient trials were conducted on the Deltatrac I™ in our 
institution. Ventilators on our unit include the Siemens 300 (Siemens 
Healthcare, Surrey) and Maquet Servo I (Maquet Ltd., Tyne & Wear 
Sunderland). One successful trial yielded VCO2: 164 ml/min, VO2: 217ml/min, 
energy expenditure of 1450kcal and RQ: 0.73. Thereafter no physiological 
measurements were ever obtained. VO2 consistently displayed an error 
reading of 999, with no RQ and no energy expenditure obtained. Advice was 
sought from Pekka Meriläinen (Parameter Research Director from GE 
Healthcare, Finland). A suggested trial canopy run was conducted and failed.  
 
A number of experts in the field of indirect calorimetry were contacted for 
advice. Prof Singer reported that the Deltatrac™ did not appear to be 
compatible with many of the modern ventilators (e.g. Wella, Siemens, 
Maquet). Prof Singer used Puritan Bennett 840 and Evita 4 during Deltatrac™ 
research and patients were heavily sedated (Singer 2011). 
Prof Wernerman confirmed that the Deltatrac™ appeared not to function well 
with all modern ventilators. Patients in Prof Wernerman’s recent study were 
ventilated using the Evita XL ventilator, (Dräger, Germany) in pressure 
support or pressure controlled modes (Sundstrom 2012). 
Modern ventilators supply respiratory gas into the breathing circuit throughout 
the entire breathing cycle – this is to allow sensitive detection of patient 
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respiratory effort. This ‘bias flow’ or ‘flow by’ modes, which have been 
incorporated to assist the patient with breathing, may interfere with 
Deltatrac™ measurements. 
 
3.1.3 Deltatrac II™ comparison exercise 
  
Since the Deltatrac 1 did not work in our institution I decided to evaluate the 
Deltatrac 11.  Three such machines were available in London from University 
College London, Guys & St Thomas’ NHS Foundation Trust and Chelsea & 
Westminster NHS Foundation Trust. These were compared on the Intensive 
Care Unit at Charing Cross Hospital. The aim of this study was to compare 
the results of these calorimeters on the same critically ill patient on the same 
day, in steady state.  This was done as investigators locally were questioning 
the reliability of the Deltatrac, unusual values for VO2 and RQ were observed 
and investigators wondered whether the bias flow from ventilators could 
potentially interrupt readings. We therefore wanted to assess the readings that 
would be obtained from three different calorimeters that were compared on 
the same patient, same day and same ventilator, even though bias flow could 
not be turned off in this ventilator. 
A suitable stable mechanically ventilated patient was identified on pressure 
support mode of ventilation with a FiO2 of 0.35. The patient was fed over 24h 
as per ICU protocol on a 1kcal/ml fibre based feed which provided 1800kcal 
and 72g protein per 24h. There was no evidence of vomiting and the gastric 
residual volumes were < 200ml over 24h indicating that the patient was 
absorbing her enteral feed. There were no contra-indications to indirect 
calorimetry: FiO2 was below 60%, the patient was not on any renal 
replacement therapy, no gas leaks were evident and no chest drains were in 
situ either. 
All Deltatrac II™ calorimeters had flow calibrations, gas calibrations and 
alcohol burn testing performed on-site prior to testing. The machines were 
warmed up for 30 minutes per manufacturer’s recommendations prior to 
calibration and respiratory quotients’ ranged from 0.67 to 0.69, suggesting 
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appropriate calibration. A steady state was accepted when values for VCO2 
and VO2 were within 10% difference over 10 minutes during testing. The room 
temperature on the intensive care unit was recorded as 23 - 24°C during 
testing. The ventilator used was a Servo-i ventilator (Maquet Critical Care AB, 
Sweden), bias flow could not be turned off in this ventilator. 
 
3.1.3.1 Results: Deltatrac™ comparison study 
 
Measurements from the three Deltatrac calorimeters are summarised in Table 
3-1.  
 
Table 3-1: Measuring three calorimeters on the same ICU patient 
 St Thomas’ 
Deltatrac 
University College 
London Deltatrac 
Chelsea & 
Westminster 
Deltatrac 
% 
Difference 
VCO2 
(ml/min) 
166.6 177 172.2 5.9% 
VO2 
(ml/min) 
201.2 221.8 213.9 9.3% 
RQ 0.83 0.799 0.805 3.7% 
REE 
(kcal) 
1375 1506 1454 8.7% 
 
 
3.1.3.2 Discussion: Deltatrac™ comparison study 
 
The findings of this study show that all three Deltatrac II™ machines 
measured within 10% of each other on the same ICU patient (Table 3-1). This 
suggests that they are all working consistently. As no other measure was 
available to compare the Deltatrac II™ to or validate against it could only be 
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concluded that the Deltatrac II™ appeared to work consistently, however 
accuracy could not be measured in this study.   
In summary, patient data collection could not be obtained for indirect 
calorimetry as Deltatrac I™ measurements were not feasible in our institution. 
All other Deltatrac II™ metabolic monitors in London were in use at the time 
and were not available either on loan.  
 
3.2 Muscle ultrasound reliability studies 
 
Three reliability studies for muscle ultrasound measurements were performed 
to ensure intra- and inter-rater reliability and calibration of the equipment 
including:  
 Transducer calibration against an industry standard phantom limb 
 Intra-rater reliability testing (N=20 healthy subjects) 
 Inter-rater (two raters) reliability testing (N=12 healthy subjects) 
 
3.2.1 Tranducer calibration  
 
In order to calibrate the transducer against an industry standard tissue 
phantom (Gammex, Nottingham, UK) and to determine the accuracy of the 
ultrasound machine’s internal calliper, the transducer was applied to the top of 
the ‘tissue phantom’. The tissue phantom consisted of a gel container with 
wires visible on ultrasound, these wires are positioned at known, fixed 
distances from each other. The transducer was applied to the top of the 
phantom and the callipers were used to measure the distance between the 
different wires, Figure 3-1. 
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Figure 3-1: Calibration of transducer against a tissue phantom 
 
3.2.2 Intra-rater reliability study 
 
Twenty healthy volunteers (eight male, 12 female) were recruited from staff at 
Imperial College Healthcare NHS Trust. Muscle depth measurements were 
made on each subject at four different sites as per methodology described in 
Chapter 2, section 2.9 (page 71). Each subject had two measurements, one in 
the morning and one in the afternoon of the same day. I recorded the results 
separately and did not access the morning readings prior to the afternoon test 
to avoid biasing the results.  
 
Statistical analyses were performed using Statistical Package for Social 
Sciences 20 (SPSS IBM, Chicago, IL) and GraphPad Prism 6.02 for Windows 
(GraphPad Software, La Jolla, CA).  
 
The following reliability tests were selected: 
 Intra-class correlation coefficients (ICC): To determine degree of 
correspondence and agreement in one model (Shrout and Fleiss 
1979). For intra-class correlation with one rater measuring 20 subjects 
Second wire. 2.02cm 
measured to this point. 
First wire. Measured 
from this point. 
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on two different occasions a two way mixed model was used (rater as a 
fixed effect, subjects as random effects, hence a mixed model).  
 Bland Altman analysis: to determine levels of agreement (Bland and 
Altman 1986). 
 Standard error of measurement (SEM): To reflect response stability or 
reliability of the response by assessing the standard deviation of the 
measurement error. 
 
These three measurements (ICC, Bland Altman and SEM) were selected on 
the basis that these tests provide a more accurate indication of muscle 
ultrasound reliability than correlations or coefficients of variations (Rankin and 
Stokes 1998).   
Coefficient of variation was not used as this is not considered to be an 
appropriate measure of reliability. Within-subject standard deviation is of 
importance, not the between-subject standard deviation which is mostly 
supplied with CV calculations (Chinn 1990;Rankin 1998).  
Pearson’s or Spearman’s correlations were not used either as this would 
demonstrate linear association only, not agreement.  
 
3.2.2.1 Intra-class correlation coefficient results 
 
The results are shown in (Table 3-2) with good reliability suggested by the 
high ICC. Nevertheless some variation is seen between the four sites. 
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Table 3-2: Intra-rater reliability, a two way mixed model  
Site Intra-class 
Correlation 
Coefficient * 
95% 
Confidence 
Interval 
Total sites** 0.984 0.958-0.993 
Bicep 0.719 0.415-0.878 
Forearm 0.600 0.226-0.820 
Thigh 1.000 1.000-1.000 
Thigh (12cm) 0.950 0.871-0.981 
* > 0.90: good reliability and validity; > 0.75: good reliability;                                        
< 0.75: poor to moderate reliability 
** Total sites = bicep + forearm+thigh+thigh (12cm) 
 
3.2.2.2 Bland Altman analysis results 
 
Table 3-3 summarises the descriptive statistics for Bland Altman analysis 
from morning and afternoon readings, showing small differences between the 
two measurements. This suggests that my measurement technique produced 
consistent results in the same individual.  
 
Table 3-3: Descriptive statistics from morning and afternoon ultrasound 
measurements for total muscle sites from one rater (N=20) 
 N Min Max Mean SD SEM 
Difference 20 -0.79 0.76 -0.05 0.39 - 
Morning 20 5.62 13.75 10.51 1.83 0.23cm 
Afternoon 20 5.61 13.66 10.56 1.77 0.22cm 
SD: standard deviation; SEM: standard error of measurement; SEM = SD1-reliability 
coefficient. 
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Figure 3-2 below shows the Bland Altman agreement plot for my morning and 
afternoon readings. Mean difference score was -0.05cm, the 95% upper limit 
of agreement (2 SD above the mean) was 0.73cm. The 95% lower limit of 
agreement (2 SD below the mean) was -0.83cm. This analysis is used to 
assess level of agreement visually by assessing the difference between 
measurements plotted compared to the mean value for each subject. 95% of 
the difference values fall within 2 standard deviations above and below the 
mean difference value, 95% limits of agreement (Bland 1986;Ottenbacher and 
Tomchek 1993). Discrepancies are small, 0.78cm (2 SD) above and below the 
mean with the limits of agreement (-0.83 and 0.73) small enough to be 
confident in the level of agreement. The mean difference close to zero 
indicates good agreement, the standard deviation close to zero indicates low 
variation. 
 
 
Figure 3-2: Bland Altman plot of muscle ultrasound from one rater (N=20) 
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3.2.2.3 Standard error of measurement results 
 
Descriptive statistics for my morning and afternoon readings is summarised in 
Table 3-3. Standard error of measurement was calculated separately for 
morning and afternoon measurements and suggested that error was low and 
consistent between morning and afternoon readings. 
 
3.2.2.4 Discussion 
 
Overall it can be concluded that my muscle ultrasound technique 
demonstrated good reliability with good levels of agreement when the 
technique was repeated at different time points on the same subjects. 
Measurement error was low.  
An advantage of using the ICC includes that it takes into account individual 
differences between raters and subjects, biological variability and variability in 
testing conditions or between days of testing (Shrout 1979). Of interest is the 
breakdown in individual site scores per measurement (Table 3-2). Intra-class 
correlation coefficients were > 0.9 for total sites, thigh and T12cm indicating 
good reliability. The ICC for bicep and forearm individually do not show high 
ICC scores. The bicep and particularly the forearm were initially the most 
difficult measurements to perform in healthy subjects and the ICU patient 
group. With the forearm the main issue was in identifying the exact location 
‘on-screen’ where the measurement should be taken from. It was not always 
straightforward to visualise the structures and to find a level bony surface to 
measure from. Therefore repeatability of this particular measurement was 
initially found to be difficult. Reliability for total measurement sites, thigh and 
T12cm were good. Ultrasound measurements of bicep and forearm only 
should not be considered. Total measurement sites were included in the final 
analysis. 
Standard error of measurement reflects the standard deviation of 
measurement error. The SEM has the advantage that it can be interpreted 
clinically, measurement errors for muscle depth on ultrasound of 0.23cm and 
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0.22cm from maximum measurements of 13.75cm and 13.66cm respectively 
seem acceptable. It should however be noted that differences of up to 0.2cm 
were accepted in research subject measurements as outlined in the protocol. 
Coefficient of Variation (CV) and correlations were not included due to their 
limitations as reliability tests, CV was not included as this is not considered to 
be an appropriate measure of reliability. Within-subject standard deviation is 
of importance, not the between-subject standard deviation which is mostly 
supplied with CV calculations (Chinn 1990;Rankin 1998). Pearson’s or 
Spearman’s correlations were not included as this would demonstrate linear 
association only, not agreement.  
 
3.2.3 Inter-rater reliability study 
 
Since patient recruitment was to occur on several sites a research assistant 
was employed to help with data collection. This meant I needed to assess the 
consistency of our measurement techniques. Thus, inter-rater reliability testing 
was carried out.  
Twelve healthy volunteers (two male, ten female) were recruited from staff at 
Imperial College Healthcare NHS Trust. Measurements were made at four 
sites following the protocol outlined in Chapter 2. Subjects were measured on 
the same day by the research assistant and I. The images were stored for 
analysis later, and the two raters did not have access to the other’s 
measurements.  
Statistical analyses were performed using Statistical Package for Social 
Sciences 20 (SPSS IBM, Chicago, IL) and GraphPad Prism 6.02 for Windows 
(GraphPad Software, La Jolla, CA).  
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Selected reliability tests include: 
 Intra-class correlation coefficients - to determine degree of 
correspondence and agreement in one model between two raters. The 
intra-class correlation coefficient was calculated, however, on this 
occasion a two way random effects model was chosen as both the 
raters and the subjects were seen as random effects.  
 Bland Altman analysis - to determine levels of agreement between 
measurements of two raters. 
 Standard error of measurement - to reflect response stability or 
reliability of the response by assessing the standard deviation of the 
measurement error. 
 
3.2.3.1 Inter-rater intra-class correlation coefficient results 
 
Results shown in Table 3-4 indicate good reliability as demonstrated by high 
ICC. Some variation occurs between the four sites. 
 
Table 3-4: Inter-rater reliability with ICC per site, two way random model 
Site Intra-class 
Correlation 
Coefficient * 
95% 
Confidence 
Interval 
Total sites** 0.965 0.882-0.990 
Bicep 0.937 0.798-0.982 
Forearm 0.793 0.427-0.936 
Thigh 0.866 0.550-0.965 
Thigh (12cm) 0.827 0.504-0.947 
* > 0.90: good reliability and validity; > 0.75: good reliability; < 0.75: poor to moderate 
reliability; **Total sites = bicep + forearm + thigh + thigh12cm 
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3.2.3.2 Bland Altman analysis results 
 
Descriptive statistics of Bland Altman analysis for two raters are summarised 
in Table 3-5. 
 
Table 3-5: Descriptive statistics for reliability testing for all muscle sites 
between two raters (N=12) 
 N Min Max Mean SD SEM 
Difference 12 -0.95 1.00 0.02 0.51 - 
Rater 1 12 7.61 13.50 11.28 1.84 0.34cm 
Rater 2 12 7.14 13.72 11.23 2.00 0.37cm 
SD: standard deviation; SEM: standard error of measurement; SEM = SD1-reliability 
coefficient. 
 
Figure 3-3 shows the Bland Altman plot from two raters. The mean score is 
0.02. The 95% upper limit of agreement is 1.04cm and the 95% lower limit of 
agreement is -1.0cm. 95% of the difference scores fall within 2 standard 
deviations above and below the mean difference score (95% limits of 
agreement). Discrepancies are larger than that measured by one rater (one 
rater 0.78cm versus two raters 1.02cm). Limits of agreement are wider (-1.0 
and 1.04).  
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Figure 3-3: Bland Altman plot of muscle ultrasound between two raters (N=12) 
 
 
3.2.3.3 Standard error of measurement results 
 
Descriptive statistics for muscle ultrasound measurements between two raters 
are depicted in Table 3-5. There is a 0.03cm difference between rater 1 and 2 
SEM, error is consistent between the two raters however this was higher than 
SEM recorded by one rater on morning and afternoon readings. 
 
3.2.3.4 Inter-rater reliability discussion 
 
Good reliability has been demonstrated between the researcher and research 
assistant for this muscle ultrasound technique with ICC > 0.9.  
Bland Altman analysis showed wider limits of agreement than that observed in 
the analysis of one rater. There was a 0.03cm difference recorded for 
standard error of measurement between the two raters, error was consistent 
between two raters however higher than that observed in one rater. One 
possible explanation for this difference could be time constraint. Error could 
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have been introduced when researchers attempted to speed measurements 
up as the equipment was continually requested for clinical use during this 
reliability study. Future muscle ultrasound reliability studies should ensure that 
measurements could be undertaken undisturbed. 
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Chapter 4. Nutritional Tipping Point 
 
4.1 Introduction 
 
In this observational study in critically ill patients I wanted to assess whether a 
notional ‘nutritional tipping point’, where anabolism starts to exceed 
catabolism, could be identified within a period of critical illness. If such a point 
could be identified, nutritional strategies could be targeted in an effort to 
minimise protein breakdown. Nutrition guidelines often refer to targeting 
nutritional interventions once patients are in the ‘anabolic’ or ‘recovery phase’, 
however this point has not yet been defined during a period of critical illness.  
 
Additionally the inter-relationships between nutritional and inflammatory 
markers in the critically ill have been explored and are described in this 
chapter. Lastly this current data set was explored for surrogate endpoints that 
could be used in future nutritional clinical trials. 
 
This observational study was conducted in adult patients at Imperial College 
Healthcare NHS Trust on Intensive Care Units at Charing Cross, 
Hammersmith and St Mary’s Hospitals. 
 
4.1.1 Research Question 
 
Is there a “nutritional tipping point” (the point where anabolism starts to 
exceed catabolism) where a nutritional intervention is more likely to be 
effective in attenuating muscle mass loss on ICU? 
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4.1.2 Aims 
 
1) To identify a nutritional tipping point where anabolism starts to exceed 
catabolism during a period of critical illness. 
2) To explore inter-relationships between inflammatory and nutritional 
markers during critical illness. 
3) To explore data for surrogate endpoints for use in a future nutritional 
clinical trial where effect size and sample size could be determined 
from the current dataset. 
 
4.2 Methods 
4.2.1 Outcome measures  
 
The data collection methods for outcome measures were described in 
Chapter 2, the study plan describing the timing of data collection can be seen 
in Figure 4-1.   
The primary outcome measures were muscle depth change and nitrogen 
balance. Muscle depth change (cm) was measured by ultrasound on alternate 
days during the first week of the study and twice weekly thereafter, see 
chapter 2, section 2.9, p72. 
Nitrogen balance (g/day) was calculated using both the British Dietetic 
Association’s Parenteral and Enteral Nutrition Group (PENG) recommended 
equation and the Deacon equation (Deacon 2009), see chapter 2, section 2.8, 
p70. 
Secondary outcome measures include: 
Inflammatory markers C-reactive protein (CRP) (mg/L) and serum albumin 
levels (g/L) were obtained from the Imperial College Healthcare Trust clinical 
chemistry results database. CRP and albumin levels were collected on days 
1, 3, 7, 14 and 20 of the study. The new prognostic inflammatory and 
nutritional index (PINI) was calculated from CRP and serum albumin levels. 
The ‘new PINI’ method includes calculation of log (CRP) /Albumin. Cytokines 
 111 
IL-6 (pg/ml) and IL-10 (pg/ml) were measured from plasma samples collected 
on days 1, 3, 7, 14 and 20 of the study, see chapter 2, section 2.1, p64. 
Urinary studies for 3-methylhistidine (µmol/24h) and urinary urea (mmol/24h) 
were performed on days 1, 3, 7, 14 and 20 of the study, see chapter 2, section 
2.7, p69. 
 
4.2.2 ICU data  
 
Other data collected included estimated weight (kg) and height (m) of patients 
to ascertain pre-admission body mass index (BMI, kg/m2). Medical notes were 
checked for recent measurements. Relatives were asked for weight and 
height data if none were recorded in the medical notes. Additionally the age 
(years) and gender of each patient was recorded. Daily energy (kcal) and 
protein (grams) intakes were recorded from ICU observation charts. Gastric 
residual volumes (ml) and incidence of vomiting were collected to describe 
tolerance to enteral feeding. Occurrence of diarrhoea was also recorded. 
Various ICU data were recorded as descriptors of the type and severity of the 
illness or injury: diagnosis, past medical history, Acute Physiology and 
Chronic Health Evaluation (APACHE) II score, admission Sequential Organ 
Failure Assessment (SOFA) score, Glasgow Coma Scale, ventilation status, 
use of renal replacement therapy, ICU length of stay (days) and ICU outcome 
(dead or alive). Although the SOFA was designed for serial collection during a 
period of critical illness, in two of the hospitals admission SOFA was collected 
only. 
Functional outcomes via the Katz and Barthel indices were recorded (Chapter 
2, section 2.10, p77). Both indices were used on the same patient at the same 
time point. Any uncertainty in functional assessment was clarified with the 
senior ICU physiotherapist.  
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Other ICU data thought to potentially influence muscle integrity or muscle 
depth measurements were recorded including use of steroids during ICU stay, 
sedation use, insulin administration (units/24h), fluid balance (ml/24h) and 
physiotherapy (particularly mobility or rehabilitation therapy). 
 
4.2.3 Study plan 
 
The study plan for this study is depicted below in Figure 4-1 where data 
collection from each time point can be seen. 
 
 
Figure 4-1: Study plan for Nutrition Tipping Point study 
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4.2.4 Sample Size Calculation 
 
By convention for regression analysis and multilevel models, ten patients 
should be recruited per variable observed. Eight variables will be included in 
the model (C-reactive protein, albumin, IL-6, IL-10, urinary urea, 3-
methylhistidine, nitrogen balance and muscle depth), therefore 80 patients 
should be required.  
 
4.2.5 Statistical Analysis 
 
Descriptive statistics analyses were performed using Statistical Package for 
Social Sciences 20 (SPSS IBM, Chicago, IL) and GraphPad Prism 6.02 for 
Windows (GraphPad Software, La Jolla, CA). Significance was set at 0.05%. 
Descriptive data were checked for normality and subsequently presented as 
mean (SD) or median (IQR) for continuous data. Categorical data are 
presented as frequencies. Histograms and bar plots were used in order to 
describe the distribution of patient characteristics. (Appendix VII, p247).  
 
CRP, albumin, urinary urea, 3-methylhistidine, nitrogen balance, total muscle 
depth, IL-6 and IL-10 were measured serially in patients. Multilevel models 
were used to determine the changes over time taking into account the 
correlated nature of repeats within individuals. Multilevel modelling was 
selected as there were multiple predictors i.e. more than one explanatory term 
in the model with a repeated measures design of a single outcome; this type 
of analysis is multivariate analysis (Hidalgo and Goodman 2013). In this way 
the individual trajectories were compared and contrasted according to other 
factors (day of measurement, age, gender, BMI, ICU length of stay). The 
precise form of multilevel model depended on the distribution of that particular 
outcome. Normality was tested for all outcomes using histograms and PP 
plots and several transformations were also tested. Where the outcome was 
transformed to square root transformation to obtain normal distribution (CRP, 
albumin, urinary urea, 3-MH and total muscle depth) linear multilevel models 
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were used. Interleukin-10 could not be transformed to normality but was 
dichotomised at <0pg/ml and >0pg/ml, since this was a clinically meaningful 
cut-off, and a logistic multilevel model was used to characterise changes over 
time. Nitrogen balance (assessed via the PENG and Deacon equations) and 
IL-6 could not be transformed to normality, for these non-parametric (median) 
multilevel models were used. Day of measurement (Day 1, 3, 7 or 14 of study) 
was included as a factor in all models. Day 1 of study was not necessarily day 
1 on ICU as patients were recruited to the study within 72h of their ICU 
admission. Other variables (age, gender, BMI and ICU length of stay) were 
incorporated in turn to find the best fitting models. Both forwards and 
backwards stepwise approaches were used to verify that the results did not 
differ according to method selected. For nitrogen balance, other biomarkers 
were also investigated as potential predictors. 
 
Normalising transformations (i.e. square, square root, inverse, inverse of 
square root and logarithmic) were applied for C-reactive protein, albumin, 
urinary urea, 3-methylhistidine, muscle depth, interleukin-10, interleukin-6 and 
nitrogen balance (The Parenteral and Enteral Nutrition Group (PENG) of the 
Bristish Dietetic Association and Deacon equations were used). Square root 
transformation produced normality for CRP, albumin, urinary urea, 3-MH and 
muscle depth. None of the tested transformations led to normal distribution for 
nitrogen balance (PENG and Deacon equations), IL-10 or IL-6. Patients were 
dichotomized to those with IL-10 levels equal to 0.00 pg/ml (i.e. undetectable 
IL-10 values) and those with IL-10 levels > 0.00 pg/ml.  
 
For variables where a transformation was used in order to achieve normally 
distributed data and for normally distributed variables, linear multilevel models 
were used to evaluate the association of day of measurement (i.e. time) with 
the biomarker levels, taking into account age, gender, BMI and total duration 
of stay on the ICU. (Jose Pinheiro, Douglas Bates, Saikat DebRoy, Deepayan 
Sarkar and the R Development Core Team (2013). R package version 3.1-
108). Multilevel modelling for binary responses was used for IL-10 to evaluate 
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the association of day of measurement (i.e. time) with the odds of having IL-
10 levels >0.00 pg/ml, taking into account age, gender, BMI and total duration 
on the ICU. (Douglas Bates, Martin Maechler and Ben Bolker (2012). R 
package version 0.999999-0). 
For those variables where no transformation was found appropriate median 
multilevel models were used in order to evaluate the association of day of 
measurement (i.e. time) with a change in median levels of response variables, 
taking into account age, gender, BMI and total length of stay in the ICU. 
(Marco Geraci (2012). R package version 1.02). 
Results regarding square root transformations are presented as b-coefficients 
(95% Confidence Intervals), while results for logarithmic transformations are 
presented as exponentiated b-coefficients (95% Confidence Intervals).  
Predicted values for each response variable were also calculated and 
presented along with their corresponding 95% confidence intervals. Predicted 
values are a range of values one might expect to see for each biomarker 
given that biomarkers were modelled against fixed variables: day of 
measurement, age, gender, BMI and ICU length of stay. The strength of 
association between biomarkers and fixed variables were therefore assessed. 
Tables with predicted values are presented in Appendix X, p254. 
Further analyses of factors related to biomarkers were performed taking into 
account ICU outcome (alive/dead), steroid use (yes/no) and nutritional 
adequacy (calories received versus prescribed and grams of protein received 
versus prescribed). Calories received versus prescribed were documented as 
“% energy intake” and grams of protein received versus prescribed were 
documented as “% protein intake”. These variables were included in the 
model with best fit derived from the previous analysis (where biomarkers were 
modelled against day of measurement, age, gender, BMI, ICU length of stay) 
and multiple regression models were performed. (Section 4.3.9, p157 results; 
section 4.4.7, p180 discussion). 
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For comparison of the new prognostic inflammatory and nutritional index (new 
PINI) a Friedman test was used (two way analysis of variance by ranks) for 
non-parametric data. This was used as an alternative to repeated measures 
ANOVA for non-parametric data to detect change over time in PINI scores 
from days 1 to day 14. 
 
4.2.6 Surrogate endpoints methodology 
 
Data were explored for plausible surrogate endpoints to be used in a future 
nutritional clinical trial where effect size and sample size could be determined 
from the current dataset. Values from CRP, serum albumin, urinary urea, 3-
MH and muscle depth were assessed from the current data set. A 5%, 10%, 
15% and 20% effect size was calculated from each mean value for days 7 and 
14 and the difference between days 7 to 14 to determine what a meaningful 
change in the result might look like. A sample size estimate was then 
determined from each of these changes. Early intervention before day 7 was 
thought unlikely to change an endpoint, therefore results from day 7 and 14 
were used. For muscle depth results for day 1 and day 14 were however used 
as the first day of muscle ultrasound measurement on ICU reflected the 
highest muscle bulk. In each case the power (β) was selected as 0.8 and 
alpha was selected as 0.05. 
 
4.3 Results: Nutrition Tipping Point Study 
4.3.1 Screening and recruitment 
 
This observational study was conducted from September 2010 to February 
2013, during which 1475 ICU patients were screened for potential inclusion 
into this study. The target of recruiting 80 patients for this study was achieved. 
The number of patients excluded from this research was 1395 patients.  
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Patient screening, exclusions and recruitment are shown in Figure 4-2. 
Although 80 patients were recruited to the study two patients died before 
testing commenced. The total number of patients included in the analysis is 
therefore 78. Additional patients could not be recruited due to time constraints. 
Patients were recruited within 72h of their ICU admission, ‘Day 1’ refers to day 
1 of  study, which occured between day 1-3 of the patient’s ICU admission. 
APACHE II score was determined according to day of admission to the ICU, 
not day 1 of study. 
 
 
 
Figure 4-2: Patient recruitment for the Nutrition Tipping Point study 
 
(CXH: Charing Cross Hospital; HH: Hammersmith Hospital; SMH: St Mary’s Hospital; KCH: 
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The majority of patients were recruited from Charing Cross and Hammersmith 
Hospitals. One patient was recruited from Kings College Hospital during the 
time that I was recruiting there for the amino acid supplementation study (See 
Chapter 5). Reasons for patient exclusion have been indicated in Figure 4-2 
and Figure 4-3. The majority of exclusions 765 (55%) were due to patient 
extubation within 48h of their ICU admission. ‘Other’ reasons included patients 
unable to provide retrospective consent due to learning difficulties or 
dementia, patients enrolled into other studies, patients receiving long term 
steroids and wheelchair bound patients. 
 
 
Figure 4-3: Patient exclusions for the Nutrition Tipping Point study, N=1395 
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4.3.2 Demographics  
 
Demographic data are presented in Table 4-1.  
Table 4-1: Demographic data of ICU patient cohort (N=78) 
Demographic factors ICU patients N=78 
Age (years) 
   Mean (SD) 
   Range  
 
59 (16) 
24-89 
Sex Male n (%) 54 (69.2%) 
BMI (kg/m²) 
   Median (IQR) 
 
25.9 (22 -30.6) 
APACHE II score 
   Mean (SD) 
 
21.6 (7.7) 
ICU Length of stay (days) 
   Median (IQR) 
 
10 (6 -16) 
Diagnostic categories:  
Vascular surgery 6 (7.6%) 
Major Trauma 6 (7.6%) 
Traumatic Brain Injury 6 (7.6%) 
Cardiology/Cardiac surgery 14 (17.9%) 
HIV 2 (2.5%) 
Gastroenterology 3 (3.8%) 
Respiratory failure 19 (24%) 
Neurology/neurosurgery 9 (11.4%) 
Gastrointestinal Surgery 3 (3.8%) 
Sepsis/Septic Shock 8 (10.1%) 
Multi-organ failure 1 (1.3%) 
Renal Failure 1 (1.3%) 
ICU: Intensive Care Unit; SD: standard deviation; IQR: interquartile range; BMI: Body Mass Index; 
APACHE II: Acute physiological and chronic health evaluation II; HIV: Human immunodeficiency virus. 
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Baseline values for nutritional and inflammatory markers at day one of 
measurement are presented in Table 4-2. Notably median CRP and IL-6 
values at baseline are higher than the normal range (<5 mg/L and > 1.8pg/mL 
respectively). Median serum albumin is lower than the normal range (35-
50g/L), 3-MH (a surrogate marker for muscle breakdown respectively) is 
elevated and nitrogen balance is negative at baseline. No laboratory normal 
range is quoted for urinary urea per 24h. On day one of measurement an 
amplified inflammatory response and catabolic response is evident. 
 
Table 4-2: Baseline values for nutritional and inflammatory markers (1st day of 
measurement). Results are presented as median (IQR). 
Biomarker (Normal range) Valid Median (IQR) 
C-reactive protein, mg/L 
(0.0-5.0 mg/L) 
78 110 (67, 196) 
Serum albumin, g/L 
(35-50 g/L) 
78 22 (17, 26) 
Urinary urea, mmol/24h 
(no laboratory normal range) 
57 243 (118, 419) 
3-Methylhistidine, µmol/24h 
(75-226µmol/24h)* 
58 274 (178, 448) 
Nitrogen balance (PENG equation), g/day 
(> 0 g/day) 
54 -10 (-15, -2.75) 
Nitrogen balance (Deacon equation), g/day 
(> 0 g/day) 
54 -5.67 (-9.85, 1.01) 
Muscle depth, cm 75 6.78 (4.37, 9.51) 
Interleukin-10, pg/mL 
(7.8pg/ml)** 
78 0.00 (0.00, 211) 
Interleukin-6, pg/mL 
(<1.8pg/ml)*** 
75 34 (8.7, 102) 
* (Lukaski et al. 1981;Sjolin et al. 1989) ** (Nemunaitis et al. 2001) *** (Haack et al. 2007) 
 
 121 
4.3.3 Muscle depth loss in ICU patients 
 
Of the 78 patients entered into this study three were excluded from muscle 
ultrasound results as they were measured at one time point only. Fourty five 
patients completed 7 days of ultrasound measurement and displayed a 
significant muscle depth loss over 7 days on ICU, Table 4-3. Seventeen 
patients completed 14 days of ultrasound measurement and displayed a 
significant muscle depth loss over this period, Table 4-4 and (Figure 4-4).  
 
Table 4-3: Muscle depth change over 7 days (N=45) 
 Starting muscle 
depth (cm), N=45 
End muscle 
depth (cm), N=45 
P value 
Mean (SD) 7.60 (3.68) 6.50 (3.13) * <0.0001 
95% CI 6.45-8.75 5.52-7.47  
* paired t-test 
 
 
Table 4-4: Muscle depth change over 14 days (N=17) 
 Starting muscle 
depth (cm), N=17 
End muscle 
depth (cm), N=17 
P value 
Mean (SD) 8.48 (3.18) 6.81 (2.22) * <0.0001 
95% CI 6.85 - 10.12 5.67 - 7.95  
* paired t-test 
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Figure 4-4: Muscle depth loss over 14 days (N=17) 
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Mean muscle loss was 1.2% per day over 14 days on ICU. Losses over the 
initial 7 days were accelerated with a mean 1.4% daily muscle depth loss 
observed over the first week. 
 
Table 4-5: Percentage muscle loss over 14 days (N=17) 
 
  Day 3 (n=17) 
Mean (SD), 95% CI 
Day 7 (n=17) 
Mean (SD), 95% CI 
Day 14 (n=17) 
Mean (SD), 95% CI 
Percentage  loss 
 
-3.28 (10.82) 
-8.84 to 2.29 
-10.11 (11.5) 
-16.24 to -3.99 
-17.37 (11.28)  
-23.17 to -11.57 
Daily loss (%) 1.1% 1.4% 1.2% 
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4.3.4 Nutritional tipping point 
 
Results are presented as median values for muscle depth loss, urinary urea, 
urinary 3-MH and CRP plotted against day of measurement on ICU to visually 
explore whether a nutritional tipping point could be identified in patients that 
remained on the ICU over 14 days. Nitrogen balance data remained negative 
during ICU stay. Afterwards multilevel modelling results are presented with 
predicted values for each variable to explore whether a nutritional tipping point 
could be identified. Lastly the new PINI equation was used to determine if a 
nutritional tipping point could be defined from this new equation. 
 
Key finding 
A nutritional tipping point is unlikely to exist during ICU stay due to a 
continuing inflammatory process, increasing protein breakdown and 
progressive muscle depth loss. 
 
In Figure 4-5 median urinary urea (N=14) was plotted alongside muscle depth 
loss as measured by ultrasound (N=14) in patients that remained on ICU over 
14 days. Results are presented as medians (IQR). Urinary urea was used as 
a surrogate marker for protein breakdown. Muscle depth loss increased over 
the 14 day period, with a 16% (-27.2 to -8) loss by day 14. Baseline 
measurement at day 1 was taken as 0% loss. On day 3 a median 1.6% (-12.2 
to 2) loss was observed and on day 7 a median 8.3% (-19.3 to -1.4) loss. 
 
Median urinary urea on day 1 of measurement was 377.8 (217.2 - 737.5) 
mmol/24h, on day 3 was 458 (231 - 596.4) mmol/24h, on day 7 was 493.3 
(410.5 to 896) mmol/24h and on day 14 was 225 (145.8 - 701.5) mmol/24h. 
Median urinary urea peaked at day 7 and decreased by day 14, however 
values remained elevated during 14 days on ICU. 
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The increasing muscle depth loss and ongoing protein breakdown over 14 
days depict an ongoing catabolic phase. This suggests that a nutritional 
tipping point is unlikely to exist during 14 days of critical illness. 
 
 In Figure 4-5 median urinary urea was plotted alongside median urinary 3-
MH over time on ICU. Results for both urinary urea and 3-MH peaked at day 7 
of measurement and both sets of results remained elevated during 14 days of 
measurement on ICU. This suggests that catabolism or protein breakdown 
persists over 14 days on ICU. 
          
In Figure 4-5 median CRP (N=17) was plotted alongside muscle depth loss 
on ultrasound (N=17) over 14 days. Results are presented as median CRP 
and IQR. CRP on day 1 of measurement was 110 (50-253) mg/L, day 3 was 
161 (90-288) mg/L, day 7 was 169 (27-298) mg/L and on day 14 was 50.6 
(15.8-217.3) mg/L.  
 
Values for CRP, although decreasing, have not returned to within a normal 
range within 14 days on ICU. Muscle depth loss has increased over this time 
as described. With an ongoing inflammatory process and increased muscle 
depth loss a nutritional tipping point is unlikely to exist within 14 days of 
measurement on ICU. 
                                                                                       
In Figure 4-5 median CRP (N=14) and median urinary urea (n=14) were 
plotted over 14 days. With an ongoing inflammatory process and persistent 
protein breakdown a nutritional tipping point is unlikely to exist within 14 days 
on ICU.     
 
In Figure 4-6 urinary 3-MH (N=14) is plotted alongside median muscle depth 
loss (N=14) over 14 days on ICU. Median 3-MH values for day 1 were 369 
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(255-572) µmol/24h, on day 3 were 315 (266-539) µmol/24h, on day 7 were 
349.5 (193-475) µmol/24h and on day 14 were 207 (65-594) µmol/24h.  
 
3-Methylhistidine values remained elevated (normal range: 75-226µmol/24h) 
during 14 days on ICU suggesting there is ongoing muscle breakdown. 
Increasing muscle depth loss over 14 days in addition to raised 3-MH levels 
suggests that a nutritional tipping point is unlikely to exist within 14 days on 
ICU and that catabolism persists during this period. 
 
Nitrogen balance remained negative during ICU stay confirming continuing 
protein breakdown. Median (IQR) nitrogen balance for day 1 was -10 (-14.8 to 
-3) g/d, day 3 was -6 (-15.8 to -1.8) g/day, day 7 was -9.6 (-19.1 to -3.3) g/day 
and day 14 results were -4.6 (-17.4 to -0.8) g/day. Nitrogen balance data are 
presented for 14 days on ICU, Figure 4-7. 
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Figure 4-5: Median urinary urea (n=14), muscle loss (n=17), 3-MH (n=14) and CRP (n=17) over 14 days on ICU
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 Figure 4-6: Median 3-MH (n=14) and muscle loss (n=14) over 14 days on ICU. 
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     Figure (a) Nitrogen balance serial measurements 
                
     Figure (b) Nitrogen balance per day of measurement 
Figure 4-7: Nitrogen balance serial measurements (a) and nitrogen balance 
values per day  of measurement on ICU (b) 
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4.3.5 Nutritional tipping point - univariate analysis 
 
Correlations were performed to assess the strength of association between 
muscle depth loss with age, maximum CRP, APACHE II score, SOFA score, 
nitrogen loss, 3-MH, 3-MH: creatinine ratio, mean daily energy intake and 
mean daily protein intake in patients who remained on the ICU over 7 days. 
Spearman Rank correlations for non-parametric data were performed, 
Figures 4-10 and 4-11. 
Muscle depth loss was correlated with age to see if older age was associated 
with more muscle depth loss, a non-significant association was observed, 
Table 4-6.  
The linear association between muscle depth loss and maximum CRP was 
assessed to see if higher CRP correlated with more muscle loss, a weak 
negative correlation was observed was seen, Table 4-6. 
The linear association between muscle depth loss and APACHE II score was 
assessed to determine if higher APACHE II scores (sicker patients) were 
associated with higher muscle loss, a non-significant association was 
observed, Table 4-6. 
Muscle depth change was plotted with the Sequential Organ Failure 
Assessment (SOFA score). SOFA scores are used on the ICU to track the 
patients’ status and severity of illness during their stay on ICU. Unfortunately 
admission SOFA scores only could be used as serial scores were not 
collected on a daily basis at all the hospitals. Linear association between 
muscle depth loss and SOFA was assessed to determine if sicker patients 
demonstrated higher muscle loss, a non-significant association was observed, 
Table 4-6. 
The strength of association between muscle and nitrogen loss was assessed, 
a  non-significant association was seen,Table 4-6. 
The strength of association between muscle depth change and the urinary 3-
MH: creatinine ratio was assessed. Urinary 3-MH: creatine ratio has been 
used as 3-MH measurements are thought to have larger interindividual 
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variation, concerning in particular muscle mass, than what the 3-MH: 
creatinine ratio might have (Lukaski 1981;Sjolin 1989). This ratio was however 
not used in results presented in this research (multilevel modelling) as one 
major disadvantage of using the 3-MH: creatinine ratio is that urinary 
creatinine excretion has been found to be increased during infection and 
trauma (Long et al. 1981;Sjolin 1989). Investigators studying protein 
catabolism via urinary 3-MH losses in the critically ill patient tend not to use 
the urinary creatinine ratio for this reason (Welle 1999). Nevertheless a non-
significant association was observed, Table 4-6. 
  
The strength of association between muscle depth change and energy intake 
was assessed to determine if lower muscle depth was associated with lower 
energy intake. The mean energy intake over 7 days in 45 subjects was 
1119kcal/day, a non-significant association was found, Table 4-6. 
Equally, the strength of association between protein intake and muscle depth 
change over 7 days was assessed to determine if lower protein intakes were 
associated with lower muscle depth. Mean protein intake over 7 days in 45 
subjects was 50g/day, a non-significant association was found, Table 4-6. 
 
The strength of association between nitrogen loss and 3-MH change was 
assessed. A strong positive association was observed, r=0.715, p=0.000272. 
(Figure 4-8) 
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   Nitrogen loss and 3-MH change  
                
Figure 4-8: Correlation between the change in 3-MH and nitrogen loss over 7 
days (N=21) 
Apart from a clear strength of association between nitrogen loss and 3-MH 
excretion all other correlations were weak. No confounding factors could 
however be assessed with univariate analysis, correlation therefore provides 
limited information. 
As CRP is regulated by Interleukin-6, univariate correlation was performed to 
determine the strength of relationship. A positive association was observed, r 
= 0.535, p<0.000 in n=192 data points, which was derived from all patients 
over all time points. 
 
Figure 4-9: Spearman’s rank correlation between CRP and IL-6
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Table 4-6: Correlation matrix for muscle depth loss  
 
Spearman 
rank 
correlation 
Muscle 
depth loss 
Age Maximum 
CRP 
APACHE II 
score 
SOFA 
score 
Nitrogen 
loss 
3-MH: 
creatinine 
ratio 
Energy 
intake 
Protein 
intake 
Muscle 
depth loss 
1.00 -0.04 -0.289 -0.124 -0.138 -0.025 0.230 -0.031 -0.074 
Significance - 0.8 0.054 0.442 0.395 0.917 0.358 0.837 0.629 
N - 45 45 42 40 20 18 45 45 
 
134 
 
                               Age                                Maximum CRP 
                    
                          APACHE II score        SOFA score                                                  
                                     
Figure 4-10: Correlation between percentage muscle loss and age (N=45), max CRP (N=45), APACHE II (N=42) and SOFA score (N=40) 
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Nitrogen Loss                  3-MH: creatinine ratio                                                  
                                     
                        Energy intake         Protein intake 
                                             
Figure 4-11: Correlation between percentage muscle depth loss and nitrogen loss (N=20), 3-MH: creatinine ratio (N=18), energy intake 
(N=45) and protein intake (N=45)
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 4.3.6 Nutritional tipping point - multilevel modelling results 
 
Multilevel modelling results confirm the findings that a nutritional tipping point 
is unlikely to exist during ICU stay. Predicted values for CRP, serum albumin, 
urinary urea, 3-MH and muscle depth indicate persistent protein breakdown, 
increasing muscle depth loss and a continuing inflammatory process during 
20 days on ICU. Predicted values were calculated from multilevel models, 
these values represent the range of values one might expect to see for CRP, 
serum albumin, urinary urea, 3-MH and muscle depth when these markers 
were modelled against fixed variables (day of measurement, age, gender, BMI 
and ICU length of stay). Predicted values are presented as means (95% 
confidence intervals). Tables containing predicted values are presented in  
Appendix X, p247. 
 
4.3.6.1 Predicted values for C-reactive protein  
 
Although C-reactive protein values decrease over time they remain above the 
normal range (0.0-5.0 mg/L) during 20 days on ICU, reflecting an ongoing 
inflammatory response. CRP levels were predicted to be on average ~115 
mg/L (95% CI: 95 - 136 mg/L) for the 1st day of measurement during ICU 
stay, which may fall to ~36 mg/L (95%CI: 16 - 65 mg/L) for the 20th day of 
measurement.  
 
4.3.6.2 Predicted values for serum albumin 
 
Serum albumin levels remained below the normal range (35-50g/L) during 20 
days on ICU. Albumin levels were predicted to be ~20.6 g/L (95% CI: 19.2 - 
22.1 g/L) on average for the 1st day of measurement on ICU, which may 
increase to ~21.4 g/L (18.7 - 24.3 g/L) on average for the 20th day of 
measurement.     
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Figure 4-12: Predicted values for CRP (mg/L) and serum albumin (g/L) with corresponding 95% confidence intervals according to day 
of measurement on ICU.      
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 4.3.6.3 Predicted values for urinary urea 
 
Predicted urinary urea levels increased during 20 days on ICU suggesting 
increasing protein loss during this period. Urinary urea levels were predicted 
to be on average ~262 mmol/24h (95% CI: 205 - 326 mmol/24h) for the 1st 
day of measurement on ICU, which may increase to ~327 mmol/24h (167- 
541 mmol/24h) for the 20th day of measurement. Sicker patients will continue 
to deteriorate and display increasing protein loss however those patients that 
are improving should get better and protein loss should improve. 
                
Predicted urinary urea excretion was converted to nitrogen and protein loss  
using the following equations, see Table 4-7: 
Nitrogen loss (g/day) = (urinary urea x 0.028) + 2.2 (losses of nitrogen through 
faeces or sweat) (Deacon 2009).  
Protein loss (g/day) = Nitrogen loss x 6.25. 
 
Table 4-7: Predicted values of urinary urea, nitrogen loss and protein 
breakdown 
 Urinary urea 
(mmol/24h) 
Nitrogen loss 
(g/day) 
Protein loss 
(g/day) 
Day 1 (95% CI) 262 
(205 - 326) 
9.54 
(7.94 – 11.33) 
59.6 
(49.63 – 70.8) 
Day 20 (95% CI) 327 
(167 - 541) 
11.36 
(6.88 – 17.34) 
71 
(43 – 108.4) 
 
Laboratory normal ranges for urinary urea were not provided. In the literature 
the following urine nitrogen ranges have been identified: 
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In healthy subjects: 11.68 - 17.16g nitrogen per 24h (Bingham and Cummings 
1985). This was determined over 28 days whilst subjects continued to eat 
their usual diet. 
In trauma patients: 11.4 - 21.8g nitrogen per 24h (Buonpane et al. 1989). 
In healthy patients: 3.88 - 13.6g nitrogen per 24h and 1.8 - 6.39g nitrogen per 
24h in septic patients (Long 1981). 
  
There is clearly a lot of variation in reference ranges quoted, my cohort does 
not initially appear to display accelerated loss. However, daily protein loss 
may be nearly 60g protein on day 1 of measurement which may increase to 
71g loss by day 20. It is clear that unless approximately 60-70g of protein 
(Table 4-7) was consumed, on average, these losses would not be 
counteracted. Mean daily protein intake for this cohort was 52.7 g/day, yet 
estimated mean daily protein requirement was 97g/day. Protein intake 
therefore only met 54% of their daily protein requirement.  
 
4.3.6.4 Predicted values for 3-methylhistidine 
 
3-Methylhistidine levels, although decreasing over time, remained above the 
normal range (75 - 226 µmol/24h) over 15 days on ICU suggesting ongoing 
protein breakdown. 3-Methylhistidine values were predicted to be on average 
~336 µmol/24h (287 - 388 µmol/24h) on the 1st day of measurement in, for 
example, 52 year old patients and decreased to ~255 µmol/24h (174 - 351 
µmol/24h) on the 15th day of the measurement, suggesting maximal muscle 
wasting occurs early on. 
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                          3-Methylhistidine (µmol/24h)              
                                                                
 
 
Figure 4-13: Predicted values for urinary urea (mmol/24h) and 3-MH (µmol/24h) with corresponding 95% confidence intervals 
according to the day of measurement on ICU
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4.3.6.5 Predicted values for total muscle depth  
 
Total muscle depth decreased over time during patients’ ICU stay. Starting 
muscle depth values were predicted to be on average ~7.1cm (6.2 - 8.0cm) 
on the 1st day of measurement in, for example, 52 year old male patients. 
This decreased to ~5.7cm (5.0 - 6.5cm) on the 15th day of the measurement. 
For 63 year old male patients predicted muscle depth was on average ~6.7cm 
(5.9 - 7.7cm) on the 1st day of measurement which decreased to ~5.7cm (4.9 
- 6.5cm) on the 11th day of measurement. 
 
           
Figure 4-14: Predicted values for total muscle depth (cm) in 52 year old male 
patients (L) and 63 year old male patients (R) per day of measurement (95% 
confidence intervals included). 
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4.3.7 The new prognostic inflammatory and nutritional index  
 
The new prognostic inflammatory and nutritional index (new PINI) does not 
appear to provide any indication of a notional nutritional tipping point.  
The new PINI, calculated as log (CRP) /Albumin was assessed over 14 days 
to determine whether the new PINI would provide any indication of a 
nutritional tipping point. This calculation was performed in N=45 patients that 
remained on intensive care for a minimum of seven days. Results are 
presented as median PINI (IQR). Higher PINI is associated with an 
inflammatory response.  
 
Table 4-8: The new PINI measured over 14 days  
 PINI day 1 PINI day 3 PINI day 7 PINI day 14 
N 45 45 45 17 
Median 
(IQR) 
0.104 
(0.072-0.1445) 
0.103 
(0.067-0.1425) 
0.079 
(0.059-0.1235) 
0.066 
(0.055-0.115) 
 
The Friedman test was used as an alternative to repeated measures ANOVA 
for non-parametric data to detect change over time in PINI scores. Results 
indicate a non significant reduction in median PINI from days 1 to 14, 0.104 to 
0.066, p=0.464. The Friedman test for 3 groups, PINI from days 1 to 7 
showed a significant reduction in PINI from 0.104 on day 1 to 0.079 on day 7, 
p=0.0278. 
New PINI score therefore showed a significant reduction between day 1 to 
day 7, but not between days 1 to day 14. The fall in PINI on day 7 of 
measurement relates to the decrease in observed CRP values.  
 
Analysis was repeated for the 17 patients that remained on ICU for 14 days. 
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Table 4-9: The new PINI measured over 14 days in 17 patients 
 PINI day 1 PINI day 3 PINI day 7 PINI day 14 
N 17 17 17 17 
Median 
(IQR) 
0.102 
(0.071-0.119) 
0.098 
(0.075-0.137) 
0.109 
(0.066-0.137) 
0.066 
(0.055-0.115) 
 
New PINI in the 17 patients that remained on the ICU for 14 days did not 
change significantly over time, p=0.464. Change from day 1 to day 7 was not 
significant either, p=0.984, nor were changes significant between day 1 and  
day 3, p=0.552. Day 1 to day 3 change was determined by Wilcoxon 
matched-pairs signed rank test.  
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4.3.8 Inter-relationships between inflammatory and nutritional markers 
during critical illness  
 
Multilevel modelling results are presented where CRP, serum albumin, urinary 
urea, 3-MH, muscle depth, nitrogen balance, IL-10 and IL-6 were modelled 
against fixed variables: day of measurement, age, gender, BMI and ICU 
length of stay.  
Multilevel modelling revealed that each additional day of measurement on ICU 
was significantly associated with an expected decrease of CRP, muscle depth 
and interleukin-10 levels. With every year increase in a patient’s age levels of 
muscle depth and 3-methylhistidine were significantly reduced and the odds of 
having detectable IL-10 levels were significantly increased.  
 
4.3.8.1 C-reactive protein 
 
Results from multilevel modelling revealed that the day of measurement was a 
significant predictor of CRP levels. Each additional day of measurement was 
associated with an expected decrease in the square root of CRP by 0.24 units 
(95% CI: -0.36 to -0.13), see Table 4-10.   
 
4.3.8.2 Serum albumin 
 
Multilevel modelling results indicate that each additional day of measurement 
was associated with an expected increase in the square root of albumin 
concentration by 0.004 units (95% CI: -0.015 to 0.023), Table 4-10. 
Although the predicted values for serum albumin indicate that additional 
measurement days were associated with an increase in albumin 
concentration, serum albumin levels increased to ≈ 21.4 g/L only on the 20th 
day of measurement. 
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Table 4-10: Results from linear mixed modelling to assess the characteristics related to inflammatory and nutritional markers (square 
root transformations). Results for fixed variables are presented as b-coefficients (95% CI).  
 
  CRP (N=78) 
 
Albumin (N=78) 
 
 
Urinary Urea (N=60) 
 
 
3-MH (N=60) 
 
Muscle depth (N=75) 
  coefficient (95% CI) coefficient (95% CI) coefficient (95% CI) coefficient (95% CI) coefficient (95% CI) 
Fixed variable 
          
Days -0.24 
(-0.36, -
0.13) 
0.004 
(-0.015, 
0.023) 
0.100 
(-0.186, 
0.385) 
-0.169 (-0.38, 0.04) -0.021 (-0.03, -0.02) 
Age, years 
      
-0.153 (-0.23, -0.07) -0.009 (-0.017, -0.0006) 
Female gender 
        
-0.394 (-0.67, -0.12) 
 Shaded areas demonstrate significant interactions; CRP: C-reactive protein; 3-MH: 3-methylhistidine 
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4.3.8.3 Urinary urea 
 
Results from multilevel modelling revealed that each additional day of 
measurement was associated with an expected increase in the square root of 
urinary urea of 0.100 units (95% CI: -0.18 to 0.385), Table 4-10. 
Urinary urea levels increased with each additional day of measurement, this 
suggests that protein breakdown increased during ICU stay and that 
catabolism continued during this period. Predicted values suggest that urinary 
urea levels increased rather than decreased during 20 days on ICU, from ≈ 
262 mmol/24h on day 1 of measurement to ≈ 327 mmol/24h on day 20 of 
measurement. Urinary urea levels may also be affected by dietary protein 
intake, however only 54% of patients’ daily protein requirement was met.  
 
4.3.8.4 Urinary 3-methylhistidine 
 
Results from multilevel modelling revealed that for each additional day of 
measurement the square root of 3-methylhistidine levels were expected to 
decrease by 0.169 units (95% CI: -0.38 to 0.04), controlling for age. Age was 
found to be a significant predictor of 3-MH levels. One year increase in 
patient’s age was associated with an expected decrease in the square root of 
3-methylhistidine levels of 0.153 units (95% CI: -0.23 to -0.07) measured at 
the same day of measurement, Table 4-10. 
 
For example, for a 24 year old patient 3-MH predicted levels were on average 
~511 µmol/24h (95% CI: 381 to 660 µmol/24h) on day 1 of measurement, 
which may decrease to ~417 µmol/24h (95% CI: 277 to 584 µmol/24h) on the 
9th day of measurement.  
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As age increased there was a decrease in the predicted values of 3-MH. 3-
Methylhistidine may decrease from ~233 µmol/24h (95% CI: 184 to 288 
µmol/24h) for a 72 yr-old on day 1 of measurement to ~166 µmol/24h (95% 
CI: 98 to 252 µmol/24h) on day 15 of measurement. 
The 3-MH values decreased over time on ICU, however results remain above 
the normal range suggesting ongoing protein or muscle breakdown. Young 
patients demonstrate higher rates of protein or muscle breakdown than older 
subjects do, as measured by urinary 3-MH. 
 
4.3.8.5 Total muscle depth 
 
Day of measurement, age and gender were all found to be significant 
predictors of total muscle depth. For each additional day of measurement the 
square root of total muscle depth levels were expected to decrease by 0.021 
units (95% CI: -0.03 to -0.02), controlling for age and gender. Age was found 
to be a significant predictor of total muscle depth. One year increase in a 
patients’ age was associated with an expected decrease in the square root of 
total muscle depth levels by 0.009 units (95%CI: -0.017 to -0.0006) measured 
at the same day and controlling for gender. Females were found to have lower 
levels of the square root of total muscle depth compared to males (b= -0.394, 
95% CI: -0.67 to -0.12) controlling for day of measurement and age, Table 4-
10.  
Females demonstrating lower total muscle depth compared with males of the 
same age are expected. On day 1 of measurement, total muscle depth was 
predicted to be 5.6 cm (95%CI: 4.4 - 7.0 cm) for a 44 year old female and 7.6 
cm (95%CI: 6.6 - 8.8 cm) for a male patient of the same age. The muscle 
depth reduced to 4.8 cm (95% CI: 3.7 - 6.1 cm) for a 44 year old female 
participant on the 9th day of the measurement and reduced to 6.2 cm (95%CI: 
5.3 - 7.2 cm) for a male participant of the same age on the 14th day of the 
measurement. 
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For a 52 year old female patient day 1 measurements were predicted to be 
5.3cm (95%CI: 4.2 - 6.5cm) and 4.1cm (95%CI: 3.2 - 5.1cm) on day 14. A 
male patient of the same age have day 1 predicted measurements of 7.3cm 
(95%CI: 6.4 - 8.2cm) and on day 15 predicted depth of 5.7cm (95%CI: 5.0 - 
6.5cm). 
A 63 year old female may have predicted total muscle depth of 4.9cm (95%CI: 
3.9 - 6.0cm) on day 1 which may reduce to 4cm (95%CI: 3.1 - 4.9cm) on day 
11. A male of the same age may have a predicted day 1 muscle total depth of 
6.7cm (95%CI: 5.9 - 7.7cm) which may reduce to 5.7cm (95%CI: 4.9 - 6.5cm) 
on day 11. 
A 72 year old female may have predicted total muscle depth of 4.5cm (95%CI: 
3.5 - 5.6cm) on day 1 of measurement which may reduce to 3.3cm (95%CI: 
2.5 - 4.3cm) on day 15 of measurement. Male patients of the same age may 
have a predicted total muscle depth of 6.3cm (95%CI: 5.3 - 7.4cm) on day 1 
which may reduce to 5.7cm (95%CI: 4.7 - 6.7cm) on day 7 of measurement. 
 
See Figure 4-15 and Figure 4-16. 
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Figure 4-15: Predicted values for muscle depth loss (cm) with corresponding 
95% confidence intervals selected for age (years) in female patients 
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Figure 4-16: Predicted values for muscle depth loss (cm) with corresponding 
95% confidence intervals selected for age (years) in male patients  
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4.3.8.6 Nitrogen balance 
 
For each additional day of measurement the median for nitrogen balance 
(PENG equation) was increased by 0.47 units (95% CI: -0.51 to 1.45), Table 
4-11. 
Median nitrogen balance (PENG equation) on day 1 of measurement was -
10g/day (IQR: -15 to -2.75 g/d). With each additional day of measurement the 
median nitrogen balance was predicted to increase suggesting that nitrogen 
balance (PENG) improved over time. 
Similarly, for one day increment in the day of measurement the median for 
nitrogen balance (calculated by the Deacon equation) was increased by 0.18 
units (95% CI: -0.31 to 0.68), Table 4-11. 
Median nitrogen balance measurement (Deacon equation) on day 1 of 
measurement was -5.67g/day (IQR: -9.85 to 1.01 g/d). With each additional 
day of measurement the median nitrogen balance was predicted to increase 
by 0.18 units suggesting that nitrogen balance (Deacon), although negative, 
improved over time. 
 
4.3.8.7 Interleukin-6 
 
For each additional day of measurement the median interleukin-6 levels 
(pg/ml) decreased by 0.84 units (95% CI: -2.6 to 0.90). The lack of association 
remained when all other predictors were also tested in the model, Table 4-11.   
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Table 4-11: Results from median regression mixed models assessing the 
characteristics related to nitrogen balance (PENG and Deacon equation) and 
IL- 6. Results for the fixed variable are presented as a b-coefficient (95% Confidence 
Intervals).  
  
Nitrogen balance      
(PENG equation) 
N=58 
Nitrogen balance 
(Deacon equation) 
N=58 
Interleukin-6 
N=75 
  coefficient (95% CI) coefficient (95% CI) coefficient (95% CI) 
Fixed variable 
      
Days 0.47 (-0.51, 1.45) 0.18 (-0.31, 0.68) -0.84 (-2.6, 0.90) 
PENG: Parenteral & Enteral Nutrition Group; IL-6: interleukin-6. 
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4.3.8.8 Interleukin-10 
 
The odds of having levels of interleukin-10 > 0 pg/ml tended to decrease over 
time. For each additional day of measurement a 5% lower odds (on average) 
of having IL-10 levels > 0 pg/ml (95% CI: 0.81 to 1.11) was expected. The 
odds of having detectable IL-10 levels are expected to be higher as age 
increases. One year increase in patients’ age was associated with 12% higher 
odds, on average, of having IL-10 levels > 0 pg/ml (95% CI: 1.02 to 1.23), 
taking into account the day of the measurement, Table 4-12. 
 
More specifically, for the 1st day of measurement patients have on average 
~53% lower odds of having interleukin-10 levels > 0 pg/ml (95% CI: 0.14 to 
1.62) whilst on the 20th day of measurement it was on average ~84% less 
likely to have interleukin-10 levels > 0 pg/ml (95% CI: 0.01, 3.01), Figure 4-
17. 
                     
Figure 4-17: Predicted values for the odds of having interleukin-10 levels > 0 
pg/ml with corresponding 95% confidence intervals, according to day of 
measurement.
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Table 4-12: Results from multilevel binary modelling to assess the 
characteristics related with the odds of having interleukin-10 levels > 0 pg/ml 
(n=77). Results for the fixed variables are presented as exponentiated b-coefficients (95% 
Confidence Intervals). 
  Model 1.0 
  coefficient (95% CI) 
Fixed variable 
  
Days 0.95 (0.81, 1.11) 
Age 1.12 (1.02, 1.23) 
                             Shaded areas indicate significant interactions 
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4.3.8.9 Multilevel modelling with nitrogen balance 
 
This analysis was conducted to evaluate the association between nitrogen 
balance (PENG and Deacon equations) and inflammatory and nutritional 
markers. The additional effect of fixed variables (day of measurement, age, 
gender, BMI and total days in ICU) was also considered.  
Increased albumin, urinary urea and 3-MH levels were associated with 
decreased median nitrogen balance levels. Additional days of measurement 
of urinary urea were associated with increased nitrogen balance.  
C-reactive protein was negatively associated with nitrogen balance (PENG) 
levels, Table 4-13. As the inflammatory process increased, nitrogen balance 
became more negative. C-reactive protein was however positively associated 
with nitrogen balance from the Deacon equation, Table 4-13. These 
differences likely reflect differences in the nitrogen balance equations. 
An increase of 1 g/L in albumin levels was associated with an on average 
decrease of the median for nitrogen balance by 0.33 units (95% CI: -0.66 to -
0.008) in the PENG equation and by 0.29 units (95% CI: -0.52 to -0.05) in the 
Deacon equation, Table 4-13. The decrease refers to the median of nitrogen 
balance, therefore adjusted for ‘day of measurement’. Patients with longer 
ICU length of stay may have lower nitrogen balance, therefore median 
nitrogen balance tended to be negative. This change may also be due to a 
small number of patients with serum albumin levels increasing due to albumin 
administration. As albumin administration data were not captured accurately 
the exact number of patients receiving albumin is unknown. 
Every 1mmol/24h increase in urinary urea was associated with an on average 
decrease of the median for nitrogen balance (PENG) levels by 0.03 units 
(95% CI: -0.03 to -0.02) and by 0.02 units (95% CI: -0.03 to -0.02) for the 
Deacon equation. In addition, the day of measurement was positively 
associated with the levels of nitrogen balance for both equations and 
remained significant when all other predictors were also present in the model, 
Table 4-13. Increased urninary urea was associated with decreased nitrogen 
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balance as protein breakdown persists. These results are expected as urinary 
urea is included in the nitrogen balance calculation. 
 
Every 1 µmol/24h increase in 3-methylhistidine levels was associated with a 
decrease of the median for nitrogen balance for both the PENG end Deacon 
equations, Table 4-13. Increased 3-MH reflects muscle or protein breakdown, 
this may be associated with a decrease in nitrogen balance. 
 
Table 4-13: Multilevel modelling associations with nitrogen balance 
 
An increase of: 
Nitrogen balance (PENG) 
(95% CI) 
Nitrogen balance ( Deacon) 
(95% CI) 
 
1mg/L CRP  
 
↓ 0.002 units 
(-0.04, 0.03) 
 
↑ 0.0002 units 
(-0.03, 0.03) 
 
1g/L albumin 
 
↓ 0.33 units * 
(-0.66, -0.008) 
 
↓ 0.29 units * 
(-0.52, -0.05) 
 
1mmol/24h urinary 
urea 
 
1 day of 
measurement 
 
↓ 0.03 units * 
(-0.03,-0.02) 
 
↑ 0.39 units * 
(0.04, 0.74) 
 
↓ 0.02 units * 
(-0.03, -0.02) 
 
↑ 0.42 units * 
(0.10, 0.74) 
 
1µmol/24h 3-MH 
 
↓ 0.03 units * 
(-0.04, -0.02) 
 
↓ 0.02 units * 
(-0.03, -0.01) 
* Significant associations  
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4.3.9 Additional Analysis 
 
Additional analysis was performed based on the inclusion of ICU outcome 
(dead/alive), steroid use (yes/no) and nutritional adequacy: 
Based on the Schwarz Bayesian Criterion (BIC) - a criterion which is used for 
model comparison taking into account the explanatory variables and sample 
size in each model - no other model provided a better fit than the models 
described previously for each biomarker where day of measurement, age, 
gender, BMI and ICU length of stay were modelled against each biomarker. 
The lowest BIC indicates the best fit for the model (indicated in grey boxes in 
Table 4-14). Analysis therefore confirmed that, according to BIC, inclusion of 
additional variables (ICU outcome, steroid use and nutritional adequacy) were 
not significant predictors to any of the measured outcomes. Previous selected 
models with day of measurement, age, gender, BMI and ICU length of stay 
retained the best fit. 
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Table 4-14: Biomarkers and best model fit for analysis including ICU outcome, 
steroid use and nutritional adequacy 
  df BIC 
CRP 
  
Day 4 1381 
Day, Death, Steroid, %Energy, %protein 8 1412 
Albumin 
  
Day 6 379 
Day, Death, Steroid, %Energy, %protein 10 429 
Urinary urea 
  
Day 4 855 
Day, Death, Steroid, %Energy, %protein 8 874 
3-MH 
  
Days, Age 5 818 
Day, Age, Death, Steroid, %Energy, %protein 9 830 
Nitrogen Balance (PENG) 
  
Day 5 924 
Day, Death, Steroid, %Energy, %protein 9 933 
Nitrogen Balance ( Deacon) 
  
Day 4 893 
Day, %Energy 8 879 
Total Muscle Depth 
  
Day, Age, Gender 8 19 
Day, Age, Gender, Death, Steroid, %Energy, 
%protein 
12 36 
Interleukin-10 
  
Day 3 211 
Day, Death, Steroid, %Energy, %protein 7 217 
Interleukin-6 
  
Day 4 2207 
Day, Death, Steroid, %Energy, %protein 8 2224 
Day: Day of measurement; Death: ICU outcome; Steroid: steroid use; % Energy: % energy 
intake; % protein: % protein intake; CRP: C-reactive protein; 3-MH: 3-methylhistidine 
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An exception was found for predicting nitrogen balance with the Deacon 
equation only. Results show that among all factors tested % energy intake 
was significantly related with the outcome, and its’ inclusion provided the best 
model. In particular, for 1% increase in energy intake the median for nitrogen 
balance is increased by 0.09 units (95% CI: 0.05, 0.13), controlling for the day 
of measurement. 
 
Table 4-15: Nitrogen Balance (Deacon equation) modelled against day of 
measurement and % energy intake. 
  
Nitrogen Balance 
(Deacon) 
  coefficient (95% CI) 
Fixed variable 
  
Intercept -8.04 (-9.81, -6.27) 
Day -0.44 (-0.90, 0.02) 
% Energy intake 0.09 (0.05, 0.13) 
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4.3.10 Functional Outcomes 
 
 
Katz Index 
The Katz index scoring minimum is zero (very dependent) with a maximum 
score of six (independent). In this cohort of 78 patients the score improved 
from zero to one only in 6 (7.7%) patients. No further improvements were 
observed, thus according to the Katz score all patients remained highly 
dependent. The improvement from the score of zero to one was seen in the 
‘continence’ category (complete self control over bladder and bowel 
movements). 
 
Barthel Index 
The Barthel index scoring total is from zero (highly dependent) to 100 (highly 
independent). In this cohort of 78 patients 11 (14%) improved from a score of 
zero to a score of five; 2 (2.5%) patients improved to a score of 10; 2 (2.5%) 
patients improved to a score of 15 and 3 (3.8%) patients improved to a score 
of 20. No improvement beyond 20 out of 100 was observed. 
The categories in which improvements were seen were in ‘bladder’, ‘bowels’ 
and ‘transfers’. Bladder function improvements include scores improving from 
zero (incontinent or catheterised) to five (occasional accident) or to 10 (fully 
bladder continent). Bowel movement scores improved from zero (incontinent) 
to five (occasional accident) or to 10 (fully bowel continent). Transfer scores 
improved from zero (unable, no sitting balance) to five (major help required by 
one or two people, does have sitting balance). No improvements beyond 
these categories were observed. 
 
 
 
 161 
4.3.11 Data for surrogate endpoints for future nutritional clinical trials 
 
Mathematically results indicate that a 10 - 20% change in day 7 and day 14 
values for CRP, urinary urea and 3-MH may potentially provide feasible 
sample size estimates for use in future clinical trials in addition to 5 - 20% 
change in day 7 and day 14 values for albumin and muscle depth. Many of 
these variables may however be vulnerable to confounding and would unlikely 
be used as primary endpoints in future nutritional studies. Change in trajectory 
between day 7 and day 14 variables did not provide feasible sample size 
estimates, these large sample size estimates imply that much more data 
would be required in order to accept small differences as statistically 
significant, however in clinical practice these would not be considered as 
significant differences, Table 4-16.  
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Table 4-16: Sample size determination from current data set 
 
Variable 
 
Mean (SD) 
Estimated sample size for given effect size 
5% 10%  15% 20% 
CRP, mg/L 
Day 7  
Day 14  
Change 
 
85 (8.55) 
57 (10.96) 
28 (9.8) 
 
32 
         140 
385 
 
8 
30 
97 
 
4 
14 
43 
 
2 
8 
25 
Albumin, g/L 
Day 7  
Day 14  
Change 
 
20.9 (0.61) 
21.1 (0.97) 
0.2 (0.81) 
 
3 
7 
51497 
 
1 
2 
12875 
 
1 
1 
5722 
 
1 
1 
3219 
Urinary urea, mmol/24h 
Day 7  
Day 14  
Change 
 
282 (36.2) 
306 (64.6) 
24 (52) 
 
52 
140 
14739 
 
13 
35 
3685 
 
6 
16 
1638 
 
4 
9 
922 
3-MH, µmol/24h 
Day 7  
Day 14  
Change 
 
274 (24.5) 
236 (40) 
38 (33.2) 
 
26 
88 
2397 
 
7 
23 
600 
 
3 
11 
267 
 
2 
6 
150 
Muscle depth, cm 
Day 1  
Day 14  
Change 
 
6.5 (0.41) 
5.8 (0.39) 
0.7 (0.40) 
 
13 
15 
1026 
 
4 
4 
257 
 
2 
2 
104 
 
1 
1 
65 
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4.4 Discussion 
 
A notional nutritional tipping point could not be identified during 20 days on 
ICU, markers point towards a continuing inflammatory response, negative 
nitrogen balance and progressive muscle depth loss. A conceptual diagram of 
this period on ICU has been proposed below: 
 
                           
Figure 4-18: Conceptual diagram of the proposed trajectories of pro-
inflammatory responses and anabolic switch in the critically ill. 
 
Multilevel modelling revealed that each additional day spent on ICU was 
significantly associated with an expected decrease of C-reactive protein, 
muscle depth and interleukin-10 levels. With every year increase in a patient’s 
age levels of muscle depth and 3-methylhistidine were significantly reduced 
and the odds of having detectable IL-10 levels were significantly increased.  
The biomarkers used to estimate sample size were studied at a point in the 
patient’s recovery when data suggest that the cohort is catabolic, thus not at a 
time for nutritional intervention. Sample size estimates may provide some 
guidance as to the orders of magnitude needed for a late intervention study, 
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based on the biomarkers as endpoints, however estimates are not satisfactory 
and should be viewed with caution. 
 
4.4.1 Screening and recruitment 
 
Patient recruitment to a study requiring critically ill patients was one of the 
most demanding aspects of this research. Recruiting from three different 
hospitals provided the benefit of increasing patient numbers, however, cross-
site recruitment required detailed planning, and required research nurses to 
assist with recruitment when I was on another site. Research nurses were not 
always available and were not dedicated to this single study, nor were they 
able to carry out the full data collection. Recruitment was improved when a 
part time research assistant helped with both patient recruitment and data 
collection. Training a research assistant to conduct muscle ultrasound greatly 
facilitated cross-site recruitment and data collection. Thus, this study shows 
that in order to maximise ICU patient recruitment and data collection at least 
one dedicated research assistant is required per two hospital sites.  
 
4.4.2 Patient demographics  
 
This cohort of 78 patients appears to be representative of any general 
intensive care unit, with mean age of 59 years, predominantly male patients 
(69%), mean APACHE II score of 21.6 and median ICU length of stay of 10 
days. The study cohort was compared to national data from the Intensive 
Care National Audit and Research Centre (ICNARC) annual data for the same 
period as the study (https://www.icnarc.org/CMS, accessed 1 July 2013). 
Mean age from national figures was 60 years with predominantly male 
admissions, 56%, and median length of stay of around 2.2 days.  
Median length of stay in my cohort appears longer than national figures 
however, patients with short length of stay of 1-2 days were excluded from 
this study. National figures additionally include routine post operative 
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admissions with shorter length of stay. A higher percentage of patients in my 
study cohort were male in comparison to national figures, 69% versus 55% 
respectively, this may be due to the majority of trauma and cardiac 
admissions in the study cohort being male. Ten (83%) trauma admissions in 
this cohort were male and twelve (86%) of cardiac admissions were male.  
 
4.4.3 Muscle depth change on ICU 
 
Patients on ICU lost a significant amount of muscle depth, 1.2% per day over 
14 days. The finding confirms previous studies reporting muscle depth losses 
of between 1-2% per day in the critically ill (Campbell 1995;Gamrin 
1997;Plank and Hill 2000b;Reid 2004). Higher rates of wasting were observed 
in nine multi-organ failure patients where daily rates of wasting were recorded 
between 2-9% per day, median 6% per day (Campbell 1995). My study 
followed the same protocol as Campbell et al and Reid et al, measuring 
muscle depth on ultrasound over the bicep, thigh and forearm and is the 
largest study to date in which serial ultrasound measurements were 
performed in critically ill patients. Reid et al found a median 1.6% muscle 
depth loss per day in their cohort of 50 ICU patients measured over 7 days, in 
my study cohort daily percentage muscle loss observed at 7 days was 1.4%. It 
appears that muscle wasting is at a maximum around the 7 day period and 
that, although muscle wasting still persists over the following 7 days, the rate 
of loss is reduced, which may perhaps be associated with recovery. The 
population included by Reid et al appear to have similar demographics to this 
study cohort with mean age of 56 years (19-79), 52% male patients, APACHE 
II score of 17 (2-43) as well as inclusion of medical, surgical and trauma 
(including head injured) patients. 
It is worth noting that different techniques and measurement points are 
described in the ultrasound literature which may lead to variation of reported 
results. Some investigators measure muscle depth over three sites (Campbell 
1995;Reid 2004) and others measure muscle depth on one limb only, usually 
on the quadriceps muscle (Gruther et al. 2008). Some use a variety of muscle 
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sites (Cartwright et al. 2013) and others use cross sectional area over the 
rectus femoris muscle rather than muscle depth (Bloch et al. 2013;Seymour 
2009). 
Campbell et al found that by combining measurements over the thigh, bicep 
and forearm this provided the best estimate of lean body mass as compared 
to skinfold measurements, three combined sites showed a correlation of r = 
0.843. The muscle ultrasound and skinfold correlation were performed in 70 
healthy subjects. Lean tissue mass was compared between ultrasound and 
DEXA scanning in 36 subjects (healthy volunteers and patients attending 
outpatient clinics). The three ultrasound sites demonstrated significant 
correlation with lean mass measured by DEXA scanning, biceps r=0.788, 
forearm r=0.842 and thigh r=0.796, p<0.001. In nine ICU patients with multi-
organ failure muscle depth measurements were compared to arm 
circumference measurements over 15 days. Arm circumference 
measurements showed no consistent pattern of change over time, these 
measurements may have been confounded by oedema, whilst muscle depth 
measurements were negatively correlated with time (Campbell 1995).  
Gruther et al measured muscle depth in both legs over the vastus intermedius 
and rectus femoris, on two occasions only. Significant negative correlations 
between muscle depth and length of stay on the ICU were described, (right 
thigh p=0.005 and left thigh p=0.004) however p-values only were reported in 
this study without correlation coefficients.  
Cartwright et al assessed muscle thickness of tibialis anterior, rectus femoris, 
abductor digiti minimi, biceps and diaphragm muscle in 16 ICU patients over 
14 days on at least four occasions. Gray-scale analysis from stored images 
were also performed, each pixel was assigned a value between 0 (black) and 
255 (white) to allow calculation of means and standard deviations of the area 
of interest (Cartwright 2013). No significant reduction in muscle depth was 
observed, however gray-scale standard deviations reduced significantly for 
tibialis anterior (33.87 to 28.01, p=0.001) and rectus femoris (31.40 to 28.73, 
p=0.041).  
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Two studies report measurement of the rectus femoris cross sectional area, 
one in high risk elective cardiac surgical patients (Bloch 2013) and the other in 
26 healthy volunteers and 30 COPD patients (Seymour 2009). Bloch et al 
reported a 3.5% daily loss in 23 patients measured over one week following 
cardiac surgery. Median length of stay on the ICU was short for this cohort, 
one day only (Bloch 2013). Seymour et al did not perform serial 
measurements, however ultrasound measurements between healthy subjects 
and COPD patients were compared. A significant reduction in rectus femoris 
cross sectional area in COPD patients was observed, mean 350mm2 versus 
460mm2 in healthy subjects, p=0.001. Rectus femoris cross sectional area 
was also correlated to quadriceps strength testing in COPD patients. 
Quadriceps strength was assessed by isometric maximum voluntary 
contraction and by twitch tension, correlation coefficients were r=0.78 and 
r=0.69 respectively, p<0.001(Seymour 2009). 
As corticosteroid administration is linked to muscle wasting (Hasselgren 2010) 
steroid administration was recorded in my study cohort. Twenty-three patients 
(29%) received steroids during their ICU stay of which three patients received 
Dexamethasone, 15 patients received Hydrocortisone and five Predisolone.  
(See additional analysis section 4.4.7 for steroid use and muscle depth loss.) 
 
Limitations to the muscle depth ultrasound technique  
Muscle ultrasound requires a lot of training and practice. Intra-rater and inter-
rater reliability must be tested as appropriate. Very clear standard operating 
procedures are required to ensure that consistent measurements are taken. 
Procedures should include consistent positioning of the ultrasound probe on 
the limb, ensuring that underlying soft tissue is not compressed and using 
indelible ink to mark the midpoint of each limb to ensure day-by-day 
consistency of serial measurements. In addition, the operator should ensure 
that the patient’s foot is pointing upwards at 90° as small changes in the 
position of the foot could alter the depth measurement.  
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Strengths of the muscle depth ultrasound technique 
A strength of this technique is that it has been validated in ICU patients in the 
presence of oedema. No other non-invasive techniques are readily available 
to perform serial measurements of muscle mass in the critically ill. It is safe, 
non-invasive and ultrasound equipment is readily available on most intensive 
care units nowadays. We have additionally demonstrated good intra-rater and 
inter-rater reliability with this technique. Depth measurement per se is easier 
and quicker to perform than the rectus femoris cross sectional area 
measurement, the latter technique requires a much larger ultrasound machine 
and transducer.  
 
4.4.4 Nutritional tipping point 
 
The main finding from this study is that a nutritional tipping point is unlikely to 
exist within 20 days on intensive care due to a continuing inflammatory 
process, increasing protein breakdown and progressive muscle depth loss. 
This is the first study attempting to identify a notional nutritional tipping point, 
where anabolism starts to exceed catabolism, during a period of critical 
illness. Results demonstrate increasing muscle depth loss with urinary urea, 
3-MH and CRP values remaining above the normal range and nitrogen 
balance remaining negative. These findings were confirmed by multilevel 
modelling results.  
The clinical significance of this work is that additional nutritional strategies 
may have to be targeted after a period of critical illness. Whilst patients should 
continue to receive standard nutrition support during their ICU stay, any 
additional nutritional strategy may have to be targeted outside of the ICU 
environment. ‘Aggressive’ or additional nutritional strategies may not be 
assimilated whilst the process of catabolism is dominant. It appears that a 
metabolic switch, nutritional tipping point or anabolic phase is likely to take 
place outside of the ICU environment once the inflammatory process and 
acute phase response has resolved and protein catabolism has eased off. 
 169 
Although nutritional strategies to promote anabolism may be best targeted 
outside of the ICU environment, strategies to reduce catabolism might be 
beneficial during the earlier stages of critical illness such as drug interventions 
with Propranolol and Oxandrolone. 
The prognostic inflammatory and nutritional index (PINI) (Ingenbleek 1985) 
was the nearest concept to a tipping point study that could be identified 
however this index was used to stratify patients for risk of complication or 
death, rather than to identify a point of metabolic shift per se. 
One similar study assessed the risk of adverse outcomes that may be 
modified by nutrition therapy in the ICU setting (Heyland et al. 2011b). This 
score was developed using prospective data from 597 ICU patients in which 
multivariate modelling was used to determine what variables should remain in 
the final scoring system. A conceptual model helped to identify variables 
associated with starvation, inflammation, nutritional status and clinical 
outcomes. These variables included age, APACHE II score, baseline SOFA 
score, number of comorbidities, days from hospital admission to ICU 
admission and IL-6, which were all significantly associated with 28-day 
mortality (all p<0.001). As the score increased, duration of mechanical 
ventilation and mortality rate increased. The authors report that this may help 
to identify critically ill patients most likely to benefit from aggressive nutrition 
therapy (Heyland 2011b). Data from my research however suggests patients 
may not benefit from ‘aggressive’ nutrition therapy during critical illness.    
Negative nitrogen balance has been reported previously. Buonpane et al 
described in a cohort of 12 trauma ICU patients how nitrogen balance 
remained negative during ICU stay. At baseline a negative nitrogen balance 
was reported as -14g/day and by day 21 on ICU nitrogen balance was - 4g 
/day (Buonpane 1989).  
Other groups describe ongoing protein breakdown during a period of critical 
illness. Plank et al described a 13-15% body protein loss observed in a group 
of ICU patients with severe sepsis and trauma (Plank 2000b), Streat et al 
describe a 12.5% body protein loss (mean 1.5kg, SE: 0.3kg, p=0.001) in 
septic ICU patients monitored over 10 days (Streat et al. 1987), Gamrin et al 
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described a 10% loss of protein content in muscle tissue over five days in 
surgical and trauma ICU patients (Gamrin 1997) and Monk et al describe a 
1.62kg (16%) total body protein loss, (p<0.0002), of which 1.09kg (67%) was 
from skeletal muscle over 21 days. Total body protein was determined by 
gamma in vivo neutron activation analysis and skeletal muscle mass via 
DEXA scanning. The equipment used to determine these changes in body 
composition is not readily available in most institutions (Monk et al. 1996). 
 
4.4.5 Univariate analysis - correlations 
 
A weak correlationwas identified between muscle depth loss and maximum 
CRP only. No correlation was observed between the amount of muscle depth 
lost and the amount of calories consumed. This lack of association has been 
reported previously (Reid 2004). No correlation was observed either between 
protein intake and muscle depth loss.  
There was a strong positive correlation between nitrogen loss and 3-MH. 
Approximately 80% of nitrogen loss is via urine with the remaining 20% via 
faeces or via the skin. Of the 80% nitrogen lost via urine (total urine nitrogen), 
approximately 80-90% will be from urinary urea (urine urea nitrogen). 
Approximately 1% of total urine nitrogen loss is via 3-MH. Nitrogen loss 
originates largely from body protein breakdown in critically ill patients. Once 3-
methylhistidine is liberated during protein catabolism it cannot be re-utilised 
and appears in the urine. Therefore the strong correlation observed (Welle 
1999). 
A positive correlation was furthermore observed between CRP and IL-6, CRP 
is mainly produced by hepatocytes and regulated by IL-6 (Ho and Lipman 
2009). 
Univariate analysis provides limited information as potential confounding 
factors were not assessed. Although multiple regression models might be able 
to describe relationships between variables and muscle depth loss per se, 
multivariate multilevel models were chosen as a repeated measures design 
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was used in which there were multiple predictors of a single outcome with the 
aim of identifying a nutritional tipping point.  
 
4.4.6 Multilevel modelling 
 
Multilevel modelling revealed that each additional day spent on ICU was 
significantly associated with an expected decrease of C-reactive protein, 
muscle depth and interleukin-10 levels. With every year increase in a patient’s 
age expected levels of muscle depth and 3-methylhistidine were significantly 
reduced and the odds of having detectable IL-10 levels were significantly 
increased.  
Day of measurement was a significant predictor of CRP levels, with each 
additional day of measurement CRP was expected to decrease. This reflects 
improvement in patients’ inflammatory status. Predicted values for CRP on the 
20th day of measurement still remained above the normal range, therefore 
although patients may be improving over time the inflammatory process hadn’t 
completely resolved.  
Each additional day of measurement was associated with an expected 
increase in serum albumin levels. This association was not statistically 
significant, however hypoalbuminemia over 20 days may be of clinical 
significance (Arif et al. 2002). Hypoalbuminemia may reflect an ongoing 
inflammatory response and albumin concentration is a measure of either the 
presence of disease or the severity thereof (Goldwasser and Feldman 1997). 
Serum albumin concentrations decrease with expansion of the vascular 
compartment. Increased vascular permeability in the acute phase of illness 
may cause increased protein flux and redistribution of albumin (Margarson 
and Soni 1998). Plasma concentrations of albumin and transferrin are initially 
decreased, hence being described as ‘negative acute phase proteins’. After 
this initial reduction in albumin synthesis an increase in overall hepatic protein 
synthesis is observed, including albumin synthesis (Margarson 1998). 
Albumin synthesis may therefore follow a biphasic pattern where the synthesis 
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is initially decreased followed by increased production (Mansoor et al. 1997). 
The hypoalbuminemia observed in my study cohort may also be a reflection of 
the long half life of albumin, around 20 days (Rothschild et al. 1972). 
Persistent hypoalbuminemia observed may be due to plasma albumin moving 
into the extravascular space (Mansoor 1997). 
A limitation to data collection concerning serum albumin is that albumin 
administration was not clearly documented. Only a handful of patients were 
recorded as receiving human albumin solution 20% at 100ml twice daily, yet 
dramatic increases in serum albumin levels in three patients suggest that 
these data were not recorded accurately during data collection for this study. 
Albumin administration is however used infrequently within the intensive care 
units in which this study was performed. 
 
Multilevel modelling results indicated that each additional day of measurement 
was associated with an expected increase in urinary urea levels. This 
association was not significant however raised urinary urea on the 20th day of 
measurement may be of clinical significance in particular as predicted 71 g 
protein loss per day. An increase in urinary urea during ICU stay reflects 
either overfeeding of protein or increased protein breakdown. As only 54% of 
the patients’ daily protein requirement was met, it seems that increasing levels 
of urinary urea reflect continuing protein breakdown during a period of critical 
illness. Urinary urea excretion is still commonly used to estimate protein 
breakdown (Welle 1999).  
The breakdown of protein, especially from muscle, in the critically ill is in part 
an adaptive response. Protein breakdown provides amino acid substrates that 
are used for synthesis of acute phase proteins. These proteins are required 
for immune response, tissue regeneration, wound healing and replacement of 
lost blood during trauma and critical illness (Welle 1999). Protein breakdown 
occurs despite provision of nutrition support in the critically ill (Plank 2000b). 
Not providing any form of nutrition support during critical illness may however 
accelerate losses.  
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Studies assessing urine nitrogen excretion are mostly described in trauma 
patients. Buonpane et al describe mean nitrogen excretion of 18.2 (SD: 3.6) 
g/day (Buonpane 1989) which may reflect the enhanced protein breakdown 
experienced by trauma patients or the differences in equations used to 
determine nitrogen loss. 
Few studies have assessed whether urinary urea measurements correlate 
with other methods of protein metabolism assessment. In children suffering 
from burn injury urine urea nitrogen correlated well with stable isotope 
determined protein balance (r2=0.77, p<0.001), although levels of agreement 
between the two methods were not satisfactory (Prelack et al. 1997).  
Urinary collection in critically ill patients requiring continuous renal 
replacement therapy (CRRT) may be difficult. Serum and effluent (dialysate or 
ultrafiltrate) urea and creatinine concentrations were however determined for 
calculations of protein loss in general ICU patients (Leblanc et al. 1998), in 
septic multi-organ failure patients requiring CRRT (Frankenfield et al. 1994) 
and in trauma patients undergoing CRRT (Klein et al. 2002). In my cohort, 
patients on CRRT were excluded from urinary studies as the technique to 
determine nitrogen excretion from CRRT patients was not used in our 
institution. 
Stable isotope techniques are however far more robust in describing protein 
metabolism, in particular as whole body protein turnover can be determined. 
Negative nitrogen balance from whole body protein breakdown was observed 
from stable isotope studies in head injured patients (Mansoor 1997) and in 
multi-organ failure patients (Arnold 1993). Increased whole body protein 
breakdown is described along with increased whole body protein synthesis, 
the negative balance occurs as the breakdown by far outweighs the synthesis. 
Reduced muscle protein synthesis has been observed post surgery 
(Petersson et al. 1994) and following head injury (Mansoor 1997).  
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Limitations to using urinary urea  
Urinary study results are dependent on the 24h collection method, spillage or 
incomplete collections will cause inaccuracies. During this research there 
were inevitable cases of misplaced 24h urine collections, however clear 
instructions and documentation limited these occurrences. A further limitation 
is that our laboratory did not provide a quoted normal reference range for 24h 
urine urea, ideally a reference range should be derived from the analytical 
methodology. Furthermore, estimates of urine urea nitrogen may 
underestimate total urine nitrogen losses in patients with trauma and critical 
illness as losses via other routes, including wound losses, are likely 
underestimated (Dickerson 2005;Grimble 1988;Welle 1999). The different 
equations available in the literature to determine nitrogen excretion make 
interpretation of results difficult. These limitations should be considered with 
interpretation of the results of this study. Additionally, in this study patients 
requiring CRRT were excluded from urinary studies as described.  
 
 Strengths of using urinary urea  
Urinary urea excretion is used as a surrogate marker for protein breakdown 
which provides a measure of catabolism. In the absence of more robust 
techniques, such as protein turnover, 24h urine urea provides information as 
to the overall nitrogen balance of a patient. Urine collections over a 24h period 
are much simpler to perform than stable isotope studies. The latter may take 
up to 6 hours to complete per patient, patients are required to be fasted for 8 
hours and multiple staff might be required to conduct the studies in 
mechanically ventilated patients. An additional strength of urinary urea 
collections in this study is that serial measurements were performed in 
patients, this enabled assessment of change over time. 
Predicted values for 3-MH reduced over time on ICU, however, results 
remained above the normal range reflecting ongoing protein breakdown. Age 
was found to be a significant predictor of 3-MH levels. One year increase in a 
patient’s age was associated with an expected decrease in 3-MH levels. This 
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suggests that older patients may have lower levels of 3-MH than younger 
patients have and that younger patients, by displaying higher levels of 3-MH, 
potentially demonstrate greater muscle or protein breakdown. This may be 
due to younger patients generally having larger muscle bulk than older 
patients do. It has previously been reported that ICU patients with ‘thicker’ 
muscle at the start of their ICU stay lost significantly more muscle depth than 
patients with ‘thinner’ muscles (Reid 2004). Reid et al studied 50 ICU patients, 
in which patients with thicker muscle lost 0.8cm (IQR: 0.2 to 2.3) in 7 days 
compared to 0.35cm (IQR: 0 to 1.1) lost in patients with thinner muscles, 
p=0.001 (Reid 2004). This observed difference with age and 3-MH levels may 
also be due to the different diagnostic categories represented in this study 
cohort. Most of the young patients represented in this cohort were from 
multiple trauma admissions. Trauma patients are known to exhibit accelerated 
protein losses, particularly in head injured patients, with reported losses of 
1.62kg of body protein and 1.09kg skeletal muscle loss (Mansoor 1997;Monk 
1996). 
Urinary 3-methylhistidine is derived from the contractile myofibril proteins, 
actin and myosin that make up approximately one third of the total protein 
mass of the body. Studying myofibrillar breakdown via 3-MH analysis in urine 
is therefore a popular manner of studying protein metabolism (Welle 1999).  
The urinary 3MH: creatine ratio was not used as creatinine excretion is 
increased during infection and trauma (Lukaski 1981;Sjolin 1989), variable in 
patients presenting with acute kidney injury during critical illness (Westhuyzen 
et al. 2003) and impaired with tubular injury, consequently the use of 3-MH: 
creatinine ratio is less commonly used the critically ill (Welle 1999).  
 
Limitations to using 3-MH 
A potential limitation of 3-MH is that meat intake affects 3-MH excretion, 
however all patients were exclusively fed via either enteral or parenteral 
nutrition in my study. Defining a normal range for 3-MH is complicated due to 
the influence of meat intake on 3-MH excretion levels. Lukaski et al defined a 
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normal range of between 150-226 µmol/24h in healthy men and 75-210 
µmol/24 in healthy females on a meat-free diet (Lukaski 1981). Sjolin et al 
described a mean 215 µmol/24h (SD: 55) 3-MH excretion in men and a mean 
150 µmol/24h (SD: 30) 3-MH excretion in women on a meat-free diet (Sjolin 
1989).  
A further limitation includes that muscle breakdown alone may not be the sole 
contributor to 3-MH excretion (Chinkes 2005). Actin is present in all cells, 
therefore 3-MH is not derived exclusively from muscle protein (Welle 1999). 
Additionally, as 3-MH is derived from actin and myosin, breakdown reflects 
that of all muscle which may include skeletal, smooth and cardiac muscle. 
However, using 3-MH as a surrogate measure for muscle breakdown in 
conjunction with other outcome measures to detect muscle or protein 
breakdown may reduce this limitation.  
The manner in which 3-MH results are reported presents another potential 
limitation to interpretation of 3-MH data. 3-Methylhistidine may be reported as 
µmol per kg per 24h (µmol/kg/24h), as µmol 3-MH per mmol creatinine 
excretion (µmol/mmol creatinine) or as µmol per 24h (µmol/24h). Body weight 
varies greatly on ICU due to daily fluctuations in fluid balance, reporting of 3-
MH per body weight was therefore not selected in this research. Additionally, 
body weight is usually estimated on ICU and rarely measured. The reporting 
via creatinine excretion was not selected either in this research as creatinine 
excretion may vary greatly in ICU patients, in particular in those presenting 
with acute kidney injury (Westhuyzen 2003). 
 
Strengths of using 3-MH 
Strengths of this outcome measure include the ease of use of performing 24h 
urine collections within intensive care in comparison to other methods used to 
determine protein breakdown. Additionally, 3-MH produced from protein 
breakdown cannot be recycled into use for protein synthesis. The only route of 
elimination of 3-MH from protein breakdown appears to be via urine, 
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consequently 3-MH provides useful index of myofibrillar breakdown (Welle 
1999). 
This technique remains popular in studies assessing muscle breakdown in the 
critically ill (Kuhls 2007;Mansoor 2007;Nissen 1996;Stein 1999;Voerman 
1995) and can be used as a surrogate marker to assess muscle breakdown 
despite the known limitations.  
Multilevel modelling with muscle depth loss revealed three significant 
interactions, for each additional day of measurements muscle depth was 
expected to decrease, controlling for age and gender. Age was a significant 
predictor, for every year increase in a patient’s age muscle depth was 
expected to decrease measured at the same day and controlling for gender. 
Females were found to have lower muscle depth compared to males, again 
controlling for day of measurement and age. Muscle depth decreasing over 
time during ICU stay has been discussed previously. Females presenting with 
lower muscle depth is expected. With increasing age muscle depth 
decreases, this again is expected, however this appears to be a conflicting 
finding to what the 3-MH results suggest. Multilevel modelling results 
suggested that an increase in age was associated with a decrease in 3-MH 
values. Lower 3-MH values may imply lower breakdown of muscle which may 
in turn be due to thinner muscles (Reid 2004). It is well recognised that aging 
is associated with loss of muscle mass otherwise known as sarcopenia 
(Doherty 2003).  
It is worth considering the differences between these two outcome measures, 
3-MH and muscle depth change via ultrasound. Although both may be used to 
reflect muscle breakdown, there are some distinct differences. The muscle 
depth measurement used in this study assesses change in muscle thickness 
over the bicep, thigh and forearm only. 3-MH as an index of actin and myosin 
breakdown reflects all muscle breakdown, which by definition includes 
skeletal, smooth and cardiac muscle. Additionally, actin is present in cells 
other than muscle (Welle 1999) which was discussed as a limitation in the use 
of 3-MH as a marker for muscle breakdown. Thus, older patients may have 
lower muscle depth over time on ICU where younger patients may display 
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higher rates of protein breakdown overall. This again may be related to the 
diagnosis differences between the older and younger patients in this cohort 
with the younger patients mostly representing a trauma population.  
Multilevel modelling results for nitrogen balance revealed non-significant 
associations between day of measurement and nitrogen balance. Median 
nitrogen balance for both the PENG and Deacon equation increased with 
each additional day of measurement. Nitrogen balance therefore improved 
over time. Buonpane et al described how nitrogen balance improved over 28 
days on ICU to 4g/day (Buonpane 1989).  
Associations between CRP, albumin, urinary urea and 3-MH were additionally 
assessed with nitrogen balance. Increased albumin, urinary urea and 3-MH 
levels were associated with decreased median nitrogen balance levels. An 
additional day of measurement of urinary urea was associated with increased 
median nitrogen balance.  
An increase in serum albumin levels was associated with a decrease in 
nitrogen balance for both the PENG and Deacon equations. This finding 
cannot be explained by the data collected for this research study. Patients that 
remain on ICU for longer may already have lower levels of nitrogen balance, 
therefore median nitrogen balance tended to be negative. This small change 
may additionally be due to a small number of patients with increasing levels of 
serum albumin due to albumin administration. Unfortunately data collection on 
albumin administration was incomplete in this study. Additional potential 
confounders for serum albumin levels, such as inflammatory status, were not 
assessed at the same time in the model.  
An increase in urinary urea was associated with a decrease of the median for 
nitrogen balance levels for both the PENG and Deacon equations. This is 
expected as increased urinary urea levels reflect ongoing catabolism, which is 
demonstrated by negative nitrogen balance. Furthermore, urinary urea is used 
in the calculation to determine nitrogen balance.  
An increase in 3-methylhistidine levels was associated with a decrease of the 
median for nitrogen balance for both the PENG and Deacon equations. 
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Increased 3-MH reflects protein breakdown: this is associated with decreased 
nitrogen balance. 
CRP was negatively associated with nitrogen balance (PENG) levels, yet 
positively associated with nitrogen balance from the Deacon equation. The 
differences observed here reflect the inherent differences of these equations. 
Few hospitals have the facility to measure total urinary nitrogen directly. The 
use of equation may underestimate losses from the skin, wounds and 
gastrointestinal losses and may therefore underestimate total nitrogen losses 
in the critically ill (Dickerson 2005;Grimble 1988). 
Multilevel modelling results for IL-6 showed a non-significant reduction in 
median IL-6 levels over time. This is expected as IL-6 levels decrease over 
time as patients improve. IL-6 is both a pro- and anti-inflammatory cytokine 
which promotes acute-phase protein synthesis (Callahan 2009).  
Multilevel modelling analysis for IL-10 indicated that day of measurement was 
a significant predictor for IL-10 levels. The odds of having detectable IL-10 
levels decreased over time. Results also indicated that the odds of having 
detectable IL-10 levels were expected to be higher as age increases, when 
day of the measurement was taken into account. Interleukin-10 production 
has been found to be higher from leukocytes in the elderly than from those in 
young subjects (Cakman et al. 1997). Interleukin-10 release by leukocytes 
from the elderly occurs faster and in higher concentrations than that released 
by leukocytes from young subjects (Rink et al. 1998).  
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4.4.7 Additional analysis: Inclusion of ICU outcome, steroid use and 
nutritional adequacy 
 
Day of measurement remained a significant predictor of CRP levels, additional 
analysis including day of measurement, ICU outcome, steroid use and 
nutritional adequacy were not significant predictors of CRP levels. 
For serum albumin levels, urinary urea and nitrogen balance (PENG 
equation), day of measurement was best associated with biomarker levels, 
not the additional analysis including day of measurement, ICU outcome, 
steroid use and nutritional adequacy.  
Day of measurement and age remained the best predictors of 3-MH levels, 
with age being a significant predictor. Additional analysis including day of 
measurement, ICU outcome, steroid use and nutritional adequacy were not 
significant predictors. 
Nitrogen balance (Deacon equation) was the only outcome measure where an 
increase in energy intake was significantly related to an increase in the 
median levels for nitrogen balance. 
Day of measurement, age and gender remained significant predictors for total 
muscle depth. Inclusion of additional analysis consisting of day of 
measurement, age, gender, day of measurement, ICU outcome, steroid use 
and nutritional adequacy were not significant predictors of total muscle depth. 
Day of measurement remained the best predictor for both IL-10 and IL-6 
levels, not the additional analysis including day of measurement, ICU 
outcome, steroid use and nutritional adequacy. 
The models shown in Table 4.14 (p158) represent relationships that were 
sought between biomarkers and variables, the variables include day of 
measurement on ICU, age, gender, BMI, ICU length of stay, ICU outcome, 
steroid use and nutritional adequacy. For example, does day of measurement 
on ICU relate to CRP levels? Previous analysis demonstrated a significant 
relationship existed between CRP and day of measurement, for each 
additional day of measurement on the ICU, the CRP value reduced, which 
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was associated with patients recovering. No significant relationship was 
identified when CRP or any of the other biomarkers, including total muscle 
depth, were modelled against ICU outcome, steroid use and nutritional 
adequacy. The only significant outcome was for nitrogen balance (Deacon 
equation), where an increase in energy intake was related to an increase in 
nitrogen balance levels.  
These models were used to explore the inter-relationships between variables 
and biomarkers. The rationale for exploring these inter-relationships was firstly 
to see if a nutritional tipping point could be identified from overall inspection of 
the data and secondly to understand the relationships of biomarkers and 
variables such that it would inform the design of a future nutritional clinical trial 
in addition to the surrogate endpoint data. 
Clinically, multilevel modelling results can therefore be summarised: for each 
additional day spent on ICU the levels of CRP, total muscle depth and IL-10 
are expected to decrease. For every year increase in a patient’s age levels of 
total muscle depth and 3-MH will reduce and the odds of having detectable 
levels of IL-10 are expected to increase. An increase in energy intake is 
related to an increase in nitrogen balance levels from the Deacon equation. 
It is perhaps surprising that steroid use and nutritional adequacy did not seem 
to be significant predictors of total muscle depth. A limitation to the steroid 
data is that the dose of steroids administered was not included in this 
analysis, only whether patients received steroids during their ICU admission 
or not. Future studies should explore whether any relationship exists between 
different doses of steroid administration and muscle wasting as high-dose 
steroid administration has been linked to muscle wasting (Hasselgren et al. 
2010). Nutritional adequacy was defined as calories received versus 
prescribed and grams of protein received versus prescribed. Calorie 
prescription was not derived from indirect calorimetry but from predictive 
equations as assessed by the unit dietitian and/or the researcher which is a 
further limitation to current data.  The data is furthermore limited by the fact 
that day 1 of study was not necessarily day 1 of ICU admission as patients 
were recruited within 72h of their ICU admission. 
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4.4.8 Prognostic Inflammatory and Nutritional Index  
 
The ‘new PINI’ did not provide any additional suggestion of a nutritional 
tipping point, it has been used mostly to predict risk of infection or death. The 
PINI has been used rarely in the past within critical care, in trauma patients 
PINI reduced over time (Vehe et al. 1991). It has furthermore been used in 
burns patients as prognostic indicator for infection or death (Gottschlich et al. 
1992) and in respiratory failure patients on ICU where the PINI formula was 
used as an independent predictor of the weaning trial outcome in 
mechanically ventilated patients (Schlossmacher et al. 2002). No study within 
critical care was identified where PINI was used to identify a nutritional tipping 
point per se. 
 
4.4.9 Functional Outcomes 
 
The Katz and Barthel indices did not appear to detect the potential subtle 
changes in function that ICU patients might display. Low scores could be due 
to patients genuinely lacking the ability to demonstrate improvement, or may 
be due to insensitivity of the tool to detect meaningful change in patients with 
lower levels of function, highlighting a ‘floor’ effect in both tools. 
The Barthel index may be better suited to assess functional status in patients 
discharged from critical care (van der 2008). Reliability for both the Katz and 
Barthel indices has not yet been established in critical care (Black et al. 2001). 
More tools have recently been designed to detect functional recovery in the 
critically ill, these are discussed in Chapter 5 (Corner et al. 2013;Denehy et al. 
2012;Zanni et al. 2010). 
 
4.4.10 Surrogate endpoints for future nutritional clinical trials  
 
Sample size estimates for CRP, serum albumin, urinary urea, 3-MH and 
muscle depth may mathematically appear as reasonable estimates from day 7 
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and day 14 results, however the clinical significance of these changes may 
not be large enough. The large sample sizes observed in the change variable 
mean that much more data would be required in order to accept very small 
differences as statistically significant, although in clinical practice these are 
unlikely to be of clinical significance. 
Endpoints of any study should reflect the intervention studied and should not 
be vulnerable to confounding. If confounding factors could not be measured 
directly the study relies only on the process of randomisation to adjust for 
imbalances between groups. Small studies may be vulnerable to confounders 
that cannot be measured, therefore an increased sample size may be 
required to anticipate requirement for post hoc adjustment if there is 
accidental imbalance in the randomization. 
C-reactive protein and albumin levels will be vulnerable to confounders as 
markers of an inflammatory state. Serum albumin is additionally not a 
sensitive nutritional marker due to the long half life of albumin, due to the large 
intra-vascular pool and due to albumin’s role as a negative acute phase 
protein. Although data for CRP, albumin, urinary urea and 3-MH were 
mathematically explored these data may be too vulnerable to confounders not 
related to the intervention. This means in practice that although these data 
may be collected in nutritional trials, they should not be used as primary 
endpoints to power nutritional studies. 
Surrogate endpoints to detect rate of change of collected biomarkers may be 
feasible in some studies, however from the current data set this does not 
appear to be the case. 
It can therefore be concluded that the biomarkers used to estimate sample 
size were studied at a point in the patient’s recovery when the data suggest 
that the cohort is catabolic, thus not at a time for nutritional intervention. Early 
pharmacological intervention, such as Oxandrolone or Propranolol, may be 
used in earlier stages as this type of intervention is designed to have some 
aggresive effect on the catabolic state of the patient. These sample size 
estimates therefore provide some guidance as to the orders of magnitude 
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needed for a late intervention study, based on the biomarkers as endpoints, 
however estimates are not satisfactory and should be viewed with caution. 
  
Nutrition studies in the critically ill are often confounded by heterogeneous 
patient groups and by poorly selected outcome measures. Heterogeneous 
populations in studies in the critically ill may result in conflicting findings in 
studies assessing similar nutritional interventions (Vincent and Preiser 2013). 
Studying subsets of patients in which risk stratification can be performed is 
more likely to highlight the type of intervention that might benefit these specific 
patients, rather than studying a large cohort (Berger and Mechanick 2013). 
Nutritional markers per se may not be the best outcome measures to use in 
trials of nutrition support. When selecting outcome measures to assess 
efficacy of nutrition one should consider whether nutrition is expected to have 
an effect on mortality, ICU length of stay, rate of complication or indeed 
whether nutrition should be used as a surrogate marker for functional recovery 
(Vincent 2013). Broader outcome measures assessing health-related quality 
of life or physical function may need to be considered instead in the critically ill 
provided with nutritional interventions (Heyland 2013). Equally, the chosen 
endpoint should reflect the intervention studied. 
 
4.5 Conclusion 
 
A notional nutritional tipping point does not exist during a period of critical 
illness, patients demonstrate a continuing inflammatory response, increased 
protein breakdown and progressive muscle depth loss. Patients are unlikely to 
benefit from aggressive nutritional strategies during this time, however 
standard nutrition support should be continued during their ICU stay. 
Nutritional strategies that might promote anabolism are likely best targeted 
outside fo the ICU environment. Drug interventions aimed at reducing 
catabolism, such as Oxandrolone and Propranolol, may however be more 
effective in the earlier stages of critical illness. Multilevel modelling revealed 
various inter-relationships, each additional day spent on ICU was significantly 
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associated with an expected decrease of C-reactive protein, muscle depth 
and interleukin-10 levels. With every year increase in a patient’s age expected 
levels of muscle depth and 3-methylhistidine were significantly reduced and 
the odds of having detectable IL-10 levels were significantly increased. 
Sample size estimates calculated from the current data set provide 
some guidance as to the patient numbers required for a late intervention 
study, based on biomarkers as endpoints, however estimates are not 
satisfactory and should be viewed with caution.  
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Chapter 5. Essential Amino Acid Supplementation in Critically Ill 
Trauma Patients – A Feasibility Study 
 
5.1 Introduction 
 
In this chapter the feasibility of using a leucine-enriched essential amino acid 
supplement in mechanically ventilated trauma patients will be discussed. The 
methods used in this study were described in Chapter 2. Similar outcome 
measures were used as in the Nutritional Tipping Point study. Assessment 
included markers of inflammation and cytokines, urinary studies to assess 
muscle breakdown and assessment of muscle depth change on ultrasound. In 
this study protein turnover was assessed in trauma patients via stable isotope 
studies using a 1-13C leucine tracer.  
This study was conducted at Kings College Hospital in London in the adult 
Medical and Surgical Intensive Care Units. Kings College Hospital is one of 
London’s major trauma centres. Critically ill trauma patients only were 
recruited to this feasibility study. 
 
5.1.1Research question  
 
Leucine-enriched essential amino acid (L-EAA) supplementation may 
attenuate muscle depth loss in mechanically ventilated trauma patients. 
 
5.1.2 Research aims  
 
1) To determine whether the trauma population represent a feasible group 
to study within critical care. 
2) To determine whether the intervention, leucine-enriched essential amino 
acid supplementation, is feasible to study within critical care. 
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3) To assess whether the outcome measures and endpoints used in this 
study would be both practical and scientific for use in future nutritional 
clinical trials. 
4) To develop a strategy that will minimise muscle mass decline during 
critical illness. 
 
5.2 Methods 
5.2.1 Study groups 
 
Trauma patients were selected for this study on the basis that they were 
thought to provide a reasonable study population within critical care. They are 
generally younger patients with less comorbidity and were thought to stay on 
ICU for a reasonable length of time. Two groups were studied: 
 
 Control group (N=4): The control group received usual care where 
standard enteral feed was provided according to patient need.  
 Interventional group (N=4): The interventional group received standard 
enteral feed in addition to leucine-enriched essential amino acid 
supplementation administered five times per day via enteral feeding 
tubes. 
 
5.2.2 Study outcome measures 
 
Inflammatory markers C-reactive protein (CRP) (mg/L) and serum albumin 
levels (g/L) were obtained from the Kings College Hospital clinical laboratory. 
CRP and albumin levels were collected on days 1, 3, 7 and 14 of the study. 
Cytokines IL-6 (pg/ml) and IL-10 (pg/ml) were measured from plasma samples 
on days 1, 3, 7 and 14 of the study, see chapter 2, section 2.1, p64. 
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Muscle depth change (cm) was measured by muscle ultrasound, on alternate 
days in the first week of study and twice weekly thereafter, see chapter 2, 
section 2.9, p72. 
Urinary studies for 3-methylhistidine (µmol/24h) and urinary urea (mmol/24h) 
were performed on days 1, 3, 7 and 14 of the study, see chapter 2, section 
2.7, p69. 
Nitrogen balance (g/day) was calculated as described in chapter 2, section 
2.8, p70. Nitrogen intakes were estimated from artificial nutrition support 
(enteral nutrition only in this study) and the amino acid supplement provided to 
patients during their ICU stay. 
Stable isotope studies were performed to determine protein turnover in trauma 
patients, see chapter 2, section 2.12, p80. These studies were planned to take 
place on days 1, 5 and 10 of the study period.  
 
5.2.3 ICU data collection  
 
Data collected included estimated weight (kg) and height (m) of patients to 
ascertain pre-admission body mass index (BMI, kg/m2), age (years) and 
gender. Daily energy (kcal) and protein (grams) intakes were recorded from 
observational charts. Estimated energy and protein requirements were 
calculated, based on recommended requirements for the critically ill, 25-
30kcal/kg/day for energy and 1.2g/kg/day for protein (Kreymann 
2006;McClave 2009). Enteral feed tolerance was monitored by assessing 
gastric residual volumes (ml) and incidence of vomiting. Occurrence of 
diarrhoea was also recorded. 
ICU demographics were recorded as descriptors of the type and severity of 
the injury: diagnosis, past medical history,  Acute Physiology and Chronic 
Health Evaluation (APACHE) II scores, Injury Severity Score (ISS), Glasgow 
Coma Scale, ventilation status, use of renal replacement therapy, ICU length 
of stay (days), ICU outcome (dead or alive) and hospital length of stay. 
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Functional outcomes (Katz and Barthel indices) were recorded as well as the 
MRC strength assessment, see chapter 2, sections 2.10, p77 and 2.11, p78 
respectively. 
Other ICU data thought to potentially influence muscle integrity, or muscle 
depth measurements, were recorded including use of steroids during ICU 
stay, sedation use, insulin administration (units/24h), fluid balance (ml/24h) 
and physiotherapy (particularly mobility or rehabilitation therapy). 
 
5.2.4 Screening and recruitment 
 
Screening and recruitment took place from 1 May 2012 until 31 January 2013 
on the surgical and medical critical care units at Kings College Hospital 
London, with combined bed capacity of 32 beds.  
 
Inclusion criteria: 
Trauma admissions (head or multiple trauma) expected to be ventilated for > 
48h 
Patients over 18 years of age  
Patients entered into the study within 72h of their ICU admission.  
 
Exclusion criteria: 
Medical or non-trauma surgical ICU patients 
Patients enrolled into another interventional clinical trial 
If enteral feeding was contra-indicated 
Congestive cardiac failure 
End stage renal failure  
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Chronic obstructive pulmonary disease  
Chronic liver disease (cirrhosis)  
Patients not for active medical treatment  
Extensive psychiatric illness precluding provision of informed consent.  
 
5.2.5 Randomisation 
 
A computer generated block randomisation schedule was provided by the trial 
statistician. The schedule numbers were placed into sealed, numbered 
envelopes by an independent research nurse not located at the study site. 
The sealed envelopes were placed into the trials folder. After assent was 
obtained a research nurse not involved in the study randomised the patients 
to either standard care or the L-EAA supplement.  
 
5.2.6 Intervention: Leucine enriched essential amino acid supplementation  
 
Leucine-enriched essential amino acid powder supplementation (Nutricia Ltd., 
Wiltshire, United Kingdom) was administered in 100ml solutions given five 
times per day via enteral feeding tubes, see chapter 2, section 2.13, p89. The 
composition of the supplement is included in Table 5-1. In Figure 5-1 the L-
EAA supplement can be seen. Interventional patients received the L-EAA 
supplement in addition to their standard enteral feed. No placebo product was 
used during this study as the manufacturer was not able to provide a suitable 
product.  
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Table 5-1: Composition of L-EAA supplement 
Amino Acid grams 
Cystine 0.8 
Histidine 0.8 
Isoleucine 2.1 
Leucine 9.5 
Lysine 2.5 
Methionine 0.8 
Phenylalanine 1.2 
Threonine 2.2 
Tryptophan 0.6 
Tyrosine 1.8 
Valine 2.7 
 
 
The 25g daily supplement was provided in 5 doses per day. The branched-
chain amino acid ratio for valine: leucine: isoleucine of 1:5:1 was based on a 
previous study by Borsheim et al where the additional leucine was thought to 
promote muscle protein synthesis (Borsheim 2008). 
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Figure 5-1: Leucine-enriched Essential Amino Acid supplement showing the 
supplement as delivered (in white pots) and as dispensed for the patient 
(bottles) 
(Photo L Wandrag) 
 
5.2.7 Study plan 
 
The study plan and data collection time points can be viewed in Figure 5-2 
below. The L-EAA supplement was given daily until discharge from ICU or 
until enteral feeding tubes were removed. Stable isotope studies were 
planned for days 1, 5 and 10, however these studies invariably had to be 
advanced as patients’ length of stay on ICU were shorter than anticipated. 
Additionally, as three people were required to perform each study they could 
only be performed on days when two esearch nurses were on duty.  
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Figure 5-2: Study plan of essential amino acid supplementation study 
 
 
5.2.8 Statistical Analysis 
 
Two-sided tests were used to all hypotheses tested, and the significance level 
was set to 0.05. Descriptive statistics were performed using SPSS V.20 (IBM 
Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. 
Armonk, NY: IBM Corp.).  
Results for the continuous variables are presented as median (1st-3rd quartile). 
Differences between the control and essential amino-acid groups were 
assessed with Mann-Whitney U-test. 
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 5.3 Results  
5.3.1 Screening and recruitment 
 
During the period from 1 May 2012 until 31 January 2013, 324 patients were 
admitted to the surgical and medical intensive care units at Kings College 
Hospital London. The combined bed capacity for the two units was 32 beds. 
Of the 324 patients 84 patients (25.9%) were major trauma admissions into 
critical care and 8 patients (9.5%) were recruited to this feasibility study. 
Patient recruitment is illustrated in Figure 5-3.   
    
 
Figure 5-3: Patient recruitment for the feasibility study 
CCF: Congestive cardiac failure; EN: enteral nutrition; ICU: Intensive care unit; L-EAA: 
leucine-enriched essential amino acid supplement; NGT: nasogastric tube; NOK: next of kin. 
 
N = 324 ICU  patients screened 
N = 8 patients randomised
N = 84 major trauma ICU 
patients screened
N = 76 excluded
N=34 Extubated/Lev el 2 patients
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N=6 No research staf f
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N=2 EN contra-indicated
N=2 CCF
N=1 Patient 15 y ears old
N=1 Recent ICU admission
N=1 Re-admission
N = 4 Control 
patients
N = 4 L-EAA 
patients
N = 240 non-trauma 
patients excluded
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5.3.2 Demographic data 
 
Demographic data is summarised in Table 5-2.  
Table 5-2: Demographic data of trauma ICU patient cohort 
 
Demographic factors 
Control 
(n=4) 
L-EAA 
(n=4) 
 
P value 
Age (years) 
Median (IQR) 
 
59.5 (26.2, 57.7) 
 
52.5 (32, 93) 
 
0.66 
a
 
Sex 
Male n (%) 
 
2 (50) 
 
4 (100) 
 
0.43 
b
 
BMI (kg/m²) 
Median, (IQR) 
 
22.95  
(20.13, 27.35) 
 
25.3  
(21.50, 27.68) 
 
0.69 
a
 
APACHE II (0-71) 
Median (IQR) 
 
13.5 (13, 18.5) 
 
15 (11.25, 21) 
 
0.88 
a
 
Injury Severity Score    
(0-75) 
Median (IQR) 
 
27 (16, 32.75) 
 
41.5 (24.5, 48.75) 
 
0.20 
a
 
Diagnosis n (%) 
Multiple trauma (no TBI) 
TBI only 
Trauma including TBI 
 
1 (12.5) 
1 (12.5) 
2 (25) 
 
1 (12.5) 
1 (12.5) 
2 (25) 
 
ICU LOS (days) 
Median (IQR) 
 
4.5 (2.5, 5.75) 
 
9.5 (8.0, 13.25) 
 
0.03 
a
 
Hospital LOS (days) 
Median (IQR) 
 
14.5  (4.5, 27.50) 
 
14 (9.25, 26.25) 
 
0.69 
a
 
a 
 Mann-Whitney U test, 
b
 Fischer’s exact test, L-EAA:Leucine-enriched essential amino acid; IQR: 
Interquartile range; BMI: Body Mass Index; APACHE II: Acute Physiology and Chronic Health 
Evaluation II; TBI: Traumatic brain injury; ICU: Intensive Care Unit; LOS: Length of stay. 
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Six (75%) of the patients suffered traumatic brain injuries. Two patients 
presented with polytrauma without traumatic brain injuries. 
 
There were no significant differences between the two groups apart from ICU 
length of stay. Patients in the L-EAA group appear sicker with higher APACHE 
II and injury severity scores than the control patient group. Although these 
differences did not reach significance this may be due to the small sample 
size. In the control group, one patient was discharged to his referring hospital 
after 4 days on ICU. Another patient died after 5 days on ICU, the third patient 
was transferred to the HDU after 2 days in ICU and the fourth control patient 
was transferred to HDU after 6 days on ICU. 
 
5.3.3 L-EAA supplement received 
 
The L-EAA doses received are presented in Table 5-3. The majority of 
omissions were due to unavoidable clinical reasons. 
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Table 5-3: L-EAA doses received and reasons for omissions 
Participant 
number 
Doses received Percentage 
received 
Reasons for 
omisions 
P401 0 out of 5 0% No NGT, discharge 
to HDU 
P403 45 out of 53 85% Vomiting 
NBM for stable 
isotope study 
P404 7 out of 19  37% Vomiting, NBM for  
isotope study, 
procedures, RIP 
P407 39 out of 47 83% NBM for isotope 
study, 2 x doses 
misplaced on ward 
(NGT: nasogastric tube; HDU: high dependency unit; NBM: nil by mouth; RIP: rest in peace) 
 
5.3.4 Outcome measures 
 
Outcome measures could not be compared directly between groups due to 
the small sample size and short length of stay, however feasibility of data 
collection for the whole cohort is described.  
C-reactive protein data were collected on 16 (100%) occasions, data for the 
whole cohort over 14 days ranged from 1 - 312 mg/L. Serum albumin data 
were collected on 16 (100%) occasions, data ranged from 22 - 39 g/L. One 
patient received albumin administration. Interleukin-6 data were collected on 
15 (94%) occasions, data ranged from 9 -141 pg/ml. Interleukin-10 data were 
collected on 15 (94%) occasions, data ranged from 0 - 2100 pg/ml. Urinary 
urea, 3-MH and nitrogen balance data were collected on 13 (81%) occasions, 
three urine collections could not be performed as patients were transferred out 
of ICU. No urine samples were misplaced in this study. Urinary urea data 
ranged from 51 - 382 mmol/24h; 3-MH from 144 - 660 µmol/24h and nitrogen 
balance from -10.6 to 7.4 g/day (PENG eqation) and -6.2 to 11.2 g/day 
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(Deacon equation). Serial muscle ultrasound was only performed in 4 (50%) 
patients due to short length of stay, data ranged from 4.43 - 11.56cm. 
The Katz index remained zero for all patients throughout the study, the Barthel 
index score changed from zero on one occasion as one patient sat out in a 
chair, however major help was required to position this patient. Manual 
strength testing could not be performed in this cohort as patients were not 
able to respond appropriately to the screening questions. 
Stable isotope studies were performed on 5 (31%) occasions. Patients 
remained in a negative whole body protein balance, data ranged from - 3.9 to 
-2.1 g/day. Data collection for this outcome measure was limited due to short 
ICU length of stay and as two research nurses were required each time to 
assist me with stable isotope studies. 
 
5.3.5 Leucine kinetics  
 
In Table 5-5 leucine kinetic data are presented from stable isotope studies 
performed in trauma patients. These data were compared to leucine kinetic 
data from Mansoor et al for both a trauma ICU and healthy subject cohort 
(Mansoor 2007). A medical ICU (Whyte 2010) and a cardiac surgical ICU 
cohort (M.B. Whyte, personal communication) have additionally been included 
for comparison. 
Leucine rate of appearance seems highest in my cohort, suggesting that 
these patients may have exhibited the highest rates of whole body protein 
breakdown, followed by the Mansoor et al trauma cohort and then the Whyte 
et al’s medical ICU cohort. Interestingly, the healthy control subjects and the 
Whyte surgical ICU patients displayed similar levels of Leu Ra, suggesting 
that the cardiac surgical patients were not catabolic. Concerning whole body 
protein synthesis as assessed by NOLD, this was highest in the Mansoor et al 
trauma cohort followed by my patient cohort, then healthy controls and lastly 
medical ICU patients. These results are interesting as this suggests that both 
trauma cohorts exhibited higher whole body protein synthesis rates than 
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healthy subjects. In the Mansoor et al cohort the mean SAPS II score was 42 
(SE: 3) out of 160 (Mansoor 2007). Mean injury severity score in the Kings 
College Hospital cohort of 8 trauma patients was 32 (SD: 12.5) out of 75.  
The overall leucine kinetic balance appeared most negative in my cohort, 
followed by the medical ICU cohort and then Mansoor et al’s trauma cohort. 
My trauma patients demonstrated a 34% higher whole body protein 
breakdown than synthesis, the medical ICU cohort showed a 32% higher rate 
of whole body protein breakdown than synthesis, Mansoor et al’s cohort 
exhibited a 8.5% higher whole body protein breakdown than synthesis and 
healthy controls showed a 6.5% lower breakdown than whole body protein 
synthesis. 
These data should be interpreted with caution however as I was unable to 
perform stable isotopes in a healthy cohort due to time constraints, therefore 
although it appears as though the patients in my trauma cohort demonstrated 
the most negative leucine balance this cannot be concluded without 
confirmation of leucine turnover in a healthy cohort. 
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Table 5-4: Leucine kinetics comparator data 
 Leu Ra  
(µmol/kg/min) 
NOLD 
(µmol/kg/min) 
Leu balance 
(µmol/kg/h) 
Trauma ICU 
N=5 
Median (IQR) 
(Wandrag, 
unpublished) 
 
3.22 
(3.18-3.31) 
 
2.13 
(1.74-2.37) 
 
-65.4 
(-93.33 to      
-51.46) 
Trauma ICU 
N=12 
Mean (SE) 
(Mansoor 2007) 
 
2.62 
(0.24) 
 
2.40 
(0.21) 
 
-13.2 
(-1.8) 
Healthy 
Control N=8 
Mean (SE) 
(Mansoor 2007) 
 
1.69 
(0.11) 
 
1.80 
(0.07) 
 
6.6 
(-0.04) 
Medical ICU 
N=10  
Mean (SE) 
(Whyte 2010) 
 
2.40 
(0.22) 
 
1.63 
(0.17) 
 
-46.2 
(-3) 
Cardiac 
Surgery ICU 
N=8 
Mean (SE) 
(M.B. Whyte, 
unpublished) 
 
 
1.69  
(0.07) 
 
 
NR 
 
 
NR 
Leu Ra: leucine rate of appearance, an index of whole body protein breakdown; NOLD: non-
oxidative leucine disposal, an index of whole body protein synthesis. Leu balance is NOLD 
minus Leu Ra. IQR: interquartile range; NR: not reported; SE: standard error. 
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5.4 Discussion  
 
5.4.1 Recruitment 
 
Recruitment for this type of study in critical care was time consuming and 
resource intensive. Of the 84 major trauma admissions to ICU eight patients 
were recruited to this study. This number was lower than anticipated, 9.5% of 
screened patients were recruited. The next of kin of five potential study 
patients refused assent, mostly as they were too distressed to make a 
decision. Length of stay on the ICU was the only significant difference 
observed between the two groups with the L-EAA group displaying a longer 
length of ICU stay. The L-EAA group appeared sicker as demonstrated by 
higher ISS and APACHE II scores, albeit a non-significant difference was 
observed between groups. Even though patients were randomised according 
to a computer generated schedule, the small sample size did not allow for 
groups to be balanced. 
 
5.4.2 Determining whether the trauma population represent a feasible 
patient population to study 
 
This study identified that the trauma population is a more complicated group 
to study than originally anticipated. Trauma patients’ length of stay in ICU may 
not be long enough in the major trauma centre, therefore as a source of level 
3 patients, trauma patients may not be sufficient. Annual data show patients 
had a mean length of stay of 6.6 days or median stay of 3.9 days (Medtrack 
database, Kings College Hospital). Patients are often repatriated to their local 
or referring hospital making the actual time for research studies shorter than 
anticipated.  
Intensivists at Kings College Hospital were surprised at the short length of ICU 
stay for these patients, during the planning phases of this project ICU length 
of stay was thought to be reasonable enough to follow patients up for 14 days. 
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This illustrates that future project design should be supported by ICU 
admission and demographic data. 
Patient recruitment to critical care research is clearly difficult, even in the 
context of a large potential pool of patients to recruit from. Additionally, due to 
the young age of many of the trauma admissions and the difficulty relatives 
experienced with the circumstances of the trauma, the next of kin were often 
too distressed to provide assent to the study. Furthermore, a lot of activity 
revolves around trauma patients, they have frequent scans, procedures and 
multiple operations in comparison to other ICU patient groups. This may limit 
the available time to administer interventions and to study outcome measures. 
However, one major advantage of studying the trauma population is that they 
are generally younger and present with less comorbidity, thus making the 
impact of the critical care admission clearer to study. Furthermore, the day of 
trauma is usually known, providing a clearer model to study. 
This type of dietary intervention may be feasible in the trauma population, 
however future studies should potentially focus on following the patient across 
the trauma network, from the Major Trauma Centre in the acute stages 
through to hospital rehabilitation in the network. Results from the nutritional 
tipping point study point towards the very acute stages of critical illness not 
being the best stage to target nutritional strategies, therefore rehabilitation 
strategies are likely to benefit patients more as they are followed through the 
trauma network. 
 
5.4.3 Determining whether the intervention is feasible to study within 
trauma critical care 
 
The L-EAA supplement was practical to administer to mechanically ventilated 
trauma patients via their enteral feeding tubes. The reasons for omissions of 
doses were for the most part unavoidable. The proportion of patients receiving 
the supplement may have been modest in this cohort, however lessons were 
learnt about the ongoing education required for dietary interventional studies. 
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The intake of any dietary intervention is likely to increase once a project and 
the intervention is fully embedded on the unit. In a busy trauma ICU feasibility 
of providing this supplement to severely ill trauma patients has been 
demonstrated, however it is dependent on intensive monitoring and having a 
dedicated research assistant to oversee the delivery of the supplement to the 
patient. It is questionable whether this intervention could be routinely provided 
with sufficient consistency, should it be shown to be effective.  
 
5.4.4 Feasibility of the outcome measures and endpoints used in this 
study  
 
Inflammatory markers and cytokine data were feasible to collect on most 
occasions. Urinary studies were not performed on three occasions due to 
patients transferring out of ICU and one patient requiring renal replacement 
therapy. Although urine collections were feasible on most occasions in this 
study cohort, missing collections could be an issue in larger studies and 
limitations of this outcome measures should be considered, see chapter 4, 
section 4.4.6, p174. No samples were misplaced during this study.  
 
Serial ultrasound data in this study was limited due to the short duration of 
stay in particularly the control patient group, serial measurements were only 
performed in four patients. The use of muscle ultrasound is discussed in more 
detail in chapter 4, section 4.4.3, p167, however would only be useful in this 
type of study if patients could be followed serially for longer. 
 
The currently available tools to detect functional change are not suitable for a 
trauma ICU population. The Katz and Barthel indices demonstrated 
substantial floor effects. Strength assessment via the MRC sum score was not 
feasible in a predominantly head injured trauma population. This type of 
testing, where patient cooperation is required, is unlikely to be of use in a 
trauma population suffering from traumatic brain injury. 
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I was unable to perform manual strength testing in this cohort. Patients were 
assessed once sedation was stopped and prior to discharge from the ICU and 
none of the patients were able to answer appropriately to the initial screening 
questions required in order to perform manual strength testing. This was 
mainly due to slow neurological recovery post traumatic brain injury. 
De Jonghe et al found that 111 (54%) ICU patients studied had to be 
excluded from muscle strength assessment, 85 patients died before 
awakening, in two patients strength testing was omitted and 24 patients were 
discharged before they were awake enough to respond appropriately (De 
2002). In a later cohort De Jonghe et al were able to perform strength testing 
in 99% of the patients included in their study (De 2007). The majority of these 
patients were medical ICU patients admitted with pneumonia or exacerbation 
of COPD.  
In a general medical ICU cohort Ali et al found that 38 (22%) patients were 
unable to perform the MRC Sum Score assessment due to persistent coma or 
inattentiveness (Ali et al. 2008b). In a mixed medical and surgical ICU cohort 
Hough et al found that 101 (75%) patients had to be excluded from manual 
strength testing, mainly due to persistent coma, delirium or not being alert 
enough (Hough 2011). Hermans et al found that out of a provisional cohort of 
735 ICU patients considered for neuromuscular analysis 257 (35%) were 
never awake enough to be assessed (Hermans 2012). This ICU cohort 
consisted mainly of cardiac surgery patients, approximately 60%. 
The Katz index total score remained zero throughout when patients were 
assessed. The Barthel index score changed from zero on one occasion only 
as a patient sat out in a chair with major assistance. This patient remained 
cognitively impaired and the MRC Sum score assessment was not performed 
either in this case. Neither of these two indices appear to be sensitive enough 
to detect minor potential improvements in function, such as those we might 
see within a trauma critical care context.  
A variety of functional assessment tools for specific use in the critically ill have 
been developed in recent years, which may be of use in future research, 
however reliability and validity will need to be established. The functional tools 
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that could potentially be used in an ICU population include the functional 
independent measure (FIM) (Dodds et al. 1993), the functional status score in 
ICU (FSS-ICU) (Zanni 2010), the physical functional independence test (PFIT) 
(Skinner et al. 2009) and the Chelsea functional test (CPax) (Corner 2013). 
The FIM is used for general disability assessment with grading performed on 
18 motor and cognitive tasks, scores range from 18-126. This tool has mostly 
been used in stroke patients, higher scores indicate higher levels of function 
(Dodds 1993). This tool has not yet been validated in the ICU population 
(Corner 2013). 
The FSS-ICU utilises aspects of the FIM assessment tool, however only two 
of the functional tasks are appropriate in the ICU context. Three additional 
tasks relevant to the ICU environment were therefore included, the five 
sections in total are graded on a 7-point scoring system. As with the FIM, 
higher scores indicate higher levels of function. Categories include three 
areas where patients have not stood up yet: rolling, supine-to-sit transfer and 
unsupported sitting along with two further categories: sit-to-stand transfer and 
ambulation (Zanni 2010).  
The PFIT test was designed for ICU patients in a centre where patients were 
weaning from tracheostomies, therefore perhaps not being entirely 
appropriate for the acutely ill ICU patient. Tests relate to cardiovascular fitness 
as opposed to actual assessment of physical function (Skinner 2009). 
The CPax test was developed in London and it scores 10 components of 
physical function that would be most commonly assessed in critically ill 
patients. These include respiratory function (relating to ventilator support or 
spontaneous breathing), cough, moving within the bed, supine to sitting 
movement on the edge of the bed, dynamic sitting, standing balance, sit to 
stand movement, transfer from bed to chair, stepping and grip strength. Each 
component is graded from 0-5 giving a total score of 50. This tool was tested 
in 33 patients, inter-rater reliability for this tool was strong with κ= 0.988 
(95%CI 0.791 to 1.000) (Corner 2013). This novel tool seems comprehensive 
in assessing the small incremental changes required in ICU patients. Further 
reliability and validity testing will be required in the critically ill. 
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Protein turnover studies, although robust and dynamic in assessing whole 
body protein breakdown and synthesis, are very time consuming and intricate 
to perform in mechanically ventilated patients. This type of outcome measure 
would only be feasible in future studies performed in subsets of patients or in 
sub-studies in units where research staff are plentiful, due to the labour 
intensity required to conduct these studies in ventilated patients.  
Trauma patients in this current study seemed to have higher levels of leucine 
rate of appearance (Leu Ra), an index of whole body protein breakdown, than 
the Mansoor et al cohort displayed. Similarly to my trauma cohort, the 
Mansoor et al cohort consisted of a majority of traumatic brain injured 
patients. It is difficult to draw a direct comparison between these two cohorts 
as the acute physiology scores and injury scores were not equivalent. 
Additionally, a limitation to the injury severity score is that the severity of a 
head injury is not reflected by score, scoring is performed by the anatomical 
region injured however severity cannot be scored  (Baker et al. 1974). The 
trauma cohorts exhibited the highest rates of whole body protein breakdown, 
with perhaps surprisingly high rates of whole body protein synthesis in 
comparison to a healthy population. Breakdown appeared highest in my 
cohort with protein synthesis highest in the Mansoor et al cohort. Ideally a 
healthy cohort should have been recruited to enable a direct comparison 
between my trauma cohort and a healthy population, which is a limitation to 
this current study, however this was unfortunately not feasible at the time of 
conducting this research. These data should however be interpreted with 
caution as I was unable to perform stable isotopes in a healthy cohort due to 
time constraints, therefore although it appears as though the patients in my 
trauma cohort demonstrated the most negative leucine balance this cannot be 
concluded without confirmation of leucine turnover in a healthy cohort. 
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One of the interesting findings from the protein turnover results is that whole 
body protein synthesis was higher in both trauma cohorts than the healthy 
subjects. Mansoor et al previously demonstrated that whole body protein 
synthesis was increased 48h after traumatic brain injury. This was thought to 
be due to the synthesis of acute phase proteins (Mansoor 1997). Birkhahn et 
al studied four trauma patients and five healthy subjects and concluded that 
whole body protein breakdown increased by 79% in the trauma subjects in 
comparison to healthy controls, protein synthesis was also increased above 
normal subjects at 37% (Birkhahn et al. 1981). In a group of patients studied 
with multi-organ failure whole body protein breakdown and synthesis 
increased concurrently, this was twice as high as rates measured in healthy 
control subjects (Arnold 1993).  
Enhanced whole body protein synthesis may not be evident in all ICU 
patients, Whyte et al’s medical ICU cohort clearly exhibited lower rates than 
healthy control subjects (Whyte 2010). Klaude et al describe in an ICU cohort 
with sepsis and septic shock that patients demonstrated normal protein 
synthesis rates and increased protein breakdown of up to 160% in 
comparison to healthy control subjects (Klaude 2012). 
 
5.4.5 Developing a strategy that will minimise muscle mass decline in 
critical illness 
 
Due to the small sample size recruited the effect of this particular supplement 
on minimising muscle mass decline could not be assessed directly. 
 
5.5 Conclusion  
 
The feasibility of administering an amino acid supplement to trauma patients 
on ICU has been demonstrated, however the trauma population may be more 
complicated to study than anticipated. Future researchers should carefully 
consider whether trauma patients represent the best cohort to study within 
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critical care. Outcome measures used in this research, such as the stable 
isotope studies, were resource intensive and should only be considered in 
sub-studies in institutions with sufficient research staff. The trauma population 
in this study seemed to exhibit higher rates of whole body protein breakdown 
than other ICU patients. Whole body protein synthesis appeared higher than 
healthy control subjects and medical ICU patients. Protein turnover results 
were however limited by not studying a healthy cohort at the same time as the 
trauma patients and results should therefore be interpreted with caution.  
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Chapter 6. Conclusion and future work
 
 
Muscle wasting and weakness can lead to increased morbidity and ICU length 
of stay. Recovery for survivors of critical illness should be measured in 
months to years rather than days to weeks. Muscle breakdown during critical 
illness is a progressive and multi-factorial process, and is in part an adaptive 
response. Amino acid substrates are used for synthesis of acute phase 
proteins and used in immune response, for tissue regeneration and wound 
healing during trauma and critical illness. Researchers studying interventions 
aimed at ameliorating muscle loss will have to consider that the optimum 
timing of interventions should be identified for strategies to be effective. 
The aim of this work was to understand the relationship between inflammatory 
and nutritional markers of critically ill patients such that a notional nutritional 
tipping point could be identified and a strategy to minimise muscle mass 
decline could be developed to facilitate recovery. Timing interventions in the 
knowledge of a nutritional tipping point would assist in optimising patient 
recovery.   
An observational study was performed to identify a notional nutritional tipping 
point, where anabolism starts to exceed catabolism. The inter-relationships 
between inflammatory and nutritional markers during critical illness were 
additionally assessed in this study. Current data were mathematically 
explored to identify plausible surrogate endpoints for use in future nutritional 
clinical trials.  
A feasibility study was conducted to identify whether the trauma population 
presented a viable group to study within critical care, given that these patients 
are usually younger and healthier than other patient groups and were thought 
to have a reasonable length of stay on ICU. The second aim was to determine 
how feasible the use of a leucine-enriched essential amino acid supplement 
might be as a future nutritional strategy aimed at minimising muscle loss. A 
variety of outcome measures relating to muscle depth, muscle breakdown, 
protein turnover and nutritional and inflammatory markers were explored to 
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determine how practical and scientifically sound these outcome measures 
would be for inclusion in a future larger nutritional clinical trial.  
The observational study showed that ICU patients lost a significant amount of 
muscle depth during their ICU stay. This study was conducted in 78 critically ill 
patients at three hospital sites in London. A notional nutritional tipping point 
could not be identified during 20 days on ICU with markers pointing towards a 
continued inflammatory response, negative nitrogen balance and progressive 
muscle depth loss observed. This study identified that nutritional strategies to 
optimise recovery might be best targeted outside of an ICU environment, once 
patients are in a recovery phase. This finding does not imply that patients 
should not receive their usual nutrition support during ICU stay, it only 
suggests that ‘aggressive’ or additional nutritional strategies may not be 
effective whilst the process of catabolism remains dominant.  
Multilevel modelling of variables revealed that with each additional day of 
measurement C-reactive protein, muscle depth and interleukin-10 levels 
decreased significantly. Older patients tended to have lower muscle depth and 
3-methylhistidine levels. 3-Methylhistidine reflects myofibrillar breakdown from 
all muscle, including skeletal, smooth and cardiac muscle. The lower 3-
methylhistidine levels may be due to lower protein breakdown in thinner 
muscle of older patients and therefore higher 3-methylhistidine levels in young 
patients may reflect higher rates of overall protein breakdown. This again may 
be due to younger patients in this cohort predominantly being trauma patients, 
whom have previously been shown to demonstrate accelerated rates of 
protein breakdown. Older patients were also found to have higher odds of 
having detectable levels of interleukin-10, an anti-inflammatory cytokine, than 
younger patients. The production of interleukin-10 has previously been found 
to be higher from leukocytes in the elderly than from those in the young. 
The biomarkers used to estimate sample size were studied at a point in the 
patient’s recovery when the data suggest that patients remained catabolic, 
therefore not at an appropriate time for nutritional intervention. Although the 
sample size estimates provide some guidance as to the orders of magnitude 
needed for a late intervention study, when biomarkers are used as endpoints, 
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however estimates are not satisfactory and should be viewed with caution. 
Biomarker data collected in this research: CRP, albumin, urinary urea and 3-
methylhistidine may additionally be influenced by confounding factors, 
although these data could be collected in future nutrition studies in critically ill 
patients they should not be used as primary endpoints. 
The second study identified that trauma critically ill patients presented a much 
more complicated population to study than anticipated. Length of stay was 
shorter than expected due to early repatriation to referring hospitals. Trauma 
patients are often occupied with procedures and operations and future 
researchers should therefore carefully consider these issues when planning 
interventions and data collection time points. Administering an essential amino 
acid supplement to critically ill trauma patients is feasible, however it is 
questionable whether this intervention could be routinely provided with 
sufficient consistency, should it be shown to be effective. Many of the 
outcome measures used in the feasibility study were too resource intensive to 
be used in large future nutritional studies, in particular performing stable 
isotope studies in mechanically ventilated patients. Stable isotope studies 
could only reasonably be incorporated in sub-studies in units where research 
staff are plentiful. Assessment of functional status via the Katz and Barthel 
indices did not appear to be sensitive enough to depict potential minor 
improvements in function in the critically ill and manual strength testing is not 
recommended in cohorts with predominant traumatic brain injury either. This 
study also assessed protein turnover in a small trauma cohort. Trauma 
patients remained in a negative whole body protein balance and appeared to 
exhibit higher rates of whole body protein breakdown than medical ICU or 
surgical ICU patients do in comparison to the literature. Equally, whole body 
protein synthesis was higher than that observed in medical ICU patients and 
healthy subject data from the literature, these results should however be 
interpreted with caution as a healthy control cohort were not studied at the 
same time as the trauma cohort. The efficacy of a leucine- enriched essential 
amino acid supplement could not be assessed in this study due to small 
sample size. 
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Future research in this field could focus on either aiming to reduce catabolism 
during an ICU admission or by promoting anabolism after a period of critical 
illness. Potential strategies to minimise catabolism include drug interventions 
which have shown promise in reducing catabolism and promoting lean body 
mass gain. Although these drug interventions, Propranolol and Oxandrolone, 
have been studied mostly in patients suffering from burn injury, these 
interventions could be tested in other ICU cohorts to determine if the process 
of catabolism could be turned down earlier during an ICU stay. Other 
strategies that might reduce catabolism during critical illness include 
incorporation of electrical muscle stimulus and early exercise. Pilot studies 
have shown initial promise in electrical muscle stimulus for instance, however 
large prospective randomised controlled trials would be required to ascertain 
whether these interventions could feasibly reduce muscle wasting and 
improve physical function in ICU patients. 
Outcome measures should be carefully selected to reflect the intervention 
studied. If urinary studies are conducted urinary nitrogen should be directly 
measured. If lean mass is assessed this should ideally be done via CT, such 
as has been demonstrated in trauma patients undergoing abdominal CT to 
ascertain lean body mass (Casaer et al. 2013). Muscle depth or muscle 
volume  assessment via ultrasonography is practical and feasible when no 
other techniques are available within critical care however the limitations of 
these techniques should be clearly understood. Exploratory studies into 
causes of muscle wasting should be investigated further, in particular 
assessing the relationship between muscle wasting and the dose of steroid 
administration. Muscle biopsies could additionally be performed to determine 
if muscle protein breakdown and synthesis pathways are altered due to the 
chosen intervention. 
 
In order to promote anabolism future nutritional research should focus on 
targeting additional nutritional interventions outside of the ICU environment to 
facilitate recovery. Leucine-enriched essential amino acid supplementation  
could be studied in addition to adequate intake of energy and protein. 
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Exercise or electrical muscle stimulus as well as the use of Oxandrolone 
and/or Propranolol may promote anabolism and warrants further investigation 
in other ICU cohorts. Appropriate functional and strength assessments should 
be identified in this population for use in future studies. The efficacy of a 
leucine-enriched essential amino acid supplement could additionally be tested 
in survivors of critical illness along with resistance exercise to assess whether 
functional recovery can be improved with this intervention. A specialised 
nutrition care pathway for ICU rehabilitation could be formulated in future, 
incorporating nutritional interventions shown to be effective in addition to 
appropriate measures of functional recovery. 
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Appendix I: Data Collection Sheet 
 
Data Collection Sheet Day 1 
Study: ________________                                                  Date: ________________ 
Researcher: ____________                                                Day of study: __________ 
Unit: CXH/HH/SMH (circle)                 Weight:…………..kg BMI: 
Patient:                                                                        
                                         
                                                    
 
PMH: 
 
Speciality: (circle) 
Medical  
Surgical 
Neurosurgery 
Mixed trauma  
Diagnosis: 
 
APACHE II:  
Organ Failure : ≤ 2 organs or ≥ 3 (circle)                       
Medications: 
Sedation: 
Fentanyl 
Midazolam 
Propofol 
NMBA: 
Thiopentone: 
OTHER:                        
GCS: 
Insulin: 
Units per 24h: 
 
 
Steroids 
Drug: 
 
Dose: 
 
Cardiac: 
Noradrenaline: 
Adrenaline: 
Vasopressin: 
Dobutamine: 
Albumin 
 
Activity:                                
Bedbound immobile 
Bedbound moving 
Sitting up in bed 
Sitting out 
Comment: 
Ventilation: 
ETT 
Setting: 
Physiotherapy: 
Yes 
Duration: 
No 
CVVHDF removal volume: 
Duration: 
 
Nutrition: NG/PN/Oral 
Kcal per 24h: 
Protein per 24h 
 
Vomiting: 
Yes/No 
Volume: 
 
GRV per 24h: (ml) Diarrhoea (>3 
episodes/24h)        Y/N 
 
Bristol:  
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Inflammatory Markers:        WCC:  
CRP: (mg/dl) 
 
Albumin: (mg/dl) TNF-alpha: 
IL-1beta: IL-6:  IL-10: 
 
REE:                                     fiO2:                                       VCO2: 
Kcal/24h:                              flow rate:                                 VO2: 
Vent settings: 
 
Nitrogen Balance: 
 
Urinary urea per 24h:                                                         U - Creat: 
 
Urinary urea:                                                                       S - Urea: 
 
3MH:                                                                                   S - Creat: 
 
Stable Isotope: 
CO2: 
 
KIC: 
 
Protein Turnover: 
 
 
Muscle US:                                         Fluid Balance (last 24h): 
 
 1 2 3 Average 
Bicep     
Forearm     
Thigh_half     
Thigh_12cm     
 
Muscle US: 
Total (cm):                                                                 % loss:  
 
EAA supplement 
Volume given per 24h 
 
 
Volume received: Comments: 
Katz Index 
 
Score 0 – 6 
 
(0 = Highly Dependent 
6 = Highly Independent) 
 
Barthel Index 
 
Score 0 – 100 
(0 = Highly Dependent 
100 = Highly Independent) 
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Appendix II: Barthel Index 
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Appendix III: Katz Index 
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Appendix IV: MRC Sum Score 
 
Date:    Patient: 
 
Patient has to be 100% cooperative. Ask: 
1. Do you know where you are? 
2. Can you stick your tongue out? 
3. Can you squeeze my fingers? 
 
‘Yes’ to all before commencing. 
 
 
ASSESSMENT:    Awakening/discharge (circle) 
 
Shoulder Abduction     R ……   L …… 
 
 
Elbow Flexion     R …...   L …... 
 
   
Wrist extension     R ……   L …… 
 
 
Hip Flexion      R …...   L …… 
 
  
Knee Extension     R ……   L …… 
 
 
Ankle Dorsi flexion     R ……   L …… 
 
 
 
0 = No visible contraction 
1 = Visible muscle contraction, no limb movement 
2 = Active movement, not against gravity 
3 = Active movement, against gravity 
4 = Active movement against gravity and resistance 
5 = Active movement against full resistance 
 
 
Maximum score = 60 
Minimum score = 0, quadriplegia 
ICUAW: < 48  
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Appendix V: Muscle ultrasound data collection sheet 
Muscle Ultrasound      Participant No:     CXH / HH/ SMH / KCH  
Date B 1 B 2 B 3  Mean F 1 F 2 F 3 Mean T1/2_ 1 T1/2_ 2 T1/2_3 Mean T_12cm T_12cm T_12cm Mean Total 
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
 
Document on general data collection sheet: 
Time measurement taken, 24h Fluid balance, position of leg (90° angle on bed)
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Appendix VI: IL-10 human duoset protocol 
 
1. Capture antibody was diluted to the working concentration in PBS without the carrier protein in a 
clean reservoir. A 96-well microplate was immediately coated with 100 µL per well of the diluted 
capture antibody using a multi-channelled pipette. The microplate was sealed with paraffin and 
incubated overnight at room temperature. 
 
2. Following the incubation period, the capture antibody was aspirated from the microplate and each 
well washed with 400ul of Tween
®
 wash buffer. This process was repeated for a total of three times, 
ensuring complete aspiration of Tween
®
 wash buffer between washes. After the last wash the 
remaining wash buffer was removed by aspirating and inverting the plate and blotting this against 
clean paper towels until the microplate was dry. 
 
3. After the wash, 300 µL of reagent diluent was added to each well using a multi-channelled pipette. 
The microplate was sealed with paraffin and incubated at room temperature on the rocker for a 
minimum of 1 hour. 
 
4. The process of aspirating and washing with Tween
®
 wash buffer was repeated again three times. 
The microplate was inverted after the third wash and blot dried against clean paper towels. 
 
5. Patient samples were removed from the -80C freezer and allowed to thaw at room temperature for 
a minimum of 1 hour. Serial dilutions of the standards were prepared immediately prior to washing of 
the plates. 100 µL of thawed patient samples or the serial dilution of the standards was added in 
duplicate into the microplate, using a clean pipette tip each time. The microplate was covered with 
paraffin and incubated on the rocker at room temperature for 2 hours. 
 
6. The process of aspirating and washing with Tween
®
 wash buffer was repeated again three times. 
The microplate was inverted after the third wash and blot dried against clean paper towels.  
 
7. After washing, 100 µL of the prepared detection antibody was added into each well. The microplate 
was covered with paraffin and incubated on the rocker at room temperature for 2 hours. 
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 8. The process of aspirating and washing with Tween
®
 wash buffer was repeated again three times. 
The microplate was inverted after the third wash and blot dried against clean paper towels. 
 
9. After washing, 100 µL of the working dilution of streptavidin-HRP was added to each well. The 
microplate was covered with paraffin and incubated for 20 minutes at room temperature away from 
direct light in a cupboard. 
 
10. The process of aspirating and washing with Tween
®
 wash buffer was repeated again three times. 
The microplate was inverted after the third wash and blot dried against clean paper towels. 
 
11. After washing, 6ml of colour reagent A (H2O2) was added to 6ml of colour reagent B 
(tetramethylbenzidine) in a reservoir and mixed well. 100 µL of the substrate solution was added 
immediately to each well using the multi-channelled pipette. The microplate was incubated for 20 
minutes at room temperature away from direct light in a cupboard. 
 
12. 50 µL of stop solution (2 N H2SO4) was added to each well of the microplate, using the multi-
channel pipette. The microplate was gently tapped to mix the solutions together. 
 
13. The optical density of each well was immediately determined, using a microplate reader set to 450 
nm. 
A similar protocol was followed per manufacturer’s instructions for IL-6 ELISA.  
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Appendix VII: The distribution of patients’ BMI and length of stay on 
ICU 
                 
Figure a: Body mass index (kg/m²) distribution for patients. 
 
 
              
Figure b: Distribution of patients’ length of stay on ICU (days). 
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Appendix VIII: Spread of patient data illustrated by trajectory plots 
 
                     
Figure 1: Trajectories of C-reactive protein (mg/L) for each patient during ICU stay 
 
                    
Figure 2: Trajectories of serum albumin (g/L) for each patient during ICU stay 
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Figure 3: Trajectories of urinary urea (mmol/24h) for each patient during ICU stay 
 
 
                            
 
Figure 4: Trajectories of 3-methylhistidine (µmol/24h) for each patient during ICU 
stay 
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Figure 5: Trajectories of nitrogen balance (g/day), PENG equation, for each patient 
during ICU stay 
 
                                
 
Figure 6: Trajectories for nitrogen balance (g/d), Deacon equation, per stay on ICU 
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Figure 7: Trajectories of total muscle depth (cm) for each patient during ICU stay
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Appendix IX: Multilevel modelling 
Example results from multilevel modelling to assess the characteristics related with the levels of C-reactive protein (square root transformation) (n=78). 
Results for the fixed effects are presented as b-coefficients (95% Confidence Intervals).  
  M1.0 M1.1 M1.2 M1.3 M1.4 M1.5 
  coefficient (95% CI) coefficient (95% CI) coefficient (95% CI) coefficient (95% CI) coefficient (95% CI) coefficient (95% CI) 
Fixed effects 
            
Intercept 10.95 (9.96, 11.93) 11.06 (10.06, 12.06) 11.80 (8.29, 15.31) 11.86 (8.41, 15.32) 13.12 (8.20, 18.04) 12.94 (8.02, 17.86) 
Days -0.24 (-0.36, -0.13) -0.29 (-0.43, -0.15) -0.25 (-0.36, -0.13) -0.24 (-0.35, -0.13) -0.24 (-0.35, -0.13) -0.24 (-0.36, -0.13) 
Age, yrs 
    
-0.01 (-0.07, 0.04) -0.01 (-0.06, 0.05) -0.01 (-0.06, 0.05) -0.01 (-0.06, 0.05) 
Female gender 
      
-1.42 (-3.30, 0.46) -1.43 (-3.31, 0.44) -1.38 (-3.25, 0.49) 
Body mass index, kg/m
2
 
        
-0.05 (-0.18, 0.09) -0.05 (-0.19, 0.08) 
Days in ICU 
          
0.02 (-0.03, 0.06) 
             
Random effects 
            
 
variance (sd) variance (sd) variance (sd) variance (sd) variance (sd) variance (sd) 
Subject 11.85 (3.44) 12.91 (3.59) 11.77 (3.43) 11.31 (3.36) 11.20 (3.35) 11.09 (3.33) 
Days 
  
0.08 (0.28) 
        
Residual 10.22 (3.20) 8.86 (2.98) 10.23 (3.20) 10.24 (3.20) 10.24 (3.20) 10.25 (3.20) 
             
Variance partition 
            
Subject 0.54 
 
0.59 
 
0.54 
 
0.52 
 
0.52 
 
0.52 
 
Days 
  
0.004 
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Model fit statistics 
            
BIC 1381.00 
 
1387.00 
 
1385.80 
 
1389.10 
 
1394.10 
 
1399.00 
 
logLikelihood -679.30 
 
-676.90 
 
-679.20 
 
-678.12 
 
-677.87 
 
-677.58 
 
Deviance from M1.0 
  
4.77 df=2 0.25 df=1 2.40 df=2 2.90 df=3 3.47 df=4 
Deviance from M1.1 
            
Deviance from M1.2 
      
0.20 df=1 2.66 df=2 3.24 df=3 
Deviance from M1.3 
        
0.49 df=1 1.08 df=2 
Deviance from M1.4 
          
0.58 df=1 
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Appendix X: Predicted values from multilevel modelling 
Table 1: Predicted values for C-reactive protein levels (mg/L) along with their corresponding 
95% Confidence intervals, according to the day the measurement was performed.   
Day of 
measurement 
Predicted 
value 
95% Confidence 
Interval 
1 115 (95, 136) 
2 109 (91, 129) 
3 104 (87, 123) 
4 99 (83, 118) 
5 95 (78, 113) 
6 90 (74, 108) 
7 85 (69, 104) 
8 81 (64, 100) 
9 77 (59, 96) 
10 72 (55, 92) 
11 68 (50, 89) 
12 64 (46, 86) 
13 60 (41, 83) 
14 57 (37, 80) 
15 53 (33, 78) 
16 50 (29, 75) 
20 37 (16, 65) 
 
Table 2: Predicted values for Albumin levels (g/L) along with their corresponding 95% 
Confidence intervals, according to the day the measurement was performed.   
Day of 
measurement 
Predicted 
value 
95% Confidence 
Interval 
1 20.6 (19.2, 22.1) 
2 20.7 (19.4, 22.0) 
3 20.7 (19.5, 22.0) 
4 20.8 (19.6, 22.0) 
5 20.8 (19.6, 22.0) 
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6 20.8 (19.7, 22.0) 
7 20.9 (19.7, 22.1) 
8 20.9 (19.7, 22.2) 
9 20.9 (19.6, 22.3) 
10 21.0 (19.6, 22.4) 
11 21.0 (19.5, 22.6) 
12 21.1 (19.5, 22.7) 
13 21.1 (19.4, 22.9) 
14 21.1 (19.3, 23.1) 
15 21.2 (19.2, 23.3) 
16 21.2 (19.1, 23.4) 
20 21.4 (18.7, 24.3) 
 
 
Table 3: Predicted values for Urinary Urea levels (mmol/24h) along with their corresponding 
95% Confidence intervals, according to the day the measurement was performed.   
Day of 
measurement 
Predicted 
value 
95% Confidence 
Interval 
1 262 (205, 326) 
2 266 (210, 328) 
3 269 (214, 330) 
4 272 (216, 335) 
5 276 (217, 341) 
6 279 (217, 349) 
7 282 (216, 358) 
8 286 (214, 368) 
9 289 (211, 379) 
10 292 (208, 391) 
11 296 (204, 404) 
12 299 (201, 417) 
13 303 (197, 431) 
14 306 (193, 446) 
15 310 (189, 460) 
 256 
16 313 (184, 476) 
20 327 (167, 541) 
 
Table 4: Predicted values for 3-methylhistidine (umol/24h) along with their corresponding 
95% Confidence intervals, according to patients’ age (years) and the day the measurement 
was performed.   
Day of measurement Age Predicted value 95% Confidence Interval 
1 24 511 (381, 660) 
1 27 491 (372, 625) 
1 28 484 (369, 614) 
1 30 470 (363, 592) 
1 30 470 (363, 592) 
1 32 457 (357, 571) 
1 34 444 (350, 549) 
1 36 431 (344, 529) 
1 37 425 (341, 519) 
1 39 413 (334, 499) 
1 40 406 (331, 490) 
1 41 400 (328, 480) 
1 43 388 (321, 462) 
1 44 382 (317, 453) 
1 44 382 (317, 453) 
1 46 370 (310, 436) 
1 47 364 (307, 427) 
1 47 364 (307, 427) 
1 49 353 (299, 411) 
1 51 341 (291, 396) 
1 52 336 (287, 388) 
1 52 336 (287, 388) 
1 53 330 (283, 381) 
1 53 330 (283, 381) 
1 54 325 (279, 374) 
 257 
1 54 325 (279, 374) 
1 55 319 (274, 368) 
1 55 319 (274, 368) 
1 55 319 (274, 368) 
1 56 314 (270, 361) 
1 56 314 (270, 361) 
1 57 308 (265, 355) 
1 57 308 (265, 355) 
1 57 308 (265, 355) 
1 58 303 (260, 349) 
1 59 298 (255, 344) 
1 59 298 (255, 344) 
1 59 298 (255, 344) 
1 61 287 (245, 333) 
1 61 287 (245, 333) 
1 61 287 (245, 333) 
1 62 282 (240, 328) 
1 62 282 (240, 328) 
1 63 277 (234, 323) 
1 63 277 (234, 323) 
1 63 277 (234, 323) 
1 64 272 (229, 319) 
1 64 272 (229, 319) 
1 66 262 (218, 310) 
1 66 262 (218, 310) 
1 67 257 (212, 306) 
1 67 257 (212, 306) 
1 67 257 (212, 306) 
1 67 257 (212, 306) 
1 70 242 (195, 295) 
1 71 238 (190, 291) 
1 72 233 (184, 288) 
 258 
1 72 233 (184, 288) 
1 72 233 (184, 288) 
1 73 228 (179, 284) 
1 73 228 (179, 284) 
1 73 228 (179, 284) 
1 73 228 (179, 284) 
1 75 219 (168, 278) 
1 75 219 (168, 278) 
1 76 215 (162, 275) 
1 76 215 (162, 275) 
1 77 210 (157, 272) 
1 78 206 (151, 269) 
1 80 197 (141, 263) 
1 80 197 (141, 263) 
1 81 193 (136, 260) 
1 82 189 (131, 257) 
1 84 180 (121, 252) 
1 85 176 (116, 249) 
1 85 176 (116, 249) 
1 89 160 (97, 239) 
2 53 324 (279, 373) 
2 58 297 (256, 341) 
2 62 276 (236, 320) 
2 66 256 (214, 302) 
2 67 252 (209, 298) 
2 71 233 (186, 284) 
2 72 228 (181, 281) 
2 73 223 (175, 277) 
2 73 223 (175, 277) 
2 82 184 (127, 251) 
2 84 176 (118, 246) 
2 89 156 (94, 233) 
 259 
3 24 496 (370, 641) 
3 27 476 (361, 607) 
3 28 469 (358, 596) 
3 30 456 (352, 574) 
3 34 430 (340, 532) 
3 36 418 (333, 511) 
3 39 399 (324, 482) 
3 40 393 (321, 473) 
3 43 375 (311, 445) 
3 44 369 (308, 436) 
3 46 357 (301, 419) 
3 47 352 (297, 411) 
3 49 340 (290, 395) 
3 52 324 (278, 372) 
3 53 318 (274, 365) 
3 54 313 (270, 358) 
3 55 307 (266, 352) 
3 55 307 (266, 352) 
3 56 302 (261, 346) 
3 57 297 (257, 340) 
3 57 297 (257, 340) 
3 59 286 (247, 328) 
3 59 286 (247, 328) 
3 61 276 (237, 318) 
3 61 276 (237, 318) 
3 63 266 (226, 309) 
3 63 266 (226, 309) 
3 63 266 (226, 309) 
3 64 261 (221, 304) 
3 64 261 (221, 304) 
3 66 251 (210, 296) 
3 67 246 (204, 292) 
 260 
3 67 246 (204, 292) 
3 67 246 (204, 292) 
3 72 223 (177, 274) 
3 72 223 (177, 274) 
3 73 218 (171, 271) 
3 73 218 (171, 271) 
3 75 209 (160, 265) 
3 76 205 (155, 262) 
3 76 205 (155, 262) 
3 77 201 (149, 259) 
3 78 196 (144, 256) 
3 80 188 (134, 251) 
3 81 184 (129, 248) 
3 85 167 (109, 238) 
4 30 449 (345, 566) 
4 32 436 (339, 545) 
4 39 392 (318, 475) 
4 44 363 (301, 429) 
4 47 345 (291, 404) 
4 51 323 (276, 373) 
4 52 317 (272, 366) 
4 54 307 (264, 353) 
4 55 301 (260, 346) 
4 55 301 (260, 346) 
4 56 296 (255, 340) 
4 59 280 (241, 323) 
4 59 280 (241, 323) 
4 61 270 (231, 312) 
4 62 265 (226, 308) 
4 72 218 (172, 269) 
4 73 213 (166, 266) 
4 73 213 (166, 266) 
 261 
4 80 183 (130, 246) 
4 84 167 (110, 235) 
4 85 163 (106, 233) 
5 30 442 (338, 559) 
5 32 429 (332, 538) 
5 53 306 (261, 355) 
5 59 275 (235, 318) 
5 72 213 (166, 265) 
5 73 208 (161, 262) 
5 77 191 (140, 250) 
5 78 187 (135, 247) 
5 89 144 (84, 219) 
6 28 447 (337, 574) 
6 59 269 (227, 315) 
6 61 259 (217, 305) 
6 61 259 (217, 305) 
6 66 235 (192, 283) 
7 24 466 (341, 611) 
7 40 367 (292, 450) 
7 46 332 (272, 399) 
7 47 327 (268, 391) 
7 51 305 (253, 362) 
7 52 300 (249, 355) 
7 53 294 (245, 348) 
7 54 289 (241, 342) 
7 54 289 (241, 342) 
7 55 284 (237, 336) 
7 57 274 (228, 324) 
7 58 269 (223, 318) 
7 59 264 (219, 313) 
7 59 264 (219, 313) 
7 61 254 (209, 303) 
 262 
7 63 244 (200, 293) 
7 63 244 (200, 293) 
7 72 203 (154, 259) 
7 73 199 (149, 256) 
7 73 199 (149, 256) 
7 73 199 (149, 256) 
7 77 182 (129, 243) 
7 80 170 (115, 235) 
7 81 166 (111, 232) 
7 85 150 (93, 222) 
7 85 150 (93, 222) 
8 30 421 (314, 542) 
8 32 408 (308, 522) 
8 44 337 (270, 413) 
8 49 310 (252, 374) 
8 52 294 (240, 353) 
8 55 278 (228, 334) 
8 57 268 (219, 322) 
8 67 220 (172, 275) 
8 78 173 (119, 238) 
9 24 452 (324, 601) 
9 44 331 (260, 410) 
9 59 253 (201, 310) 
9 59 253 (201, 310) 
9 73 189 (136, 252) 
10 32 395 (290, 515) 
10 47 309 (240, 386) 
10 52 282 (221, 351) 
10 54 272 (213, 338) 
10 57 257 (201, 321) 
10 73 185 (129, 250) 
10 85 138 (79, 214) 
 263 
11 44 319 (241, 408) 
11 51 282 (216, 357) 
11 63 224 (166, 290) 
11 63 224 (166, 290) 
12 59 237 (174, 310) 
13 85 127 (64, 210) 
14 24 417 (277, 584) 
14 28 392 (265, 544) 
14 32 368 (252, 506) 
14 40 323 (226, 437) 
14 44 301 (212, 406) 
14 52 260 (183, 351) 
14 53 255 (179, 345) 
14 54 250 (175, 339) 
14 55 246 (172, 333) 
14 57 236 (164, 321) 
14 77 151 (87, 234) 
14 80 140 (76, 224) 
14 85 123 (59, 209) 
15 52 255 (174, 351) 
15 59 222 (147, 311) 
15 72 166 (98, 252) 
16 73 158 (88, 249) 
20 40 287 (168, 438) 
 
 
Table 5: Predicted values for total muscle depth (cm) along with their corresponding 95% 
Confidence intervals, according to patients’ age (years), sex (male/ female) and the day the 
measurement was performed.   
Day of measurement Age Sex Predicted value 95% Confidence Interval 
1 67 Male 6.6 (5.7, 7.5) 
1 64 Male 6.7 (5.8, 7.6) 
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1 30 Male 8.3 (6.8, 10.1) 
1 72 Female 4.5 (3.5, 5.6) 
1 67 Female 4.7 (3.7, 5.8) 
1 67 Male 6.6 (5.7, 7.5) 
1 73 Male 6.3 (5.3, 7.4) 
1 59 Female 5.0 (4.0, 6.1) 
1 56 Male 7.1 (6.2, 8.0) 
1 63 Female 4.9 (3.9, 6.0) 
1 54 Female 5.2 (4.1, 6.4) 
1 51 Male 7.3 (6.4, 8.3) 
1 84 Female 4.1 (3.0, 5.3) 
1 43 Female 5.7 (4.4, 7.1) 
1 39 Male 7.9 (6.7, 9.2) 
1 37 Male 8.0 (6.7, 9.4) 
1 58 Male 7.0 (6.1, 7.9) 
1 46 Male 7.5 (6.5, 8.6) 
1 67 Female 4.7 (3.7, 5.8) 
1 66 Male 6.6 (5.7, 7.6) 
1 62 Female 4.9 (3.9, 6.0) 
1 70 Female 4.6 (3.6, 5.7) 
1 59 Female 5.0 (4.0, 6.1) 
1 73 Male 6.3 (5.3, 7.4) 
1 76 Female 4.4 (3.3, 5.5) 
1 44 Female 5.6 (4.4, 7.0) 
1 57 Male 7.0 (6.2, 7.9) 
1 73 Male 6.3 (5.3, 7.4) 
1 52 Male 7.3 (6.4, 8.2) 
1 80 Male 6.0 (4.8, 7.3) 
1 89 Male 5.6 (4.3, 7.2) 
1 55 Male 7.1 (6.2, 8.0) 
1 82 Male 5.9 (4.7, 7.2) 
1 61 Female 4.9 (3.9, 6.0) 
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1 76 Male 6.2 (5.1, 7.3) 
1 61 Male 6.8 (6.0, 7.8) 
1 53 Male 7.2 (6.3, 8.2) 
1 57 Female 5.1 (4.1, 6.2) 
1 49 Male 7.4 (6.4, 8.4) 
1 62 Male 6.8 (5.9, 7.7) 
1 75 Male 6.2 (5.2, 7.4) 
1 55 Male 7.1 (6.2, 8.0) 
1 66 Male 6.6 (5.7, 7.6) 
1 28 Male 8.4 (6.8, 10.3) 
1 63 Female 4.9 (3.9, 6.0) 
1 81 Male 6.0 (4.8, 7.3) 
1 63 Male 6.7 (5.9, 7.7) 
1 44 Male 7.6 (6.6, 8.8) 
1 56 Male 7.1 (6.2, 8.0) 
1 57 Male 7.0 (6.2, 7.9) 
1 55 Female 5.2 (4.1, 6.3) 
1 41 Male 7.8 (6.6, 9.0) 
1 71 Male 6.4 (5.4, 7.4) 
1 52 Female 5.3 (4.2, 6.5) 
1 54 Male 7.2 (6.3, 8.1) 
1 85 Female 4.0 (2.9, 5.3) 
1 85 Male 5.8 (4.5, 7.2) 
1 64 Male 6.7 (5.8, 7.6) 
1 75 Female 4.4 (3.4, 5.5) 
1 78 Male 6.1 (5.0, 7.3) 
1 61 Male 6.8 (6.0, 7.8) 
1 80 Female 4.2 (3.2, 5.4) 
1 27 Male 8.5 (6.8, 10.4) 
1 53 Male 7.2 (6.3, 8.2) 
1 24 Female 6.5 (4.6, 8.7) 
1 40 Male 7.8 (6.6, 9.1) 
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1 73 Female 4.5 (3.5, 5.6) 
1 72 Male 6.3 (5.4, 7.4) 
1 36 Male 8.0 (6.7, 9.5) 
1 77 Male 6.1 (5.0, 7.3) 
1 59 Male 6.9 (6.1, 7.8) 
1 47 Male 7.5 (6.5, 8.6) 
1 34 Male 8.1 (6.7, 9.7) 
1 32 Male 8.2 (6.8, 9.9) 
1 30 Male 8.3 (6.8, 10.1) 
1 47 Male 7.5 (6.5, 8.6) 
1 72 Male 6.3 (5.4, 7.4) 
2 73 Female 4.4 (3.4, 5.5) 
2 84 Female 4.0 (2.9, 5.2) 
2 58 Male 6.9 (6.0, 7.8) 
2 67 Female 4.6 (3.6, 5.7) 
2 66 Male 6.5 (5.6, 7.4) 
2 62 Female 4.8 (3.8, 5.9) 
2 73 Male 6.2 (5.2, 7.3) 
2 89 Male 5.5 (4.2, 7.0) 
2 82 Male 5.8 (4.6, 7.1) 
2 53 Male 7.1 (6.2, 8.0) 
2 71 Male 6.3 (5.3, 7.3) 
2 72 Male 6.2 (5.3, 7.3) 
3 67 Male 6.3 (5.5, 7.3) 
3 64 Male 6.5 (5.6, 7.4) 
3 72 Female 4.3 (3.4, 5.4) 
3 67 Female 4.5 (3.6, 5.6) 
3 67 Male 6.3 (5.5, 7.3) 
3 56 Male 6.8 (6.0, 7.7) 
3 73 Female 4.3 (3.3, 5.4) 
3 63 Female 4.7 (3.7, 5.7) 
3 54 Female 5.0 (4.0, 6.2) 
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3 43 Female 5.5 (4.2, 6.9) 
3 39 Male 7.7 (6.5, 8.9) 
3 46 Male 7.3 (6.3, 8.4) 
3 59 Female 4.8 (3.8, 5.9) 
3 76 Female 4.2 (3.2, 5.3) 
3 44 Female 5.4 (4.2, 6.8) 
3 57 Male 6.8 (6.0, 7.7) 
3 73 Male 6.1 (5.1, 7.1) 
3 52 Male 7.0 (6.2, 8.0) 
3 55 Male 6.9 (6.1, 7.8) 
3 61 Female 4.7 (3.8, 5.8) 
3 76 Male 6.0 (4.9, 7.1) 
3 57 Female 4.9 (3.9, 6.0) 
3 49 Male 7.2 (6.3, 8.2) 
3 66 Male 6.4 (5.5, 7.3) 
3 28 Male 8.2 (6.6, 10.0) 
3 63 Female 4.7 (3.7, 5.7) 
3 81 Male 5.7 (4.6, 7.0) 
3 63 Male 6.5 (5.7, 7.4) 
3 55 Female 5.0 (4.0, 6.1) 
3 85 Male 5.6 (4.3, 7.0) 
3 64 Male 6.5 (5.6, 7.4) 
3 75 Female 4.2 (3.2, 5.3) 
3 78 Male 5.9 (4.8, 7.1) 
3 61 Male 6.6 (5.8, 7.5) 
3 80 Female 4.0 (3.0, 5.2) 
3 27 Male 8.2 (6.6, 10.1) 
3 53 Male 7.0 (6.1, 7.9) 
3 24 Female 6.3 (4.4, 8.4) 
3 40 Male 7.6 (6.4, 8.9) 
3 72 Male 6.1 (5.2, 7.2) 
3 36 Male 7.8 (6.5, 9.2) 
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3 77 Male 5.9 (4.9, 7.1) 
3 59 Male 6.7 (5.9, 7.6) 
3 47 Male 7.3 (6.3, 8.3) 
3 34 Male 7.9 (6.5, 9.4) 
3 30 Male 8.1 (6.6, 9.8) 
4 30 Male 8.0 (6.5, 9.6) 
4 73 Male 6.0 (5.0, 7.0) 
4 59 Female 4.7 (3.8, 5.8) 
4 51 Male 7.0 (6.1, 7.9) 
4 84 Female 3.8 (2.8, 5.0) 
4 39 Male 7.5 (6.4, 8.8) 
4 62 Female 4.6 (3.7, 5.7) 
4 59 Female 4.7 (3.8, 5.8) 
4 73 Male 6.0 (5.0, 7.0) 
4 80 Male 5.7 (4.6, 6.9) 
4 55 Male 6.8 (6.0, 7.7) 
4 61 Male 6.5 (5.7, 7.4) 
4 55 Male 6.8 (6.0, 7.7) 
4 44 Male 7.3 (6.3, 8.4) 
4 56 Male 6.7 (5.9, 7.6) 
4 52 Female 5.0 (4.0, 6.2) 
4 54 Male 6.8 (6.0, 7.7) 
4 85 Female 3.8 (2.7, 5.0) 
4 32 Male 7.9 (6.5, 9.4) 
4 47 Male 7.2 (6.2, 8.2) 
4 72 Male 6.0 (5.1, 7.0) 
5 59 Female 4.6 (3.7, 5.7) 
5 89 Male 5.2 (3.9, 6.7) 
5 53 Male 6.8 (5.9, 7.6) 
5 78 Male 5.7 (4.6, 6.8) 
5 73 Female 4.1 (3.2, 5.2) 
5 72 Male 5.9 (5.0, 6.9) 
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5 77 Male 5.7 (4.7, 6.8) 
5 32 Male 7.8 (6.4, 9.3) 
5 30 Male 7.9 (6.4, 9.5) 
6 59 Female 4.5 (3.6, 5.6) 
6 61 Female 4.5 (3.6, 5.5) 
6 61 Male 6.3 (5.5, 7.1) 
6 66 Male 6.1 (5.3, 7.0) 
6 28 Male 7.8 (6.3, 9.5) 
7 72 Female 4.0 (3.1, 5.0) 
7 73 Male 5.7 (4.7, 6.7) 
7 59 Female 4.5 (3.5, 5.5) 
7 54 Female 4.6 (3.7, 5.7) 
7 51 Male 6.6 (5.8, 7.5) 
7 58 Male 6.3 (5.6, 7.1) 
7 46 Male 6.9 (5.9, 7.9) 
7 73 Male 5.7 (4.7, 6.7) 
7 80 Male 5.4 (4.3, 6.6) 
7 61 Female 4.4 (3.5, 5.4) 
7 53 Male 6.5 (5.7, 7.4) 
7 57 Female 4.5 (3.6, 5.6) 
7 63 Female 4.3 (3.4, 5.3) 
7 81 Male 5.3 (4.3, 6.6) 
7 63 Male 6.1 (5.3, 6.9) 
7 55 Female 4.6 (3.6, 5.7) 
7 52 Female 4.7 (3.7, 5.8) 
7 54 Male 6.5 (5.7, 7.3) 
7 85 Female 3.5 (2.5, 4.7) 
7 85 Male 5.2 (4.0, 6.5) 
7 24 Female 5.9 (4.1, 7.9) 
7 40 Male 7.1 (6.0, 8.3) 
7 73 Female 4.0 (3.0, 5.0) 
7 77 Male 5.5 (4.5, 6.6) 
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7 59 Male 6.3 (5.5, 7.1) 
7 47 Male 6.8 (5.9, 7.8) 
8 67 Male 5.8 (5.0, 6.7) 
8 44 Female 4.9 (3.8, 6.2) 
8 57 Male 6.3 (5.5, 7.1) 
8 52 Male 6.5 (5.7, 7.3) 
8 55 Male 6.3 (5.6, 7.2) 
8 49 Male 6.6 (5.8, 7.5) 
8 78 Male 5.4 (4.4, 6.5) 
8 32 Male 7.4 (6.1, 8.9) 
8 30 Male 7.5 (6.1, 9.1) 
9 73 Female 3.8 (2.9, 4.8) 
9 59 Female 4.3 (3.4, 5.3) 
9 44 Female 4.8 (3.7, 6.1) 
9 24 Female 5.6 (3.9, 7.7) 
9 59 Male 6.1 (5.3, 6.9) 
10 54 Female 4.4 (3.4, 5.4) 
10 52 Male 6.3 (5.5, 7.1) 
10 57 Female 4.3 (3.4, 5.3) 
10 85 Male 4.9 (3.8, 6.2) 
10 73 Female 3.7 (2.8, 4.7) 
10 47 Male 6.5 (5.6, 7.4) 
10 32 Male 7.2 (5.8, 8.6) 
11 51 Male 6.2 (5.4, 7.0) 
11 63 Female 4.0 (3.1, 4.9) 
11 63 Male 5.7 (4.9, 6.5) 
11 44 Male 6.5 (5.6, 7.5) 
12 59 Female 4.0 (3.2, 5.0) 
13 85 Female 3.1 (2.1, 4.2) 
14 80 Male 4.7 (3.7, 5.8) 
14 53 Male 5.8 (5.1, 6.6) 
14 57 Female 3.9 (3.1, 4.9) 
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14 28 Male 6.9 (5.5, 8.5) 
14 44 Male 6.2 (5.3, 7.2) 
14 55 Female 4.0 (3.1, 5.0) 
14 52 Female 4.1 (3.2, 5.1) 
14 54 Male 5.8 (5.0, 6.5) 
14 85 Male 4.5 (3.4, 5.8) 
14 24 Female 5.2 (3.5, 7.1) 
14 40 Male 6.4 (5.3, 7.5) 
14 77 Male 4.8 (3.9, 5.9) 
14 32 Male 6.7 (5.4, 8.1) 
15 72 Female 3.3 (2.5, 4.3) 
15 59 Female 3.8 (2.9, 4.7) 
15 52 Male 5.7 (5.0, 6.5) 
16 73 Female 3.2 (2.4, 4.1) 
20 40 Male 5.7 (4.8, 6.8) 
 
Table 6: Predicted values for the odds of having Interleukin-10 levels > 0 pg/ml along with 
their corresponding 95% Confidence intervals, according to the day the measurement was 
performed. 
Day of 
measurement 
Predicted 
value 
95% Confidence 
Interval 
1 0.47 (0.14, 1.62) 
2 0.45 (0.14, 1.48) 
3 0.42 (0.13, 1.37) 
4 0.40 (0.12, 1.31) 
5 0.38 (0.11, 1.27) 
6 0.36 (0.10, 1.25) 
7 0.34 (0.09, 1.26) 
8 0.32 (0.08, 1.29) 
9 0.30 (0.07, 1.34) 
10 0.29 (0.06, 1.41) 
11 0.27 (0.05, 1.49) 
12 0.26 (0.04, 1.58) 
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13 0.24 (0.03, 1.69) 
14 0.23 (0.03, 1.82) 
15 0.22 (0.02, 1.97) 
16 0.21 (0.02, 2.13) 
20 0.16 (0.01, 3.01) 
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Appendix XI: KIC Standard Curve 
KIC Standard Curve on Mass Spectrometry 
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Appendix  XII: Example of Patient KIC Curve 
Patient Example KIC on Mass Spectrometry 
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Appendix XIII: Example curves for 13CO2 breath and α-KIC 
samples  
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